CHEBI ONTOLOGY - ANNOTATIONS |
|
The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.
|
Term: | EC 3.4.21.26 (prolyl oligopeptidase) inhibitor |
|
Accession: | CHEBI:76779
|
browse the term
|
Definition: | Any EC 3.4.21.* (serine endopeptidase) inhibitor that interferes with the action of prolyl oligopeptidase (EC 3.4.21.26). |
Synonyms: | related_synonym: | EC 3.4.21.26 (prolyl oligopeptidase) inhibitors; EC 3.4.21.26 inhibitor; EC 3.4.21.26 inhibitors; endoprolylpeptidase inhibitor; endoprolylpeptidase inhibitors; post-proline cleaving enzyme inhibitor; post-proline cleaving enzyme inhibitors; post-proline endopeptidase inhibitor; post-proline endopeptidase inhibitors; proline endopeptidase inhibitor; proline endopeptidase inhibitors; proline-specific endopeptidase inhibitor; proline-specific endopeptidase inhibitors; prolyl endopeptidase inhibitor; prolyl endopeptidase inhibitors; prolyl oligopeptidase inhibitor |
|
|
|
G |
Akt1 |
AKT serine/threonine kinase 1 |
multiple interactions |
EXP |
Duloxetine Hydrochloride inhibits the reaction [Indomethacin results in decreased phosphorylation of AKT1 protein] |
CTD |
PMID:38701902 |
|
NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921
|
|
G |
Ar |
androgen receptor |
multiple interactions |
ISO |
Duloxetine Hydrochloride binds to and results in decreased activity of AR protein |
CTD |
PMID:25752796 |
|
NCBI chr X:63,104,771...63,273,934
Ensembl chr X:63,104,771...63,273,925
|
|
G |
Cd48 |
Cd48 molecule |
multiple interactions |
EXP |
Duloxetine Hydrochloride inhibits the reaction [Indomethacin results in increased expression of CD48 protein] |
CTD |
PMID:38701902 |
|
NCBI chr13:84,184,884...84,209,144
Ensembl chr13:84,185,532...84,209,142
|
|
G |
Cyp17a1 |
cytochrome P450, family 17, subfamily a, polypeptide 1 |
decreases activity multiple interactions |
ISO |
Duloxetine Hydrochloride results in decreased activity of CYP17A1 protein Duloxetine Hydrochloride inhibits the reaction [[CYP17A1 protein results in increased hydroxylation of Pregnenolone] which results in increased chemical synthesis of 17-alpha-Hydroxypregnenolone]; Duloxetine Hydrochloride inhibits the reaction [[CYP17A1 protein results in increased hydroxylation of Progesterone] which results in increased chemical synthesis of 17-alpha-Hydroxyprogesterone]; Duloxetine Hydrochloride inhibits the reaction [[CYP17A1 protein results in increased metabolism of 17-alpha-Hydroxypregnenolone] which results in increased chemical synthesis of Dehydroepiandrosterone]; Duloxetine Hydrochloride inhibits the reaction [[CYP17A1 protein results in increased metabolism of 17-alpha-Hydroxyprogesterone] which results in increased chemical synthesis of Androstenedione]; Duloxetine Hydrochloride inhibits the reaction [CYP17A1 protein results in increased hydroxylation of Pregnenolone]; Duloxetine Hydrochloride inhibits the reaction [CYP17A1 protein results in increased hydroxylation of Progesterone]; Duloxetine Hydrochloride inhibits the reaction [CYP17A1 protein results in increased metabolism of 17-alpha-Hydroxypregnenolone]; Duloxetine Hydrochloride inhibits the reaction [CYP17A1 protein results in increased metabolism of 17-alpha-Hydroxyprogesterone] |
CTD |
PMID:29100959 |
|
NCBI chr 1:245,535,462...245,543,148
Ensembl chr 1:245,535,462...245,541,573
|
|
G |
Cyp1a1 |
cytochrome P450, family 1, subfamily a, polypeptide 1 |
decreases activity |
ISO |
Duloxetine Hydrochloride results in decreased activity of CYP1A1 protein |
CTD |
PMID:33814510 |
|
NCBI chr 8:58,096,021...58,102,130
Ensembl chr 8:58,096,077...58,102,125
|
|
G |
Cyp1a2 |
cytochrome P450, family 1, subfamily a, polypeptide 2 |
multiple interactions |
EXP |
[furafylline results in decreased activity of CYP1A2 protein] which results in decreased glutathionylation of Duloxetine Hydrochloride; CYP1A2 protein results in increased activity of and results in increased glutathionylation of Duloxetine Hydrochloride |
CTD |
PMID:20669986 |
|
NCBI chr 8:58,075,367...58,082,255
Ensembl chr 8:58,075,367...58,082,312
|
|
G |
Cyp1b1 |
cytochrome P450, family 1, subfamily b, polypeptide 1 |
decreases activity |
ISO |
Duloxetine Hydrochloride results in decreased activity of CYP1B1 protein |
CTD |
PMID:33814510 |
|
NCBI chr 6:15,342,312...15,350,886
Ensembl chr 6:15,342,344...15,350,917
|
|
G |
Cyp2d4 |
cytochrome P450, family 2, subfamily d, polypeptide 4 |
multiple interactions |
EXP |
[Quinidine results in decreased activity of CYP2D6 protein] which results in decreased glutathionylation of Duloxetine Hydrochloride; CYP2D6 protein results in increased activity of and results in increased glutathionylation of Duloxetine Hydrochloride |
CTD |
PMID:20669986 |
|
NCBI chr 7:113,882,584...113,891,754
Ensembl chr 7:113,881,618...113,891,759
|
|
G |
Hmox1 |
heme oxygenase 1 |
increases expression |
ISO |
Duloxetine Hydrochloride results in increased expression of HMOX1 mRNA |
CTD |
PMID:29134401 |
|
NCBI chr19:13,466,287...13,474,082
Ensembl chr19:13,467,244...13,474,079
|
|
G |
Il1a |
interleukin 1 alpha |
multiple interactions |
EXP |
Duloxetine Hydrochloride inhibits the reaction [Indomethacin results in increased expression of IL1A protein] |
CTD |
PMID:38701902 |
|
NCBI chr 3:116,526,601...116,537,055
Ensembl chr 3:116,526,604...116,536,822
|
|
G |
Kcnh2 |
potassium voltage-gated channel subfamily H member 2 |
decreases activity |
ISO |
Duloxetine Hydrochloride results in decreased activity of KCNH2 protein |
CTD |
PMID:28551711 |
|
NCBI chr 4:10,826,834...10,859,009
Ensembl chr 4:10,826,928...10,859,008
|
|
G |
Kcnj3 |
potassium inwardly-rectifying channel, subfamily J, member 3 |
multiple interactions |
ISO |
Duloxetine Hydrochloride results in decreased activity of [KCNJ3 mRNA co-treated with KCNJ5 mRNA]; Duloxetine Hydrochloride results in decreased activity of [KCNJ3 mRNA co-treated with KCNJ6 mRNA] |
CTD |
PMID:22164246 |
|
NCBI chr 3:39,944,896...40,106,646
Ensembl chr 3:39,945,351...40,109,124
|
|
G |
Kcnj5 |
potassium inwardly-rectifying channel, subfamily J, member 5 |
multiple interactions |
ISO |
Duloxetine Hydrochloride results in decreased activity of [KCNJ3 mRNA co-treated with KCNJ5 mRNA] |
CTD |
PMID:22164246 |
|
NCBI chr 8:30,724,923...30,753,083
Ensembl chr 8:30,724,925...30,753,518
|
|
G |
Kcnj6 |
potassium inwardly-rectifying channel, subfamily J, member 6 |
multiple interactions |
ISO |
Duloxetine Hydrochloride results in decreased activity of [KCNJ3 mRNA co-treated with KCNJ6 mRNA] |
CTD |
PMID:22164246 |
|
NCBI chr11:34,061,702...34,308,758
Ensembl chr11:34,061,708...34,308,758
|
|
G |
Nfe2l2 |
NFE2 like bZIP transcription factor 2 |
affects localization |
ISO |
Duloxetine Hydrochloride affects the localization of NFE2L2 protein |
CTD |
PMID:29134401 |
|
NCBI chr 3:60,594,239...60,621,712
Ensembl chr 3:60,594,242...60,621,737
|
|
G |
Prl |
prolactin |
increases expression |
ISO |
Duloxetine Hydrochloride results in increased expression of PRL protein |
CTD |
PMID:17606668 |
|
NCBI chr17:37,859,999...37,870,062
Ensembl chr17:37,860,007...37,870,062
|
|
G |
Vegfa |
vascular endothelial growth factor A |
multiple interactions |
EXP |
Duloxetine Hydrochloride inhibits the reaction [Indomethacin results in decreased expression of VEGFA protein] |
CTD |
PMID:38701902 |
|
NCBI chr 9:14,955,300...14,970,641
Ensembl chr 9:14,955,300...14,970,641
|
|
|
G |
Fos |
Fos proto-oncogene, AP-1 transcription factor subunit |
multiple interactions |
ISO |
5,6,7-trimethoxyflavone inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 affects the localization of FOS protein] |
CTD |
PMID:24161485 |
|
NCBI chr 6:105,121,170...105,124,036
Ensembl chr 6:105,121,170...105,124,036
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions |
ISO |
5,6,7-trimethoxyflavone inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased expression of IL1B mRNA]; 5,6,7-trimethoxyflavone inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased expression of IL1B protein] |
CTD |
PMID:24161485 |
|
NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
|
|
G |
Il6 |
interleukin 6 |
multiple interactions |
ISO |
5,6,7-trimethoxyflavone inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased expression of IL6 mRNA]; 5,6,7-trimethoxyflavone inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased expression of IL6 protein] |
CTD |
PMID:24161485 |
|
NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
|
|
G |
Jun |
Jun proto-oncogene, AP-1 transcription factor subunit |
multiple interactions |
ISO |
5,6,7-trimethoxyflavone inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 affects the localization of JUN protein] |
CTD |
PMID:24161485 |
|
NCBI chr 5:109,894,175...109,897,268
Ensembl chr 5:109,893,145...109,897,656
|
|
G |
Nfkbia |
NFKB inhibitor alpha |
multiple interactions |
ISO |
5,6,7-trimethoxyflavone inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased phosphorylation of and results in increased degradation of NFKBIA protein] |
CTD |
PMID:24161485 |
|
NCBI chr 6:72,858,713...72,861,941
Ensembl chr 6:72,858,712...72,861,941
|
|
G |
Nos2 |
nitric oxide synthase 2 |
multiple interactions |
ISO |
5,6,7-trimethoxyflavone inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased expression of NOS2 mRNA]; 5,6,7-trimethoxyflavone inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased expression of NOS2 protein]; [5,6,7-trimethoxyflavone inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased expression of NOS2 protein]] which results in decreased abundance of Nitric Oxide |
CTD |
PMID:24161485 |
|
NCBI chr10:63,815,308...63,851,208
Ensembl chr10:63,815,308...63,851,210
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
multiple interactions |
ISO |
5,6,7-trimethoxyflavone inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased expression of PTGS2 mRNA]; 5,6,7-trimethoxyflavone inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased expression of PTGS2 protein]; [5,6,7-trimethoxyflavone inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased expression of PTGS2 protein]] which results in decreased abundance of Dinoprostone |
CTD |
PMID:24161485 |
|
NCBI chr13:62,163,936...62,172,193
Ensembl chr13:62,163,932...62,172,188
|
|
G |
Rela |
RELA proto-oncogene, NF-kB subunit |
multiple interactions |
ISO |
5,6,7-trimethoxyflavone inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 affects the localization of RELA protein] |
CTD |
PMID:24161485 |
|
NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484
|
|
G |
Stat1 |
signal transducer and activator of transcription 1 |
multiple interactions |
ISO |
5,6,7-trimethoxyflavone inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 affects the localization of STAT1 protein]; 5,6,7-trimethoxyflavone inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased phosphorylation of STAT1 protein] |
CTD |
PMID:24161485 |
|
NCBI chr 9:49,419,561...49,459,969
Ensembl chr 9:49,419,340...49,588,540
|
|
G |
Stat3 |
signal transducer and activator of transcription 3 |
multiple interactions |
ISO |
5,6,7-trimethoxyflavone inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 affects the localization of STAT3 protein]; 5,6,7-trimethoxyflavone inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased phosphorylation of STAT3 protein] |
CTD |
PMID:24161485 |
|
NCBI chr10:85,811,206...85,863,057
Ensembl chr10:85,811,218...85,863,057
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions |
ISO |
5,6,7-trimethoxyflavone inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased expression of TNF mRNA]; 5,6,7-trimethoxyflavone inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased expression of TNF protein] |
CTD |
PMID:24161485 |
|
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
|
G |
Abcb1a |
ATP binding cassette subfamily B member 1A |
increases expression multiple interactions increases activity |
ISO |
baicalein results in increased expression of ABCB1 protein baicalein inhibits the reaction [ABCB1 protein results in decreased uptake of Daunorubicin]; baicalein inhibits the reaction [ABCB1 protein results in decreased uptake of Rhodamine 123]; baicalein inhibits the reaction [Elacridar inhibits the reaction [ABCB1 protein results in decreased uptake of Daunorubicin]]; baicalein promotes the reaction [Elacridar inhibits the reaction [ABCB1 protein results in decreased uptake of Rhodamine 123]] baicalein results in increased activity of ABCB1 protein |
CTD |
PMID:34217736 |
|
NCBI chr 4:25,357,467...25,529,941
Ensembl chr 4:25,158,362...25,442,709
|
|
G |
Abcc1 |
ATP binding cassette subfamily C member 1 |
decreases activity |
ISO |
baicalein results in decreased activity of ABCC1 protein |
CTD |
PMID:15670588 |
|
NCBI chr10:528,961...655,179
Ensembl chr10:531,812...655,114
|
|
G |
Acta2 |
actin alpha 2, smooth muscle |
decreases expression multiple interactions |
ISO |
baicalein results in decreased expression of ACTA2 protein baicalein inhibits the reaction [TGFB1 protein results in increased expression of ACTA2 mRNA]; baicalein inhibits the reaction [TGFB1 protein results in increased expression of ACTA2 protein]; MIR21 mRNA inhibits the reaction [baicalein inhibits the reaction [TGFB1 protein results in increased expression of ACTA2 protein]]; SPRY1 protein affects the reaction [baicalein inhibits the reaction [TGFB1 protein results in increased expression of ACTA2 protein]] |
CTD |
PMID:30201452 |
|
NCBI chr 1:231,746,527...231,759,307
Ensembl chr 1:231,746,548...231,759,554
|
|
G |
Afp |
alpha-fetoprotein |
affects binding |
EXP |
baicalein binds to AFP protein |
CTD |
PMID:23013281 PMID:25349334 |
|
NCBI chr14:17,573,412...17,591,476
Ensembl chr14:17,573,412...17,591,480
|
|
G |
Ahr |
aryl hydrocarbon receptor |
multiple interactions affects response to substance increases activity increases expression |
ISO |
AHR protein affects the reaction [baicalein results in decreased phosphorylation of RB1 protein]; baicalein binds to and results in increased activity of AHR protein AHR protein affects the susceptibility to baicalein baicalein results in increased activity of AHR protein baicalein results in increased expression of AHR protein |
CTD |
PMID:14644660 PMID:17869316 PMID:22820424 |
|
NCBI chr 6:52,234,089...52,271,568
Ensembl chr 6:52,234,089...52,271,568
|
|
G |
Aifm1 |
apoptosis inducing factor, mitochondria associated 1 |
multiple interactions |
ISO |
5-hydroxydecanoic acid inhibits the reaction [baicalein inhibits the reaction [Bleomycin affects the expression of and affects the localization of AIFM1 protein]]; baicalein inhibits the reaction [Bleomycin affects the expression of and affects the localization of AIFM1 protein] |
CTD |
PMID:37783230 |
|
NCBI chr X:127,650,223...127,689,356
Ensembl chr X:127,650,226...127,689,256
|
|
G |
Akt1 |
AKT serine/threonine kinase 1 |
decreases phosphorylation affects binding increases phosphorylation multiple interactions |
ISO |
baicalein results in decreased phosphorylation of AKT1 protein baicalein binds to AKT1 protein baicalein results in increased phosphorylation of AKT1 protein baicalein inhibits the reaction [Cholesterol, LDL analog results in increased expression of AKT1 mRNA]; Lithium Chloride inhibits the reaction [baicalein results in decreased phosphorylation of AKT1 protein]; Wortmannin inhibits the reaction [baicalein results in increased phosphorylation of AKT1 protein] |
CTD |
PMID:18025287 PMID:22820424 PMID:36988316 PMID:38230788 |
|
NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921
|
|
G |
Alox12 |
arachidonate 12-lipoxygenase, 12S type |
multiple interactions decreases activity |
ISO |
baicalein inhibits the reaction [ALOX12 protein results in increased chemical synthesis of 12-Hydroxy-5,8,10,14-eicosatetraenoic Acid] baicalein results in decreased activity of ALOX12 protein |
CTD |
PMID:17027136 PMID:23238474 |
|
NCBI chr10:54,958,263...54,970,542
Ensembl chr10:54,958,271...54,970,542
|
|
G |
Alox15 |
arachidonate 15-lipoxygenase |
decreases activity |
ISO |
baicalein results in decreased activity of ALOX15 protein |
CTD |
PMID:23238474 |
|
NCBI chr10:55,060,169...55,068,885
Ensembl chr10:55,060,412...55,068,874
|
|
G |
App |
amyloid beta precursor protein |
multiple interactions |
EXP |
baicalein inhibits the reaction [APP protein binds to APP protein] |
CTD |
PMID:17323972 |
|
NCBI chr11:24,019,774...24,236,584
Ensembl chr11:24,019,778...24,236,561
|
|
G |
Ascl3 |
achaete-scute family bHLH transcription factor 3 |
affects expression |
ISO |
baicalein affects the expression of ASCL3 protein |
CTD |
PMID:36055377 |
|
NCBI chr 1:163,755,306...163,755,951
Ensembl chr 1:163,754,956...163,759,682
|
|
G |
Ascl4 |
achaete-scute family bHLH transcription factor 4 |
affects expression |
ISO |
baicalein affects the expression of ASCL4 protein |
CTD |
PMID:36055377 |
|
NCBI chr 7:17,940,972...17,943,215
Ensembl chr 7:17,941,709...17,942,146
|
|
G |
Atf4 |
activating transcription factor 4 |
multiple interactions |
EXP |
baicalein inhibits the reaction [Carbon Tetrachloride results in increased expression of ATF4 protein] |
CTD |
PMID:33779329 |
|
NCBI chr 7:111,804,135...111,806,457
Ensembl chr 7:111,804,183...111,806,446
|
|
G |
Atf5 |
activating transcription factor 5 |
increases expression multiple interactions |
EXP |
baicalein results in increased expression of ATF5 protein [Carbon Tetrachloride co-treated with baicalein] results in increased expression of ATF5 protein |
CTD |
PMID:33779329 |
|
NCBI chr 1:95,295,602...95,299,755
Ensembl chr 1:95,295,610...95,299,707
|
|
G |
Atf6 |
activating transcription factor 6 |
multiple interactions |
EXP |
baicalein inhibits the reaction [Carbon Tetrachloride results in increased expression of ATF6 protein] |
CTD |
PMID:33779329 |
|
NCBI chr13:82,927,579...83,106,381
Ensembl chr13:82,930,034...83,107,177
|
|
G |
Atf7 |
activating transcription factor 7 |
multiple interactions |
EXP |
[Carbon Tetrachloride co-treated with baicalein] results in increased expression of ATF7 protein |
CTD |
PMID:33779329 |
|
NCBI chr 7:133,660,491...133,750,902
Ensembl chr 7:133,663,294...133,750,848
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
multiple interactions increases expression |
ISO |
5-hydroxydecanoic acid inhibits the reaction [baicalein inhibits the reaction [Bleomycin results in increased expression of BAX protein]]; baicalein inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of BAX protein modified form]; baicalein inhibits the reaction [Bleomycin results in increased expression of BAX protein] baicalein results in increased expression of BAX protein |
CTD |
PMID:20850421 PMID:21457722 PMID:37783230 |
|
NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
multiple interactions decreases expression |
ISO |
5-hydroxydecanoic acid inhibits the reaction [baicalein inhibits the reaction [Bleomycin results in decreased expression of BCL2 protein]]; baicalein inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in decreased expression of BCL2 protein modified form]; baicalein inhibits the reaction [Bleomycin results in decreased expression of BCL2 protein] baicalein results in decreased expression of BCL2 protein MIR3663 mRNA promotes the reaction [baicalein results in decreased expression of BCL2 protein] |
CTD |
PMID:20850421 PMID:33838155 PMID:37783230 |
|
NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743 Ensembl chr13:22,684,989...22,853,743
|
|
G |
Becn1 |
beclin 1 |
multiple interactions increases expression |
EXP |
[Carbon Tetrachloride co-treated with baicalein] results in increased expression of BECN1 protein baicalein results in increased expression of BECN1 protein |
CTD |
PMID:33779329 |
|
NCBI chr10:86,231,387...86,246,742
Ensembl chr10:86,231,388...86,246,742
|
|
G |
Birc5 |
baculoviral IAP repeat-containing 5 |
multiple interactions decreases expression |
ISO |
SB 203580 inhibits the reaction [baicalein results in decreased expression of BIRC5 protein]; wortmannin promotes the reaction [baicalein results in decreased expression of BIRC5 protein] |
CTD |
PMID:18025287 |
|
NCBI chr10:103,072,530...103,081,382
Ensembl chr10:103,073,408...103,081,380
|
|
G |
Casp3 |
caspase 3 |
multiple interactions |
ISO |
5-hydroxydecanoic acid inhibits the reaction [baicalein inhibits the reaction [Bleomycin results in increased cleavage of CASP3 protein]]; baicalein inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of CASP3 protein modified form]; baicalein inhibits the reaction [Bleomycin results in increased cleavage of CASP3 protein] |
CTD |
PMID:20850421 PMID:37783230 |
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Casp8 |
caspase 8 |
multiple interactions |
ISO |
baicalein inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of CASP8 protein modified form] |
CTD |
PMID:20850421 |
|
NCBI chr 9:60,263,863...60,312,542
Ensembl chr 9:60,264,075...60,312,542
|
|
G |
Ccna1 |
cyclin A1 |
decreases expression |
EXP |
baicalein results in decreased expression of CCNA1 protein |
CTD |
PMID:11513834 |
|
NCBI chr 2:139,231,738...139,278,066
Ensembl chr 2:139,201,074...139,243,157
|
|
G |
Ccna2 |
cyclin A2 |
decreases expression |
ISO EXP |
baicalein results in decreased expression of CCNA2 protein |
CTD |
PMID:11513834 PMID:21457722 |
|
NCBI chr 2:119,427,239...119,433,645
Ensembl chr 2:119,426,089...119,433,577
|
|
G |
Ccnb1 |
cyclin B1 |
decreases expression |
ISO |
baicalein results in decreased expression of CCNB1 protein |
CTD |
PMID:18025287 |
|
NCBI chr 2:31,912,190...31,921,163
Ensembl chr 2:31,912,193...31,921,172
|
|
G |
Ccnd1 |
cyclin D1 |
multiple interactions decreases expression increases expression |
ISO |
Lithium Chloride inhibits the reaction [baicalein results in decreased expression of CCND1 protein]; N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [baicalein results in increased expression of CCND1 mRNA] |
CTD |
PMID:19160421 PMID:21457722 PMID:22820424 PMID:24560969 PMID:36988316 |
|
NCBI chr 1:200,089,002...200,098,524
Ensembl chr 1:200,089,002...200,098,602
|
|
G |
Ccnd2 |
cyclin D2 |
decreases expression |
EXP |
baicalein results in decreased expression of CCND2 protein |
CTD |
PMID:11513834 |
|
NCBI chr 4:159,966,883...159,989,261
Ensembl chr 4:159,962,363...159,989,495
|
|
G |
Ccne1 |
cyclin E1 |
decreases expression increases expression |
ISO EXP |
baicalein results in decreased expression of CCNE1 protein baicalein results in increased expression of CCNE1 protein |
CTD |
PMID:11513834 PMID:24560969 |
|
NCBI chr 1:90,781,947...90,791,188
Ensembl chr 1:90,781,949...90,791,101
|
|
G |
Cdk1 |
cyclin-dependent kinase 1 |
decreases phosphorylation decreases expression multiple interactions |
ISO EXP |
baicalein results in decreased phosphorylation of CDK1 protein baicalein results in decreased expression of CDK1 protein SB 203580 inhibits the reaction [baicalein results in decreased phosphorylation of CDK1 protein]; wortmannin promotes the reaction [baicalein results in decreased phosphorylation of CDK1 protein] |
CTD |
PMID:11513834 PMID:18025287 |
|
NCBI chr20:19,266,226...19,281,417
Ensembl chr20:19,266,248...19,281,408
|
|
G |
Cdk2 |
cyclin dependent kinase 2 |
decreases expression |
EXP |
baicalein results in decreased expression of CDK2 protein |
CTD |
PMID:11513834 |
|
NCBI chr 7:1,129,878...1,137,431
Ensembl chr 7:1,129,811...1,137,403
|
|
G |
Cdk4 |
cyclin-dependent kinase 4 |
increases expression |
ISO |
baicalein results in increased expression of CDK4 protein |
CTD |
PMID:22820424 |
|
NCBI chr 7:62,886,124...62,889,562
Ensembl chr 7:62,883,105...62,942,403
|
|
G |
Cdkn1a |
cyclin-dependent kinase inhibitor 1A |
multiple interactions increases expression |
ISO EXP |
baicalein inhibits the reaction [Mitomycin results in increased expression of CDKN1A protein] baicalein results in increased expression of CDKN1A protein |
CTD |
PMID:11513834 PMID:34624459 |
|
NCBI chr20:7,149,177...7,159,727
Ensembl chr20:7,149,217...7,159,585
|
|
G |
Cdkn2b |
cyclin-dependent kinase inhibitor 2B |
increases expression |
EXP |
baicalein results in increased expression of CDKN2B protein |
CTD |
PMID:11513834 |
|
NCBI chr 5:104,009,839...104,019,082
Ensembl chr 5:104,010,680...104,019,050
|
|
G |
Cebpa |
CCAAT/enhancer binding protein alpha |
decreases expression |
ISO |
baicalein results in decreased expression of CEBPA protein |
CTD |
PMID:24560969 |
|
NCBI chr 1:87,759,631...87,762,303
Ensembl chr 1:87,759,433...87,762,412
|
|
G |
Cebpb |
CCAAT/enhancer binding protein beta |
decreases expression |
ISO |
baicalein results in decreased expression of CEBPB mRNA |
CTD |
PMID:24560969 |
|
NCBI chr 3:156,398,035...156,399,466
Ensembl chr 3:156,397,052...156,399,473
|
|
G |
Cebpg |
CCAAT/enhancer binding protein gamma |
decreases expression |
ISO |
baicalein results in decreased expression of CEBPG mRNA |
CTD |
PMID:24560969 |
|
NCBI chr 1:87,683,060...87,692,772
Ensembl chr 1:87,684,019...87,694,569
|
|
G |
Cflar |
CASP8 and FADD-like apoptosis regulator |
multiple interactions |
ISO |
baicalein inhibits the reaction [[Galactosamine co-treated with Lipopolysaccharides] results in decreased expression of CFLAR protein] |
CTD |
PMID:20850421 |
|
NCBI chr 9:60,185,338...60,236,173
Ensembl chr 9:60,185,452...60,237,034
|
|
G |
Cftr |
CF transmembrane conductance regulator |
increases activity |
ISO |
baicalein results in increased activity of CFTR protein |
CTD |
PMID:15234961 |
|
NCBI chr 4:46,561,269...46,728,759
Ensembl chr 4:46,560,885...46,728,756
|
|
G |
Col1a1 |
collagen type I alpha 1 chain |
multiple interactions |
ISO |
baicalein inhibits the reaction [TGFB1 protein results in increased expression of COL1A1 protein] 5-hydroxydecanoic acid inhibits the reaction [baicalein inhibits the reaction [Bleomycin results in increased expression of COL1A1 protein]]; baicalein inhibits the reaction [Bleomycin results in increased expression of COL1A1 protein] |
CTD |
PMID:30201452 PMID:37783230 |
|
NCBI chr10:79,883,622...79,900,625
Ensembl chr10:79,883,622...79,900,624
|
|
G |
Col1a2 |
collagen type I alpha 2 chain |
multiple interactions |
EXP |
baicalein inhibits the reaction [TGFB1 protein results in increased expression of COL1A2 mRNA] |
CTD |
PMID:19474275 |
|
NCBI chr 4:32,563,938...32,598,868
Ensembl chr 4:32,563,381...32,598,867
|
|
G |
Csf2 |
colony stimulating factor 2 |
decreases expression |
ISO |
baicalein results in decreased expression of CSF2 mRNA |
CTD |
PMID:10718847 |
|
NCBI chr10:38,386,945...38,388,926
Ensembl chr10:38,386,945...38,389,199
|
|
G |
Ctnnb1 |
catenin beta 1 |
decreases expression multiple interactions |
ISO |
baicalein results in decreased expression of CTNNB1 protein STMN1 protein inhibits the reaction [baicalein results in decreased expression of CTNNB1 protein] |
CTD |
PMID:38317500 |
|
NCBI chr 8:120,640,008...120,667,110
Ensembl chr 8:120,639,995...120,667,111
|
|
G |
Cycs |
cytochrome c, somatic |
multiple interactions |
ISO |
baicalein inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] affects the localization of CYCS protein] |
CTD |
PMID:20850421 |
|
NCBI chr 4:79,651,894...79,653,994
Ensembl chr 4:79,651,378...79,654,054 Ensembl chr18:79,651,378...79,654,054
|
|
G |
Cyp1a1 |
cytochrome P450, family 1, subfamily a, polypeptide 1 |
increases expression decreases expression multiple interactions increases chemical synthesis decreases activity |
ISO |
baicalein results in increased expression of CYP1A1 protein baicalein results in decreased expression of CYP1A1 mRNA [CYP1A1 protein results in increased metabolism of chrysin] which results in increased chemical synthesis of baicalein; baicalein inhibits the reaction [benz(a)anthracene results in increased expression of CYP1A1 mRNA]; baicalein inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of CYP1A1 mRNA] CYP1A1 protein results in increased chemical synthesis of baicalein baicalein results in decreased activity of CYP1A1 protein |
CTD |
PMID:12224597 PMID:14644660 PMID:18451504 PMID:19666078 PMID:21053930 PMID:21482471 More...
|
|
NCBI chr 8:58,096,021...58,102,130
Ensembl chr 8:58,096,077...58,102,125
|
|
G |
Cyp1a2 |
cytochrome P450, family 1, subfamily a, polypeptide 2 |
decreases activity increases chemical synthesis multiple interactions |
ISO |
baicalein results in decreased activity of CYP1A2 protein CYP1A2 protein results in increased chemical synthesis of baicalein [CYP1A2 protein results in increased metabolism of chrysin] which results in increased chemical synthesis of baicalein |
CTD |
PMID:19666078 PMID:21053930 PMID:29753067 |
|
NCBI chr 8:58,075,367...58,082,255
Ensembl chr 8:58,075,367...58,082,312
|
|
G |
Cyp1b1 |
cytochrome P450, family 1, subfamily b, polypeptide 1 |
decreases activity increases chemical synthesis multiple interactions |
ISO |
baicalein results in decreased activity of CYP1B1 protein CYP1B1 protein results in increased chemical synthesis of baicalein [CYP1B1 protein results in increased metabolism of chrysin] which results in increased chemical synthesis of baicalein; baicalein binds to and results in decreased activity of CYP1B1 protein; baicalein inhibits the reaction [benz(a)anthracene results in increased expression of CYP1B1 mRNA] |
CTD |
PMID:12224597 PMID:19666078 PMID:21053930 PMID:21482471 |
|
NCBI chr 6:15,342,312...15,350,886
Ensembl chr 6:15,342,344...15,350,917
|
|
G |
Cyp2b3 |
cytochrome P450, family 2, subfamily b, polypeptide 3 |
increases expression |
ISO |
baicalein results in increased expression of CYP2B6 mRNA |
CTD |
PMID:25625231 |
|
NCBI chr 1:81,652,762...81,732,153
Ensembl chr 1:81,652,787...81,732,143
|
|
G |
Cyp2c6 |
cytochrome P450, family 2, subfamily C, polypeptide 6 |
decreases activity |
ISO |
baicalein results in decreased activity of CYP2C19 protein |
CTD |
PMID:29753067 |
|
NCBI chr 1:237,938,521...237,976,238
Ensembl chr 1:237,693,094...238,057,596
|
|
G |
Cyp2e1 |
cytochrome P450, family 2, subfamily e, polypeptide 1 |
decreases activity |
ISO |
baicalein results in decreased activity of CYP2E1 protein |
CTD |
PMID:29753067 |
|
NCBI chr 1:195,840,330...195,850,728
Ensembl chr 1:195,840,058...195,864,023
|
|
G |
Cyp3a2 |
cytochrome P450, family 3, subfamily a, polypeptide 2 |
decreases activity |
ISO |
baicalein results in decreased activity of CYP3A4 protein |
CTD |
PMID:21053930 PMID:29753067 |
|
NCBI chr12:9,207,978...9,230,064
Ensembl chr12:9,015,383...9,285,008
|
|
G |
Ddit3 |
DNA-damage inducible transcript 3 |
multiple interactions |
EXP |
baicalein inhibits the reaction [Carbon Tetrachloride results in increased expression of DDIT3 protein] |
CTD |
PMID:33779329 |
|
NCBI chr 7:63,115,645...63,121,203
Ensembl chr 7:63,116,380...63,121,201
|
|
G |
Dgat1 |
diacylglycerol O-acyltransferase 1 |
decreases expression |
ISO |
baicalein results in decreased expression of DGAT1 protein |
CTD |
PMID:24560969 |
|
NCBI chr 7:108,223,860...108,235,413
Ensembl chr 7:108,218,524...108,234,299
|
|
G |
Dlk1 |
delta like non-canonical Notch ligand 1 |
increases expression |
ISO |
baicalein results in increased expression of DLK1 mRNA |
CTD |
PMID:24560969 |
|
NCBI chr 6:128,410,216...128,417,518
Ensembl chr 6:128,410,316...128,417,522
|
|
G |
Egf |
epidermal growth factor |
multiple interactions |
ISO |
baicalein inhibits the reaction [EGF protein results in increased phosphorylation of EGFR protein]; baicalein inhibits the reaction [EGF protein results in increased phosphorylation of ELK1 protein] |
CTD |
PMID:25625231 |
|
NCBI chr 2:218,219,408...218,302,359
Ensembl chr 2:218,219,415...218,302,064
|
|
G |
Egfr |
epidermal growth factor receptor |
multiple interactions affects binding decreases phosphorylation |
ISO |
baicalein inhibits the reaction [Cholesterol, LDL analog results in increased expression of EGFR mRNA]; baicalein inhibits the reaction [EGF protein results in increased phosphorylation of EGFR protein]; MIR3663 mRNA promotes the reaction [baicalein results in decreased phosphorylation of EGFR protein] baicalein binds to EGFR protein |
CTD |
PMID:25625231 PMID:33838155 PMID:38230788 |
|
NCBI chr14:91,176,979...91,349,722
Ensembl chr14:91,177,067...91,344,382
|
|
G |
Egr2 |
early growth response 2 |
decreases expression |
ISO |
baicalein results in decreased expression of EGR2 mRNA |
CTD |
PMID:24560969 |
|
NCBI chr20:21,051,270...21,056,322
Ensembl chr20:21,051,277...21,055,562
|
|
G |
Eif2ak3 |
eukaryotic translation initiation factor 2 alpha kinase 3 |
multiple interactions |
EXP |
baicalein inhibits the reaction [Carbon Tetrachloride results in increased expression of EIF2AK3 protein] |
CTD |
PMID:33779329 |
|
NCBI chr 4:102,805,495...102,866,914
Ensembl chr 4:102,805,510...102,866,911
|
|
G |
Elk1 |
ETS transcription factor ELK1 |
multiple interactions |
ISO |
baicalein inhibits the reaction [EGF protein results in increased phosphorylation of ELK1 protein] |
CTD |
PMID:25625231 |
|
NCBI chr X:1,138,826...1,155,713
Ensembl chr X:1,139,756...1,155,713
|
|
G |
Epo |
erythropoietin |
increases expression |
ISO |
baicalein results in increased expression of EPO mRNA |
CTD |
PMID:37348668 |
|
NCBI chr12:19,204,258...19,207,948
Ensembl chr12:19,204,508...19,207,946
|
|
G |
Erbb2 |
erb-b2 receptor tyrosine kinase 2 |
multiple interactions decreases expression |
ISO |
baicalein results in decreased expression of and results in decreased phosphorylation of ERBB2 protein baicalein results in decreased expression of ERBB2 mRNA |
CTD |
PMID:36988316 |
|
NCBI chr10:83,411,197...83,435,078
Ensembl chr10:83,411,313...83,435,078
|
|
G |
Ern1 |
endoplasmic reticulum to nucleus signaling 1 |
multiple interactions |
EXP |
baicalein inhibits the reaction [Carbon Tetrachloride results in increased expression of ERN1 protein] |
CTD |
PMID:33779329 |
|
NCBI chr10:91,326,889...91,421,201
Ensembl chr10:91,330,654...91,421,029
|
|
G |
Esr1 |
estrogen receptor 1 |
affects binding multiple interactions |
ISO |
baicalein binds to ESR1 protein baicalein inhibits the reaction [Cholesterol, LDL analog results in decreased expression of ESR1 mRNA] |
CTD |
PMID:38230788 |
|
NCBI chr 1:41,106,335...41,499,104
Ensembl chr 1:41,210,475...41,495,002
|
|
G |
Fabp4 |
fatty acid binding protein 4 |
decreases expression |
ISO |
baicalein results in decreased expression of FABP4 protein |
CTD |
PMID:24560969 |
|
NCBI chr 2:91,580,879...91,585,567
Ensembl chr 2:91,580,885...91,585,578
|
|
G |
Fasn |
fatty acid synthase |
decreases expression |
ISO |
baicalein results in decreased expression of FASN protein |
CTD |
PMID:24560969 |
|
NCBI chr10:106,072,093...106,090,259
Ensembl chr10:106,072,091...106,090,261
|
|
G |
Fn1 |
fibronectin 1 |
multiple interactions |
ISO |
baicalein inhibits the reaction [TGFB1 protein results in increased expression of FN1 protein] |
CTD |
PMID:30201452 |
|
NCBI chr 9:73,196,044...73,264,695
Ensembl chr 9:73,196,044...73,264,678
|
|
G |
Glb1 |
galactosidase, beta 1 |
multiple interactions |
ISO |
baicalein inhibits the reaction [Mitomycin results in increased activity of GLB1 protein] |
CTD |
PMID:34624459 |
|
NCBI chr 8:114,085,508...114,158,127
Ensembl chr 8:114,085,508...114,158,127
|
|
G |
Gli1 |
GLI family zinc finger 1 |
decreases expression |
ISO |
baicalein results in decreased expression of GLI1 mRNA; baicalein results in decreased expression of GLI1 protein |
CTD |
PMID:20395211 |
|
NCBI chr 7:63,156,926...63,169,579
Ensembl chr 7:63,156,926...63,169,251
|
|
G |
Gpat3 |
glycerol-3-phosphate acyltransferase 3 |
decreases expression |
ISO |
baicalein results in decreased expression of GPAT3 protein |
CTD |
PMID:24560969 |
|
NCBI chr14:8,715,367...8,768,051
Ensembl chr14:8,714,373...8,766,490
|
|
G |
Gpx4 |
glutathione peroxidase 4 |
affects expression multiple interactions |
ISO |
baicalein affects the expression of GPX4 protein baicalein inhibits the reaction [Polymyxin B results in decreased expression of GPX4 protein]; SIRT1 protein promotes the reaction [baicalein inhibits the reaction [Polymyxin B results in decreased expression of GPX4 protein]] |
CTD |
PMID:36055377 PMID:37354967 |
|
NCBI chr 7:9,650,186...9,652,982
Ensembl chr 7:9,650,185...9,652,982
|
|
G |
Gsk3b |
glycogen synthase kinase 3 beta |
decreases phosphorylation multiple interactions |
ISO |
baicalein results in decreased phosphorylation of GSK3B protein baicalein inhibits the reaction [Mitomycin results in increased phosphorylation of GSK3B protein] |
CTD |
PMID:22820424 PMID:34624459 PMID:36988316 |
|
NCBI chr11:62,498,997...62,648,665
Ensembl chr11:62,504,316...62,648,646
|
|
G |
Hes1 |
hes family bHLH transcription factor 1 |
multiple interactions increases expression |
ISO |
N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [baicalein results in increased expression of HES1 mRNA] |
CTD |
PMID:19160421 |
|
NCBI chr11:70,705,763...70,708,176
Ensembl chr11:70,705,764...70,708,192
|
|
G |
Hey1 |
hes-related family bHLH transcription factor with YRPW motif 1 |
multiple interactions increases expression |
ISO |
N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [baicalein results in increased expression of HEY1 mRNA] |
CTD |
PMID:19160421 |
|
NCBI chr 2:93,096,605...93,100,316
Ensembl chr 2:93,095,498...93,100,312
|
|
G |
Hey2 |
hes-related family bHLH transcription factor with YRPW motif 2 |
multiple interactions increases expression |
ISO |
N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [baicalein results in increased expression of HEY2 mRNA] |
CTD |
PMID:19160421 |
|
NCBI chr 1:26,822,131...26,832,218
Ensembl chr 1:26,822,131...26,832,218
|
|
G |
Hif1a |
hypoxia inducible factor 1 subunit alpha |
multiple interactions increases expression |
ISO |
baicalein results in decreased degradation of and results in increased expression of HIF1A protein modified form baicalein results in increased expression of HIF1A mRNA; baicalein results in increased expression of HIF1A protein |
CTD |
PMID:37348668 |
|
NCBI chr 6:92,624,059...92,669,262
Ensembl chr 6:92,624,390...92,669,261
|
|
G |
Hmox1 |
heme oxygenase 1 |
increases expression multiple interactions |
ISO |
baicalein results in increased expression of HMOX1 mRNA; baicalein results in increased expression of HMOX1 protein baicalein inhibits the reaction [Polymyxin B results in decreased expression of HMOX1 protein]; baicalein inhibits the reaction [Polymyxin B results in increased expression of HMOX1 protein]; SIRT1 protein promotes the reaction [baicalein inhibits the reaction [Polymyxin B results in decreased expression of HMOX1 protein]] Hemin promotes the reaction [baicalein results in increased expression of HMOX1 protein]; HMOX1 protein promotes the reaction [baicalein inhibits the reaction [Lipopolysaccharides results in increased activity of NOS2 protein]] |
CTD |
PMID:14563492 PMID:37354967 |
|
NCBI chr19:13,466,287...13,474,082
Ensembl chr19:13,467,244...13,474,079
|
|
G |
Hsd11b2 |
hydroxysteroid 11-beta dehydrogenase 2 |
multiple interactions increases activity |
ISO |
12-Hydroxy-5,8,10,14-eicosatetraenoic Acid inhibits the reaction [baicalein results in increased activity of HSD11B2 protein] |
CTD |
PMID:18032417 |
|
NCBI chr19:33,397,656...33,402,899
Ensembl chr19:33,397,656...33,402,899
|
|
G |
Hspa5 |
heat shock protein family A (Hsp70) member 5 |
multiple interactions |
EXP |
baicalein inhibits the reaction [Carbon Tetrachloride results in increased expression of HSPA5 protein] |
CTD |
PMID:33779329 |
|
NCBI chr 3:18,055,507...18,059,969
Ensembl chr 3:18,055,405...18,059,891
|
|
G |
Igf1 |
insulin-like growth factor 1 |
multiple interactions |
ISO |
baicalein inhibits the reaction [[IGF1 protein co-treated with Estradiol] results in increased expression of JUN protein] |
CTD |
PMID:17458902 |
|
NCBI chr 7:22,282,895...22,361,972
Ensembl chr 7:22,282,930...22,359,296
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions |
ISO |
baicalein inhibits the reaction [Benzo(a)pyrene results in increased expression of IL1B protein] baicalein inhibits the reaction [Cholesterol, LDL analog results in increased expression of IL1B protein] |
CTD |
PMID:22369883 PMID:38230788 |
|
NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
|
|
G |
Il6 |
interleukin 6 |
multiple interactions |
ISO |
baicalein inhibits the reaction [Cholesterol, LDL analog results in increased expression of IL6 protein] |
CTD |
PMID:38230788 |
|
NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
|
|
G |
Ins2 |
insulin 2 |
multiple interactions increases secretion |
ISO |
baicalein promotes the reaction [Glucose results in increased secretion of INS protein] baicalein results in increased secretion of INS protein |
CTD |
PMID:17192482 |
|
NCBI chr 1:197,843,277...197,992,522
Ensembl chr 1:197,843,281...197,864,775
|
|
G |
Jun |
Jun proto-oncogene, AP-1 transcription factor subunit |
multiple interactions affects binding |
ISO |
baicalein inhibits the reaction [[IGF1 protein co-treated with Estradiol] results in increased expression of JUN protein]; baicalein inhibits the reaction [Cholesterol, LDL analog results in increased expression of JUN mRNA] baicalein binds to JUN protein |
CTD |
PMID:17458902 PMID:38230788 |
|
NCBI chr 5:109,894,175...109,897,268
Ensembl chr 5:109,893,145...109,897,656
|
|
G |
Klf2 |
KLF transcription factor 2 |
increases expression |
ISO |
baicalein results in increased expression of KLF2 mRNA |
CTD |
PMID:24560969 |
|
NCBI chr16:17,521,107...17,523,739
Ensembl chr16:17,514,552...17,523,944
|
|
G |
Klf5 |
KLF transcription factor 5 |
decreases expression |
ISO |
baicalein results in decreased expression of KLF5 mRNA |
CTD |
PMID:24560969 |
|
NCBI chr15:76,060,320...76,079,445
Ensembl chr15:76,064,258...76,079,445
|
|
G |
Lpin1 |
lipin 1 |
decreases expression |
ISO |
baicalein results in decreased expression of LPIN1 protein |
CTD |
PMID:24560969 |
|
NCBI chr 6:39,309,198...39,417,034
Ensembl chr 6:39,312,748...39,417,097
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
multiple interactions affects binding decreases phosphorylation |
ISO |
baicalein inhibits the reaction [Cholesterol, LDL analog results in increased expression of MAPK1 mRNA]; baicalein results in decreased phosphorylation of and results in decreased activity of MAPK1 protein; MIR3663 mRNA promotes the reaction [baicalein results in decreased phosphorylation of MAPK1 protein] baicalein binds to MAPK1 protein baicalein inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of MAPK1 protein modified form]; baicalein inhibits the reaction [PLA2G2A protein results in increased phosphorylation of MAPK1 protein] |
CTD |
PMID:10718847 PMID:20850421 PMID:31811862 PMID:33838155 PMID:38230788 |
|
NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
multiple interactions decreases phosphorylation |
ISO |
baicalein results in decreased phosphorylation of and results in decreased activity of MAPK3 protein; MIR3663 mRNA promotes the reaction [baicalein results in decreased phosphorylation of MAPK3 protein] baicalein inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of MAPK3 protein modified form]; baicalein inhibits the reaction [PLA2G2A protein results in increased phosphorylation of MAPK3 protein] |
CTD |
PMID:10718847 PMID:20850421 PMID:31811862 PMID:33838155 |
|
NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863
|
|
G |
Mapk8 |
mitogen-activated protein kinase 8 |
multiple interactions |
ISO |
baicalein results in decreased phosphorylation of and results in decreased activity of MAPK8 protein |
CTD |
PMID:10718847 |
|
NCBI chr16:8,638,897...8,721,960
Ensembl chr16:8,638,924...8,721,981
|
|
G |
Mir1224 |
microRNA 1224 |
increases expression |
ISO |
baicalein results in increased expression of MIR1224 mRNA |
CTD |
PMID:33838155 |
|
NCBI chr11:80,306,902...80,306,986
Ensembl chr11:80,306,902...80,306,986
|
|
G |
Mir21 |
microRNA 21 |
multiple interactions |
ISO |
baicalein inhibits the reaction [TGFB1 protein results in increased expression of MIR21 mRNA]; MIR21 mRNA inhibits the reaction [baicalein inhibits the reaction [TGFB1 protein results in increased expression of ACTA2 protein]] |
CTD |
PMID:30201452 |
|
NCBI chr10:71,405,257...71,405,348
Ensembl chr10:71,405,257...71,405,348
|
|
G |
Mir322 |
microRNA 322 |
increases expression |
ISO |
baicalein results in increased expression of MIR424 mRNA |
CTD |
PMID:33838155 |
|
NCBI chr X:132,806,594...132,806,688
Ensembl chr X:132,806,594...132,806,688
|
|
G |
Mmp2 |
matrix metallopeptidase 2 |
decreases activity multiple interactions |
ISO |
baicalein results in decreased activity of MMP2 protein baicalein inhibits the reaction [Benzo(a)pyrene results in increased expression of MMP2 mRNA] |
CTD |
PMID:21803068 PMID:22369883 PMID:36988316 |
|
NCBI chr19:14,154,657...14,182,870
Ensembl chr19:14,154,657...14,182,870
|
|
G |
Mmp9 |
matrix metallopeptidase 9 |
multiple interactions decreases expression decreases activity |
ISO |
baicalein inhibits the reaction [Tetradecanoylphorbol Acetate results in increased activity of MMP9 protein]; STMN1 protein inhibits the reaction [baicalein results in decreased expression of MMP9 protein] baicalein inhibits the reaction [Benzo(a)pyrene results in increased expression of MMP9 mRNA] baicalein results in decreased activity of MMP9 protein |
CTD |
PMID:19804834 PMID:21803068 PMID:22369883 PMID:38317500 |
|
NCBI chr 3:153,684,158...153,692,118
Ensembl chr 3:153,683,858...153,692,120
|
|
G |
Mpo |
myeloperoxidase |
multiple interactions |
ISO |
baicalein inhibits the reaction [[Ethanol co-treated with Hydrochloric Acid] results in increased activity of MPO protein] |
CTD |
PMID:27780710 |
|
NCBI chr10:72,594,883...72,608,862
Ensembl chr10:72,594,661...72,604,819
|
|
G |
Mtor |
mechanistic target of rapamycin kinase |
multiple interactions |
ISO |
baicalein results in decreased phosphorylation of and results in decreased activity of MTOR protein |
CTD |
PMID:24560969 |
|
NCBI chr 5:158,884,856...158,994,311
Ensembl chr 5:158,884,804...158,994,311
|
|
G |
Nat1 |
N-acetyltransferase 1 |
decreases expression |
ISO |
baicalein results in decreased expression of NAT1 mRNA; baicalein results in decreased expression of NAT1 protein |
CTD |
PMID:15796204 |
|
NCBI chr16:22,218,217...22,238,516
Ensembl chr16:22,208,194...22,238,520
|
|
G |
Nfkb1 |
nuclear factor kappa B subunit 1 |
decreases localization |
ISO |
baicalein results in decreased localization of NFKB1 protein |
CTD |
PMID:21803068 |
|
NCBI chr 2:224,016,214...224,132,135
Ensembl chr 2:224,016,214...224,110,404
|
|
G |
Nfkbia |
NFKB inhibitor alpha |
multiple interactions decreases phosphorylation |
ISO |
baicalein inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in decreased expression of NFKBIA protein] baicalein results in decreased phosphorylation of NFKBIA protein |
CTD |
PMID:20850421 |
|
NCBI chr 6:72,858,713...72,861,941
Ensembl chr 6:72,858,712...72,861,941
|
|
G |
Nfkbib |
NFKB inhibitor beta |
decreases phosphorylation |
ISO |
baicalein results in decreased phosphorylation of NFKBIB protein |
CTD |
PMID:21803068 |
|
NCBI chr 1:84,046,292...84,053,862
Ensembl chr 1:84,046,295...84,053,862
|
|
G |
Nos2 |
nitric oxide synthase 2 |
multiple interactions decreases expression |
ISO |
baicalein inhibits the reaction [Benzo(a)pyrene results in increased expression of NOS2 protein]; baicalein inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 protein]; Hemin promotes the reaction [baicalein inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 protein]]; HMOX1 protein promotes the reaction [baicalein inhibits the reaction [Lipopolysaccharides results in increased activity of NOS2 protein]]; tin protoporphyrin IX inhibits the reaction [baicalein inhibits the reaction [Lipopolysaccharides results in increased activity of NOS2 protein]] baicalein results in decreased expression of NOS2 protein |
CTD |
PMID:14563492 PMID:20850421 PMID:22369883 |
|
NCBI chr10:63,815,308...63,851,208
Ensembl chr10:63,815,308...63,851,210
|
|
G |
Notch1 |
notch receptor 1 |
increases activity increases expression |
ISO |
baicalein results in increased activity of NOTCH1 protein baicalein results in increased expression of NOTCH1 mRNA |
CTD |
PMID:19160421 |
|
NCBI chr 3:9,277,955...9,323,531
Ensembl chr 3:9,278,086...9,323,531
|
|
G |
Nr1i3 |
nuclear receptor subfamily 1, group I, member 3 |
affects localization |
ISO |
baicalein affects the localization of NR1I3 protein |
CTD |
PMID:25625231 |
|
NCBI chr13:83,632,940...83,638,193
Ensembl chr13:83,632,899...83,637,906
|
|
G |
Pcna |
proliferating cell nuclear antigen |
multiple interactions decreases expression |
ISO |
STMN1 protein inhibits the reaction [baicalein results in decreased expression of PCNA protein] |
CTD |
PMID:38317500 |
|
NCBI chr 3:119,499,039...119,502,911
Ensembl chr 3:119,498,810...119,502,995
|
|
G |
Pik3c3 |
phosphatidylinositol 3-kinase, catalytic subunit type 3 |
multiple interactions |
EXP |
[Carbon Tetrachloride co-treated with baicalein] results in increased expression of PIK3C3 protein |
CTD |
PMID:33779329 |
|
NCBI chr18:21,845,282...21,934,387
Ensembl chr18:21,845,295...21,929,048
|
|
G |
Pik3ca |
phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit alpha |
affects binding multiple interactions |
ISO |
baicalein binds to PIK3CA protein baicalein inhibits the reaction [Cholesterol, LDL analog results in increased expression of PIK3CA mRNA] |
CTD |
PMID:38230788 |
|
NCBI chr 2:115,175,275...115,249,034
Ensembl chr 2:115,174,984...115,249,032
|
|
G |
Pkm |
pyruvate kinase M1/2 |
increases activity |
ISO |
baicalein results in increased activity of PKM protein |
CTD |
PMID:25388478 |
|
NCBI chr 8:60,057,629...60,079,600
Ensembl chr 8:60,057,402...60,079,599
|
|
G |
Pla2g2a |
phospholipase A2 group IIA |
multiple interactions |
ISO |
baicalein inhibits the reaction [PLA2G2A protein results in increased expression of PTGS2 protein]; baicalein inhibits the reaction [PLA2G2A protein results in increased phosphorylation of MAPK1 protein]; baicalein inhibits the reaction [PLA2G2A protein results in increased phosphorylation of MAPK3 protein] |
CTD |
PMID:31811862 |
|
NCBI chr 5:151,076,442...151,079,019
Ensembl chr 5:151,076,442...151,079,014
|
|
G |
Plau |
plasminogen activator, urokinase |
decreases activity |
ISO |
baicalein results in decreased activity of PLAU protein |
CTD |
PMID:21803068 |
|
NCBI chr15:3,456,230...3,462,732
Ensembl chr15:3,456,232...3,462,775
|
|
G |
Pmaip1 |
phorbol-12-myristate-13-acetate-induced protein 1 |
multiple interactions |
ISO |
baicalein inhibits the reaction [Fenretinide results in increased expression of PMAIP1 mRNA] |
CTD |
PMID:17216584 |
|
NCBI chr18:59,986,020...59,992,434
Ensembl chr18:59,986,017...59,992,429
|
|
G |
Pparg |
peroxisome proliferator-activated receptor gamma |
decreases expression |
ISO |
baicalein results in decreased expression of PPARG protein |
CTD |
PMID:24560969 |
|
NCBI chr 4:148,423,102...148,548,471
Ensembl chr 4:148,423,194...148,548,468
|
|
G |
Prkca |
protein kinase C, alpha |
decreases phosphorylation |
ISO |
baicalein results in decreased phosphorylation of PRKCA protein |
CTD |
PMID:21803068 |
|
NCBI chr10:92,889,390...93,288,013
Ensembl chr10:92,894,012...93,288,012
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
multiple interactions |
ISO |
baicalein inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of PTGS2 protein] baicalein inhibits the reaction [Benzo(a)pyrene results in increased expression of PTGS2 mRNA]; baicalein inhibits the reaction [PLA2G2A protein results in increased expression of PTGS2 protein]; baicalein inhibits the reaction [Polymyxin B results in increased expression of PTGS2 protein] |
CTD |
PMID:19804834 PMID:22369883 PMID:31811862 PMID:37354967 |
|
NCBI chr13:62,163,936...62,172,193
Ensembl chr13:62,163,932...62,172,188
|
|
G |
Pygb |
glycogen phosphorylase B |
decreases activity |
ISO |
baicalein results in decreased activity of PYGB protein |
CTD |
PMID:37277066 |
|
NCBI chr 3:139,611,724...139,658,521
Ensembl chr 3:139,611,749...139,663,553
|
|
G |
Pygl |
glycogen phosphorylase L |
decreases activity |
ISO |
baicalein results in decreased activity of PYGL protein |
CTD |
PMID:37277066 |
|
NCBI chr 6:88,697,598...88,740,260
Ensembl chr 6:88,697,593...88,740,310
|
|
G |
Rb1 |
RB transcriptional corepressor 1 |
multiple interactions decreases phosphorylation |
ISO |
AHR protein affects the reaction [baicalein results in decreased phosphorylation of RB1 protein]; Lithium Chloride inhibits the reaction [baicalein results in decreased phosphorylation of RB1 protein] |
CTD |
PMID:22820424 |
|
NCBI chr15:48,371,295...48,502,473
Ensembl chr15:48,371,296...48,502,302
|
|
G |
Rela |
RELA proto-oncogene, NF-kB subunit |
multiple interactions decreases phosphorylation affects localization decreases localization |
ISO |
baicalein inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] affects the localization of RELA protein]; baicalein inhibits the reaction [Benzo(a)pyrene results in increased expression of RELA protein] baicalein results in decreased phosphorylation of RELA protein MIR3663 mRNA promotes the reaction [baicalein results in decreased phosphorylation of RELA protein]; NKILA mRNA promotes the reaction [baicalein affects the localization of RELA protein] baicalein results in decreased localization of RELA protein |
CTD |
PMID:20850421 PMID:21803068 PMID:22369883 PMID:29481769 PMID:33838155 |
|
NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484
|
|
G |
Rps6kb1 |
ribosomal protein S6 kinase B1 |
multiple interactions |
ISO |
baicalein results in decreased phosphorylation of and results in decreased activity of RPS6KB1 protein |
CTD |
PMID:24560969 |
|
NCBI chr10:71,323,777...71,367,908
Ensembl chr10:71,323,777...71,367,908
|
|
G |
Sh3gl1 |
SH3 domain containing GRB2 like 1, endophilin A2 |
decreases expression multiple interactions |
ISO |
baicalein results in decreased expression of SH3GL1 mRNA; baicalein results in decreased expression of SH3GL1 protein MIR3663 mRNA promotes the reaction [baicalein results in decreased expression of SH3GL1 protein] |
CTD |
PMID:33838155 |
|
NCBI chr 9:842,285...869,753
Ensembl chr 9:842,288...869,716
|
|
G |
Sirt1 |
sirtuin 1 |
multiple interactions |
ISO |
baicalein inhibits the reaction [Polymyxin B results in decreased expression of SIRT1 protein]; SIRT1 protein promotes the reaction [baicalein inhibits the reaction [Polymyxin B results in decreased expression of GPX4 protein]]; SIRT1 protein promotes the reaction [baicalein inhibits the reaction [Polymyxin B results in decreased expression of HMOX1 protein]]; SIRT1 protein promotes the reaction [baicalein inhibits the reaction [Polymyxin B results in decreased expression of SLC7A11 protein]]; SIRT1 protein promotes the reaction [baicalein inhibits the reaction [Polymyxin B results in increased acetylation of TP53 protein]] |
CTD |
PMID:37354967 |
|
NCBI chr20:25,307,225...25,329,273
Ensembl chr20:25,306,917...25,329,260
|
|
G |
Slc22a6 |
solute carrier family 22 member 6 |
decreases activity |
ISO |
baicalein results in decreased activity of SLC22A6 protein |
CTD |
PMID:32159797 |
|
NCBI chr 1:205,522,579...205,531,179
Ensembl chr 1:205,522,729...205,531,173
|
|
G |
Slc7a11 |
solute carrier family 7 member 11 |
multiple interactions |
ISO |
baicalein inhibits the reaction [Polymyxin B results in decreased expression of SLC7A11 protein]; SIRT1 protein promotes the reaction [baicalein inhibits the reaction [Polymyxin B results in decreased expression of SLC7A11 protein]] |
CTD |
PMID:37354967 |
|
NCBI chr 2:134,382,002...134,517,622
Ensembl chr 2:133,963,107...134,517,536
|
|
G |
Snca |
synuclein alpha |
multiple interactions |
ISO |
baicalein inhibits the reaction [SNCA protein binds to SNCA protein] baicalein inhibits the reaction [Rotenone promotes the reaction [SNCA protein binds to SNCA protein]]; baicalein inhibits the reaction [Rotenone results in increased expression of SNCA protein] |
CTD |
PMID:27425033 |
|
NCBI chr 4:89,696,420...89,797,240
Ensembl chr 4:89,696,420...89,796,262
|
|
G |
Spry1 |
sprouty RTK signaling antagonist 1 |
multiple interactions |
ISO |
baicalein inhibits the reaction [TGFB1 protein results in decreased expression of SPRY1 protein]; SPRY1 protein affects the reaction [baicalein inhibits the reaction [TGFB1 protein results in increased expression of ACTA2 protein]] |
CTD |
PMID:30201452 |
|
NCBI chr 2:120,557,256...120,561,917
Ensembl chr 2:120,556,706...120,566,189
|
|
G |
Src |
SRC proto-oncogene, non-receptor tyrosine kinase |
affects binding multiple interactions |
ISO |
baicalein binds to SRC protein baicalein inhibits the reaction [Cholesterol, LDL analog results in increased expression of SRC mRNA] |
CTD |
PMID:38230788 |
|
NCBI chr 3:146,091,969...146,139,492
Ensembl chr 3:146,091,841...146,139,476
|
|
G |
Srebf1 |
sterol regulatory element binding transcription factor 1 |
decreases expression |
ISO |
baicalein results in decreased expression of SREBF1 protein |
CTD |
PMID:24560969 |
|
NCBI chr10:45,007,637...45,029,650
Ensembl chr10:45,007,637...45,029,650
|
|
G |
Stat3 |
signal transducer and activator of transcription 3 |
multiple interactions |
ISO |
baicalein inhibits the reaction [TGFB1 protein results in increased phosphorylation of STAT3 protein] |
CTD |
PMID:30201452 |
|
NCBI chr10:85,811,206...85,863,057
Ensembl chr10:85,811,218...85,863,057
|
|
G |
Stmn1 |
stathmin 1 |
decreases expression multiple interactions |
ISO |
baicalein results in decreased expression of STMN1 protein STMN1 protein inhibits the reaction [baicalein results in decreased expression of CTNNB1 protein]; STMN1 protein inhibits the reaction [baicalein results in decreased expression of MMP9 protein]; STMN1 protein inhibits the reaction [baicalein results in decreased expression of PCNA protein]; STMN1 protein inhibits the reaction [baicalein results in decreased expression of WNT3A protein] |
CTD |
PMID:38317500 |
|
NCBI chr 5:146,680,757...146,687,154
Ensembl chr 5:146,681,436...146,687,154
|
|
G |
Tgfb1 |
transforming growth factor, beta 1 |
multiple interactions |
EXP ISO |
baicalein inhibits the reaction [TGFB1 protein results in increased expression of COL1A2 mRNA] 5-hydroxydecanoic acid inhibits the reaction [baicalein inhibits the reaction [Bleomycin results in increased expression of TGFB1 protein]] baicalein inhibits the reaction [TGFB1 protein results in decreased expression of SPRY1 protein]; baicalein inhibits the reaction [TGFB1 protein results in increased expression of ACTA2 mRNA]; baicalein inhibits the reaction [TGFB1 protein results in increased expression of ACTA2 protein]; baicalein inhibits the reaction [TGFB1 protein results in increased expression of COL1A1 protein]; baicalein inhibits the reaction [TGFB1 protein results in increased expression of FN1 protein]; baicalein inhibits the reaction [TGFB1 protein results in increased expression of MIR21 mRNA]; baicalein inhibits the reaction [TGFB1 protein results in increased phosphorylation of STAT3 protein]; MIR21 mRNA inhibits the reaction [baicalein inhibits the reaction [TGFB1 protein results in increased expression of ACTA2 protein]]; SPRY1 protein affects the reaction [baicalein inhibits the reaction [TGFB1 protein results in increased expression of ACTA2 protein]] |
CTD |
PMID:19474275 PMID:30201452 PMID:37783230 |
|
NCBI chr 1:81,196,532...81,212,848
Ensembl chr 1:81,196,532...81,212,847
|
|
G |
Th |
tyrosine hydroxylase |
multiple interactions |
ISO |
baicalein inhibits the reaction [Rotenone results in decreased expression of TH protein] |
CTD |
PMID:27425033 |
|
NCBI chr 1:198,071,500...198,078,832
Ensembl chr 1:198,071,503...198,109,767
|
|
G |
Tnf |
tumor necrosis factor |
decreases expression multiple interactions |
ISO |
baicalein results in decreased expression of TNF protein baicalein inhibits the reaction [Cholesterol, LDL analog results in increased expression of TNF protein] baicalein inhibits the reaction [Benzo(a)pyrene results in increased expression of TNF protein] |
CTD |
PMID:20850421 PMID:22369883 PMID:38230788 |
|
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
G |
Tp53 |
tumor protein p53 |
increases expression affects binding multiple interactions |
ISO EXP |
baicalein results in increased expression of TP53 protein baicalein binds to TP53 protein baicalein inhibits the reaction [Cholesterol, LDL analog results in increased expression of TP53 mRNA]; baicalein inhibits the reaction [Polymyxin B results in increased acetylation of TP53 protein]; SIRT1 protein promotes the reaction [baicalein inhibits the reaction [Polymyxin B results in increased acetylation of TP53 protein]] |
CTD |
PMID:11513834 PMID:21457722 PMID:37354967 PMID:38230788 |
|
NCBI chr10:54,300,070...54,311,525
Ensembl chr10:54,300,048...54,311,524
|
|
G |
Vegfa |
vascular endothelial growth factor A |
decreases expression |
ISO |
baicalein results in decreased expression of VEGFA protein |
CTD |
PMID:16638750 PMID:36988316 |
|
NCBI chr 9:14,955,300...14,970,641
Ensembl chr 9:14,955,300...14,970,641
|
|
G |
Wnt3a |
Wnt family member 3A |
decreases expression multiple interactions |
ISO |
baicalein results in decreased expression of WNT3A protein STMN1 protein inhibits the reaction [baicalein results in decreased expression of WNT3A protein] |
CTD |
PMID:38317500 |
|
NCBI chr10:44,034,174...44,078,366
Ensembl chr10:44,034,194...44,078,324
|
|
G |
Xbp1 |
X-box binding protein 1 |
multiple interactions |
EXP |
baicalein inhibits the reaction [Carbon Tetrachloride results in increased expression of XBP1 protein] |
CTD |
PMID:33779329 |
|
NCBI chr14:80,390,629...80,395,713
Ensembl chr14:80,390,643...80,395,693
|
|
G |
Xdh |
xanthine dehydrogenase |
multiple interactions |
ISO |
baicalein inhibits the reaction [[Biological Products co-treated with potassium oxonate] results in increased activity of XDH protein] |
CTD |
PMID:34044073 |
|
NCBI chr 6:21,530,463...21,592,172
Ensembl chr 6:21,530,113...21,592,268
|
|
G |
Xiap |
X-linked inhibitor of apoptosis |
multiple interactions |
ISO |
baicalein inhibits the reaction [[Galactosamine co-treated with Lipopolysaccharides] results in decreased activity of XIAP protein] |
CTD |
PMID:20850421 |
|
NCBI chr X:120,890,537...120,938,413
Ensembl chr X:120,897,907...120,934,700
|
|
|
G |
Ache |
acetylcholinesterase |
multiple interactions increases expression |
EXP |
baicalin results in increased expression of and results in increased activity of ACHE protein baicalin results in increased expression of ACHE mRNA |
CTD |
PMID:27019979 |
|
NCBI chr12:19,406,133...19,413,713
Ensembl chr12:19,407,360...19,413,651
|
|
G |
Ahr |
aryl hydrocarbon receptor |
increases activity |
ISO |
baicalin results in increased activity of AHR protein |
CTD |
PMID:17869316 PMID:26204831 |
|
NCBI chr 6:52,234,089...52,271,568
Ensembl chr 6:52,234,089...52,271,568
|
|
G |
Aif1 |
allograft inflammatory factor 1 |
multiple interactions |
ISO |
baicalin inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of AIF1 protein] |
CTD |
PMID:38016618 |
|
NCBI chr20:3,646,784...3,652,670
Ensembl chr20:3,646,777...3,652,668
|
|
G |
Alb |
albumin |
multiple interactions |
ISO |
baicalin inhibits the reaction [Arsenic Trioxide results in decreased expression of ALB protein] |
CTD |
PMID:35088608 |
|
NCBI chr14:17,607,397...17,622,814
Ensembl chr14:17,607,381...17,622,836
|
|
G |
Alox5 |
arachidonate 5-lipoxygenase |
multiple interactions |
EXP |
baicalin inhibits the reaction [Hydrogen Peroxide affects the localization of and results in increased activity of ALOX5 protein] |
CTD |
PMID:20139896 |
|
NCBI chr 4:149,531,329...149,578,696
Ensembl chr 4:149,531,515...149,578,743
|
|
G |
Angpt1 |
angiopoietin 1 |
multiple interactions |
EXP |
baicalin inhibits the reaction [Streptozocin results in decreased expression of ANGPT1 mRNA] |
CTD |
PMID:34414639 |
|
NCBI chr 7:73,528,345...73,783,953
Ensembl chr 7:73,531,486...73,784,067
|
|
G |
Atf2 |
activating transcription factor 2 |
multiple interactions |
EXP |
baicalin inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of ATF2 protein] |
CTD |
PMID:24312512 |
|
NCBI chr 3:58,718,323...58,795,280
Ensembl chr 3:58,718,332...58,795,236
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
increases expression multiple interactions |
ISO EXP |
baicalin results in increased expression of BAX protein baicalin affects the reaction [Rotenone results in increased expression of BAX mRNA]; baicalin inhibits the reaction [Rotenone results in increased expression of BAX protein] baicalin inhibits the reaction [Arsenic Trioxide results in increased expression of BAX mRNA]; baicalin inhibits the reaction [Arsenic Trioxide results in increased expression of BAX protein]; baicalin inhibits the reaction [Gentamicins results in increased expression of BAX mRNA]; baicalin inhibits the reaction [Gentamicins results in increased expression of BAX protein] baicalin inhibits the reaction [Rotenone affects the expression of BAX protein] |
CTD |
PMID:21457722 PMID:25423838 PMID:31021006 PMID:34333357 PMID:35088608 PMID:36446982 More...
|
|
NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
multiple interactions decreases expression |
EXP ISO |
baicalin inhibits the reaction [Rotenone affects the expression of BCL2 protein] baicalin results in decreased expression of BCL2 protein baicalin affects the reaction [Rotenone results in decreased expression of BCL2 mRNA]; baicalin inhibits the reaction [Rotenone results in decreased expression of BCL2 protein] baicalin inhibits the reaction [Arsenic Trioxide results in decreased expression of BCL2 mRNA]; baicalin inhibits the reaction [Arsenic Trioxide results in decreased expression of BCL2 protein]; baicalin inhibits the reaction [Gentamicins results in decreased expression of BCL2 mRNA]; baicalin inhibits the reaction [Gentamicins results in decreased expression of BCL2 protein] |
CTD |
PMID:25423838 PMID:31021006 PMID:34333357 PMID:35088608 PMID:36446982 |
|
NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743 Ensembl chr13:22,684,989...22,853,743
|
|
G |
Casp1 |
caspase 1 |
multiple interactions |
ISO |
baicalin inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of CASP1 protein]; baicalin inhibits the reaction [[1-Methyl-4-phenylpyridinium co-treated with SNCA protein] results in increased expression of CASP1 protein]; NFE2L2 protein affects the reaction [baicalin inhibits the reaction [[1-Methyl-4-phenylpyridinium co-treated with SNCA protein] results in increased expression of CASP1 protein]] |
CTD |
PMID:38016618 |
|
NCBI chr 8:2,587,812...2,597,403
Ensembl chr 8:2,587,831...2,597,383
|
|
G |
Casp3 |
caspase 3 |
multiple interactions |
EXP ISO |
baicalin inhibits the reaction [Rotenone affects the expression of CASP3 protein] baicalin affects the reaction [Rotenone results in decreased activity of CASP3 protein] baicalin inhibits the reaction [Arsenic Trioxide results in increased expression of CASP3 mRNA]; baicalin inhibits the reaction [Arsenic Trioxide results in increased expression of CASP3 protein]; baicalin inhibits the reaction [Gentamicins results in increased cleavage of CASP3 protein] |
CTD |
PMID:25423838 PMID:31021006 PMID:34333357 PMID:35088608 PMID:36446982 |
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Cat |
catalase |
multiple interactions |
ISO |
baicalin inhibits the reaction [Arsenic Trioxide results in decreased activity of CAT protein] |
CTD |
PMID:34333357 PMID:35088608 |
|
NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478
|
|
G |
Ccna2 |
cyclin A2 |
decreases expression |
ISO |
baicalin results in decreased expression of CCNA2 protein |
CTD |
PMID:21457722 |
|
NCBI chr 2:119,427,239...119,433,645
Ensembl chr 2:119,426,089...119,433,577
|
|
G |
Ccnd1 |
cyclin D1 |
increases expression decreases expression multiple interactions |
ISO |
baicalin results in increased expression of CCND1 mRNA baicalin results in decreased expression of CCND1 protein N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [baicalin results in increased expression of CCND1 mRNA] |
CTD |
PMID:19160421 PMID:21457722 |
|
NCBI chr 1:200,089,002...200,098,524
Ensembl chr 1:200,089,002...200,098,602
|
|
G |
Col1a2 |
collagen type I alpha 2 chain |
multiple interactions |
EXP |
baicalin inhibits the reaction [TGFB1 protein results in increased expression of COL1A2 mRNA] |
CTD |
PMID:19474275 |
|
NCBI chr 4:32,563,938...32,598,868
Ensembl chr 4:32,563,381...32,598,867
|
|
G |
Cyp1a1 |
cytochrome P450, family 1, subfamily a, polypeptide 1 |
multiple interactions increases expression |
ISO |
3',4'-dimethoxyflavone inhibits the reaction [baicalin results in increased expression of CYP1A1 mRNA]; 3',4'-dimethoxyflavone inhibits the reaction [baicalin results in increased expression of CYP1A1 protein]; baicalin inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of CYP1A1 mRNA] baicalin results in increased expression of CYP1A1 mRNA; baicalin results in increased expression of CYP1A1 protein |
CTD |
PMID:18451504 PMID:26204831 |
|
NCBI chr 8:58,096,021...58,102,130
Ensembl chr 8:58,096,077...58,102,125
|
|
G |
Cyp1a2 |
cytochrome P450, family 1, subfamily a, polypeptide 2 |
multiple interactions increases expression |
ISO |
3',4'-dimethoxyflavone inhibits the reaction [baicalin results in increased expression of CYP1A2 mRNA]; 3',4'-dimethoxyflavone inhibits the reaction [baicalin results in increased expression of CYP1A2 protein] resveratrol inhibits the reaction [baicalin results in increased expression of CYP1A2 mRNA]; resveratrol inhibits the reaction [baicalin results in increased expression of CYP1A2 protein] baicalin results in increased expression of CYP1A2 mRNA; baicalin results in increased expression of CYP1A2 protein |
CTD |
PMID:26204831 |
|
NCBI chr 8:58,075,367...58,082,255
Ensembl chr 8:58,075,367...58,082,312
|
|
G |
Egf |
epidermal growth factor |
multiple interactions |
ISO |
baicalin inhibits the reaction [EGF protein results in increased phosphorylation of EGFR protein]; baicalin inhibits the reaction [EGF protein results in increased phosphorylation of ELK1 protein] |
CTD |
PMID:25625231 |
|
NCBI chr 2:218,219,408...218,302,359
Ensembl chr 2:218,219,415...218,302,064
|
|
G |
Egfr |
epidermal growth factor receptor |
multiple interactions |
ISO |
baicalin inhibits the reaction [EGF protein results in increased phosphorylation of EGFR protein] |
CTD |
PMID:25625231 |
|
NCBI chr14:91,176,979...91,349,722
Ensembl chr14:91,177,067...91,344,382
|
|
G |
Elk1 |
ETS transcription factor ELK1 |
multiple interactions |
ISO |
baicalin inhibits the reaction [EGF protein results in increased phosphorylation of ELK1 protein] |
CTD |
PMID:25625231 |
|
NCBI chr X:1,138,826...1,155,713
Ensembl chr X:1,139,756...1,155,713
|
|
G |
Ern1 |
endoplasmic reticulum to nucleus signaling 1 |
multiple interactions |
ISO |
baicalin inhibits the reaction [Palmitic Acid results in increased phosphorylation of ERN1 protein] |
CTD |
PMID:29031535 |
|
NCBI chr10:91,326,889...91,421,201
Ensembl chr10:91,330,654...91,421,029
|
|
G |
Foxa2 |
forkhead box A2 |
decreases expression |
ISO |
baicalin results in decreased expression of FOXA2 mRNA; baicalin results in decreased expression of FOXA2 protein |
CTD |
PMID:32687838 |
|
NCBI chr 3:135,470,123...135,474,326
Ensembl chr 3:135,470,131...135,474,326
|
|
G |
Got1 |
glutamic-oxaloacetic transaminase 1 |
multiple interactions |
EXP |
baicalin inhibits the reaction [tert-Butylhydroperoxide results in increased activity of GOT1 protein] |
CTD |
PMID:15645217 |
|
NCBI chr 1:242,357,293...242,381,535
Ensembl chr 1:242,357,306...242,380,633
|
|
G |
Gpt |
glutamic--pyruvic transaminase |
multiple interactions |
EXP ISO |
baicalin inhibits the reaction [tert-Butylhydroperoxide results in increased activity of GPT protein] baicalin inhibits the reaction [Arsenic Trioxide results in increased activity of GPT protein] |
CTD |
PMID:15645217 PMID:35088608 |
|
NCBI chr 7:108,416,646...108,419,495
Ensembl chr 7:108,416,642...108,419,494
|
|
G |
Hes1 |
hes family bHLH transcription factor 1 |
increases expression multiple interactions |
ISO |
baicalin results in increased expression of HES1 mRNA N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [baicalin results in increased expression of HES1 mRNA] |
CTD |
PMID:19160421 |
|
NCBI chr11:70,705,763...70,708,176
Ensembl chr11:70,705,764...70,708,192
|
|
G |
Hey1 |
hes-related family bHLH transcription factor with YRPW motif 1 |
increases expression multiple interactions |
ISO |
baicalin results in increased expression of HEY1 mRNA N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [baicalin results in increased expression of HEY1 mRNA] |
CTD |
PMID:19160421 |
|
NCBI chr 2:93,096,605...93,100,316
Ensembl chr 2:93,095,498...93,100,312
|
|
G |
Hey2 |
hes-related family bHLH transcription factor with YRPW motif 2 |
multiple interactions increases expression |
ISO |
N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [baicalin results in increased expression of HEY2 mRNA] |
CTD |
PMID:19160421 |
|
NCBI chr 1:26,822,131...26,832,218
Ensembl chr 1:26,822,131...26,832,218
|
|
G |
Hmox1 |
heme oxygenase 1 |
multiple interactions increases expression |
ISO EXP |
[baicalin co-treated with 1-Methyl-4-phenylpyridinium co-treated with SNCA protein] results in increased expression of HMOX1 protein; baicalin inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of HMOX1 protein]; baicalin promotes the reaction [Carbon Tetrachloride results in increased expression of HMOX1 mRNA]; baicalin promotes the reaction [Carbon Tetrachloride results in increased expression of HMOX1 protein]; NFE2L2 protein affects the reaction [[baicalin co-treated with 1-Methyl-4-phenylpyridinium co-treated with SNCA protein] results in increased expression of HMOX1 protein] baicalin results in increased expression of HMOX1 mRNA; baicalin results in increased expression of HMOX1 protein |
CTD |
PMID:16824337 PMID:18187930 PMID:38016618 |
|
NCBI chr19:13,466,287...13,474,082
Ensembl chr19:13,467,244...13,474,079
|
|
G |
Hnf1a |
HNF1 homeobox A |
multiple interactions decreases expression |
ISO |
baicalin inhibits the reaction [HNF4A protein binds to HNF1A promoter]; HNF1A protein promotes the reaction [baicalin results in decreased secretion of Hepatitis B Surface Antigens]; HNF4A protein promotes the reaction [baicalin results in decreased expression of HNF1A mRNA]; HNF4A protein promotes the reaction [baicalin results in decreased expression of HNF1A protein] baicalin results in decreased expression of HNF1A mRNA; baicalin results in decreased expression of HNF1A protein |
CTD |
PMID:32687838 |
|
NCBI chr12:41,638,536...41,672,806
Ensembl chr12:41,645,587...41,672,104
|
|
G |
Hnf4a |
hepatocyte nuclear factor 4, alpha |
decreases expression multiple interactions |
ISO |
baicalin results in decreased expression of HNF4A protein baicalin inhibits the reaction [HNF4A protein binds to HNF1A promoter]; HNF4A protein promotes the reaction [baicalin results in decreased expression of HNF1A mRNA]; HNF4A protein promotes the reaction [baicalin results in decreased expression of HNF1A protein]; HNF4A protein promotes the reaction [baicalin results in decreased secretion of Hepatitis B Surface Antigens] baicalin results in decreased expression of HNF4A mRNA; baicalin results in decreased expression of HNF4A protein |
CTD |
PMID:32687838 |
|
NCBI chr 3:152,186,787...152,248,320
Ensembl chr 3:152,186,787...152,248,320
|
|
G |
Hspb1 |
heat shock protein family B (small) member 1 |
multiple interactions |
EXP |
baicalin inhibits the reaction [Streptozocin results in increased phosphorylation of HSPB1 protein] |
CTD |
PMID:34414639 |
|
NCBI chr12:20,794,014...20,795,675
Ensembl chr12:20,794,028...20,795,743
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions |
ISO |
baicalin inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of IL1B mRNA]; baicalin inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of IL1B protein]; baicalin inhibits the reaction [[1-Methyl-4-phenylpyridinium co-treated with SNCA protein] results in increased expression of IL1B mRNA]; baicalin inhibits the reaction [[1-Methyl-4-phenylpyridinium co-treated with SNCA protein] results in increased expression of IL1B protein]; baicalin inhibits the reaction [Arsenic Trioxide results in increased expression of IL1B protein]; baicalin inhibits the reaction [Palmitic Acid results in increased secretion of IL1B protein]; NFE2L2 protein affects the reaction [baicalin inhibits the reaction [[1-Methyl-4-phenylpyridinium co-treated with SNCA protein] results in increased expression of IL1B protein]] baicalin inhibits the reaction [Rotenone results in increased expression of IL1B protein] |
CTD |
PMID:29031535 PMID:35088608 PMID:36446982 PMID:38016618 |
|
NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
|
|
G |
Il6 |
interleukin 6 |
decreases expression multiple interactions |
EXP ISO |
baicalin results in decreased expression of IL6 mRNA; baicalin results in decreased expression of IL6 protein baicalin inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of IL6 mRNA]; baicalin inhibits the reaction [[1-Methyl-4-phenylpyridinium co-treated with SNCA protein] results in increased expression of IL6 mRNA]; baicalin inhibits the reaction [Arsenic Trioxide results in increased expression of IL6 protein]; baicalin inhibits the reaction [Palmitic Acid results in increased secretion of IL6 protein] |
CTD |
PMID:22019745 PMID:29031535 PMID:34333357 PMID:35088608 PMID:38016618 |
|
NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
|
|
G |
Ins1 |
insulin 1 |
multiple interactions |
EXP |
baicalin inhibits the reaction [Streptozocin results in decreased expression of INS1 protein] |
CTD |
PMID:34414639 |
|
NCBI chr 1:251,244,973...251,245,540
Ensembl chr 1:251,244,973...251,245,536
|
|
G |
Itga4 |
integrin subunit alpha 4 |
multiple interactions |
EXP |
baicalin inhibits the reaction [ITGA4 protein results in increased expression of KDR protein]; baicalin inhibits the reaction [ITGA4 protein results in increased expression of VEGFA protein] |
CTD |
PMID:36731809 |
|
NCBI chr 3:64,162,764...64,235,010
Ensembl chr 3:64,163,085...64,233,715
|
|
G |
Jak2 |
Janus kinase 2 |
multiple interactions |
ISO |
baicalin promotes the reaction [Arsenic Trioxide results in increased phosphorylation of JAK2 protein] |
CTD |
PMID:35088608 |
|
NCBI chr 1:226,995,334...227,054,381
Ensembl chr 1:226,995,334...227,054,189
|
|
G |
Kdr |
kinase insert domain receptor |
multiple interactions |
EXP |
baicalin inhibits the reaction [ITGA4 protein results in increased expression of KDR protein] |
CTD |
PMID:36731809 |
|
NCBI chr14:32,217,871...32,261,018
Ensembl chr14:32,217,871...32,261,018
|
|
G |
Keap1 |
Kelch-like ECH-associated protein 1 |
multiple interactions |
ISO |
baicalin inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of KEAP1 protein]; baicalin promotes the reaction [[1-Methyl-4-phenylpyridinium co-treated with SNCA protein] results in decreased expression of KEAP1 protein] |
CTD |
PMID:38016618 |
|
NCBI chr 8:19,768,375...19,777,862
Ensembl chr 8:19,768,375...19,777,862
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
multiple interactions |
EXP |
baicalin inhibits the reaction [Streptozocin results in increased phosphorylation of MAPK1 protein] |
CTD |
PMID:34414639 |
|
NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
multiple interactions |
EXP |
baicalin inhibits the reaction [Streptozocin results in increased phosphorylation of MAPK3 protein] |
CTD |
PMID:34414639 |
|
NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863
|
|
G |
Myd88 |
MYD88, innate immune signal transduction adaptor |
decreases expression |
EXP |
baicalin results in decreased expression of MYD88 protein |
CTD |
PMID:22019745 |
|
NCBI chr 8:119,074,439...119,078,508
Ensembl chr 8:119,074,437...119,079,415
|
|
G |
Nfe2l2 |
NFE2 like bZIP transcription factor 2 |
multiple interactions |
ISO |
[baicalin co-treated with 1-Methyl-4-phenylpyridinium co-treated with SNCA protein] affects the localization of NFE2L2 protein; baicalin inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of NFE2L2 protein]; baicalin inhibits the reaction [[benzyloxycarbonylleucyl-leucyl-leucine aldehyde co-treated with 1-Methyl-4-phenylpyridinium co-treated with SNCA protein] results in increased ubiquitination of NFE2L2 protein]; baicalin promotes the reaction [[1-Methyl-4-phenylpyridinium co-treated with SNCA protein] results in increased expression of NFE2L2 protein]; baicalin promotes the reaction [[benzyloxycarbonylleucyl-leucyl-leucine aldehyde co-treated with 1-Methyl-4-phenylpyridinium co-treated with SNCA protein] results in increased expression of NFE2L2 protein]; NFE2L2 protein affects the reaction [[baicalin co-treated with 1-Methyl-4-phenylpyridinium co-treated with SNCA protein] results in increased expression of HMOX1 protein]; NFE2L2 protein affects the reaction [baicalin inhibits the reaction [[1-Methyl-4-phenylpyridinium co-treated with SNCA protein] results in increased expression of CASP1 protein]]; NFE2L2 protein affects the reaction [baicalin inhibits the reaction [[1-Methyl-4-phenylpyridinium co-treated with SNCA protein] results in increased expression of IL1B protein]]; NFE2L2 protein affects the reaction [baicalin inhibits the reaction [[1-Methyl-4-phenylpyridinium co-treated with SNCA protein] results in increased expression of NLRP3 protein]]; NFE2L2 protein affects the reaction [baicalin inhibits the reaction [[1-Methyl-4-phenylpyridinium co-treated with SNCA protein] results in increased expression of PYCARD protein]]; NFE2L2 protein affects the reaction [baicalin inhibits the reaction [[1-Methyl-4-phenylpyridinium co-treated with SNCA protein] results in increased phosphorylation of RELA protein]] |
CTD |
PMID:38016618 |
|
NCBI chr 3:60,594,239...60,621,712
Ensembl chr 3:60,594,242...60,621,737
|
|
G |
Nfkbia |
NFKB inhibitor alpha |
increases expression |
EXP |
baicalin results in increased expression of NFKBIA protein |
CTD |
PMID:22019745 |
|
NCBI chr 6:72,858,713...72,861,941
Ensembl chr 6:72,858,712...72,861,941
|
|
G |
Nlrp3 |
NLR family, pyrin domain containing 3 |
multiple interactions |
ISO |
baicalin inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of NLRP3 protein]; baicalin inhibits the reaction [[1-Methyl-4-phenylpyridinium co-treated with SNCA protein] results in increased expression of NLRP3 protein]; baicalin inhibits the reaction [Palmitic Acid results in increased expression of NLRP3 protein]; NFE2L2 protein affects the reaction [baicalin inhibits the reaction [[1-Methyl-4-phenylpyridinium co-treated with SNCA protein] results in increased expression of NLRP3 protein]] |
CTD |
PMID:29031535 PMID:38016618 |
|
NCBI chr10:44,326,770...44,353,814
Ensembl chr10:44,328,566...44,352,811
|
|
G |
Nos2 |
nitric oxide synthase 2 |
multiple interactions decreases expression |
EXP ISO |
baicalin inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 mRNA]; baicalin inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 protein]; mifobate inhibits the reaction [baicalin inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 mRNA]] baicalin results in decreased expression of NOS2 mRNA; baicalin results in decreased expression of NOS2 protein baicalin inhibits the reaction [Carbon Tetrachloride results in increased expression of NOS2 mRNA]; baicalin inhibits the reaction [Carbon Tetrachloride results in increased expression of NOS2 protein] |
CTD |
PMID:18187930 PMID:22019745 PMID:24312512 |
|
NCBI chr10:63,815,308...63,851,208
Ensembl chr10:63,815,308...63,851,210
|
|
G |
Notch1 |
notch receptor 1 |
increases activity increases expression |
ISO |
baicalin results in increased activity of NOTCH1 protein baicalin results in increased expression of NOTCH1 mRNA |
CTD |
PMID:19160421 |
|
NCBI chr 3:9,277,955...9,323,531
Ensembl chr 3:9,278,086...9,323,531
|
|
G |
Nr1h3 |
nuclear receptor subfamily 1, group H, member 3 |
increases expression |
ISO |
Baicalin increases expression of NR1H3 mRNA and protein in foam cells |
RGD |
PMID:27389392 |
RGD:401842390 |
NCBI chr 3:77,158,808...77,168,907
Ensembl chr 3:77,158,808...77,168,722
|
|
G |
Pkm |
pyruvate kinase M1/2 |
increases activity |
ISO |
baicalin results in increased activity of PKM protein |
CTD |
PMID:25388478 |
|
NCBI chr 8:60,057,629...60,079,600
Ensembl chr 8:60,057,402...60,079,599
|
|
G |
Pparg |
peroxisome proliferator-activated receptor gamma |
multiple interactions |
EXP |
baicalin inhibits the reaction [Lipopolysaccharides results in increased expression of and results in increased phosphorylation of and results in decreased activity of PPARG protein] |
CTD |
PMID:24312512 |
|
NCBI chr 4:148,423,102...148,548,471
Ensembl chr 4:148,423,194...148,548,468
|
|
G |
Prima1 |
proline rich membrane anchor 1 |
increases expression |
EXP |
baicalin results in increased expression of PRIMA1 mRNA |
CTD |
PMID:27019979 |
|
NCBI chr 6:122,338,365...122,390,955
Ensembl chr 6:122,338,370...122,389,921
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
decreases expression |
EXP |
baicalin results in decreased expression of PTGS2 mRNA; baicalin results in decreased expression of PTGS2 protein |
CTD |
PMID:22019745 |
|
NCBI chr13:62,163,936...62,172,193
Ensembl chr13:62,163,932...62,172,188
|
|
G |
Pycard |
PYD and CARD domain containing |
multiple interactions |
ISO |
baicalin inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of PYCARD protein]; baicalin inhibits the reaction [[1-Methyl-4-phenylpyridinium co-treated with SNCA protein] results in increased expression of PYCARD protein]; NFE2L2 protein affects the reaction [baicalin inhibits the reaction [[1-Methyl-4-phenylpyridinium co-treated with SNCA protein] results in increased expression of PYCARD protein]] |
CTD |
PMID:38016618 |
|
NCBI chr 1:182,601,657...182,603,013
Ensembl chr 1:182,601,174...182,602,955
|
|
G |
Rela |
RELA proto-oncogene, NF-kB subunit |
multiple interactions |
EXP ISO |
baicalin affects the localization of and results in decreased expression of RELA protein baicalin inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased phosphorylation of RELA protein]; baicalin inhibits the reaction [[1-Methyl-4-phenylpyridinium co-treated with SNCA protein] results in increased phosphorylation of RELA protein]; baicalin inhibits the reaction [Arsenic Trioxide results in increased expression of and results in increased phosphorylation of RELA protein]; NFE2L2 protein affects the reaction [baicalin inhibits the reaction [[1-Methyl-4-phenylpyridinium co-treated with SNCA protein] results in increased phosphorylation of RELA protein]] |
CTD |
PMID:22019745 PMID:34333357 PMID:38016618 |
|
NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484
|
|
G |
Snca |
synuclein alpha |
multiple interactions |
ISO |
[baicalin co-treated with 1-Methyl-4-phenylpyridinium co-treated with SNCA protein] affects the localization of NFE2L2 protein; [baicalin co-treated with 1-Methyl-4-phenylpyridinium co-treated with SNCA protein] results in increased expression of HMOX1 protein; baicalin inhibits the reaction [[1-Methyl-4-phenylpyridinium co-treated with SNCA protein] results in increased expression of CASP1 protein]; baicalin inhibits the reaction [[1-Methyl-4-phenylpyridinium co-treated with SNCA protein] results in increased expression of IL1B mRNA]; baicalin inhibits the reaction [[1-Methyl-4-phenylpyridinium co-treated with SNCA protein] results in increased expression of IL1B protein]; baicalin inhibits the reaction [[1-Methyl-4-phenylpyridinium co-treated with SNCA protein] results in increased expression of IL6 mRNA]; baicalin inhibits the reaction [[1-Methyl-4-phenylpyridinium co-treated with SNCA protein] results in increased expression of NLRP3 protein]; baicalin inhibits the reaction [[1-Methyl-4-phenylpyridinium co-treated with SNCA protein] results in increased expression of PYCARD protein]; baicalin inhibits the reaction [[1-Methyl-4-phenylpyridinium co-treated with SNCA protein] results in increased expression of TNF mRNA]; baicalin inhibits the reaction [[1-Methyl-4-phenylpyridinium co-treated with SNCA protein] results in increased phosphorylation of RELA protein]; baicalin inhibits the reaction [[benzyloxycarbonylleucyl-leucyl-leucine aldehyde co-treated with 1-Methyl-4-phenylpyridinium co-treated with SNCA protein] results in increased ubiquitination of NFE2L2 protein]; baicalin promotes the reaction [[1-Methyl-4-phenylpyridinium co-treated with SNCA protein] results in decreased expression of KEAP1 protein]; baicalin promotes the reaction [[1-Methyl-4-phenylpyridinium co-treated with SNCA protein] results in increased expression of NFE2L2 protein]; baicalin promotes the reaction [[benzyloxycarbonylleucyl-leucyl-leucine aldehyde co-treated with 1-Methyl-4-phenylpyridinium co-treated with SNCA protein] results in increased expression of NFE2L2 protein]; NFE2L2 protein affects the reaction [[baicalin co-treated with 1-Methyl-4-phenylpyridinium co-treated with SNCA protein] results in increased expression of HMOX1 protein]; NFE2L2 protein affects the reaction [baicalin inhibits the reaction [[1-Methyl-4-phenylpyridinium co-treated with SNCA protein] results in increased expression of CASP1 protein]]; NFE2L2 protein affects the reaction [baicalin inhibits the reaction [[1-Methyl-4-phenylpyridinium co-treated with SNCA protein] results in increased expression of IL1B protein]]; NFE2L2 protein affects the reaction [baicalin inhibits the reaction [[1-Methyl-4-phenylpyridinium co-treated with SNCA protein] results in increased expression of NLRP3 protein]]; NFE2L2 protein affects the reaction [baicalin inhibits the reaction [[1-Methyl-4-phenylpyridinium co-treated with SNCA protein] results in increased expression of PYCARD protein]]; NFE2L2 protein affects the reaction [baicalin inhibits the reaction [[1-Methyl-4-phenylpyridinium co-treated with SNCA protein] results in increased phosphorylation of RELA protein]] |
CTD |
PMID:38016618 |
|
NCBI chr 4:89,696,420...89,797,240
Ensembl chr 4:89,696,420...89,796,262
|
|
G |
Stat3 |
signal transducer and activator of transcription 3 |
multiple interactions |
ISO |
baicalin promotes the reaction [Arsenic Trioxide results in increased phosphorylation of STAT3 protein] |
CTD |
PMID:35088608 |
|
NCBI chr10:85,811,206...85,863,057
Ensembl chr10:85,811,218...85,863,057
|
|
G |
Tek |
TEK receptor tyrosine kinase |
multiple interactions |
EXP |
baicalin inhibits the reaction [Streptozocin results in decreased expression of TEK mRNA] |
CTD |
PMID:34414639 |
|
NCBI chr 5:109,607,077...109,733,805
Ensembl chr 5:109,607,077...109,733,804
|
|
G |
Tfam |
transcription factor A, mitochondrial |
decreases expression multiple interactions |
ISO |
baicalin results in decreased expression of TFAM mRNA baicalin inhibits the reaction [Rotenone results in decreased expression of TFAM mRNA] |
CTD |
PMID:36446982 |
|
NCBI chr20:17,356,243...17,368,293
Ensembl chr20:17,356,197...17,368,292
|
|
G |
Tgfb1 |
transforming growth factor, beta 1 |
multiple interactions |
EXP |
baicalin inhibits the reaction [Streptozocin results in decreased expression of TGFB1 mRNA]; baicalin inhibits the reaction [TGFB1 protein results in increased expression of COL1A2 mRNA] |
CTD |
PMID:19474275 PMID:34414639 |
|
NCBI chr 1:81,196,532...81,212,848
Ensembl chr 1:81,196,532...81,212,847
|
|
G |
Th |
tyrosine hydroxylase |
multiple interactions |
ISO |
baicalin inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of TH protein] |
CTD |
PMID:38016618 |
|
NCBI chr 1:198,071,500...198,078,832
Ensembl chr 1:198,071,503...198,109,767
|
|
G |
Tlr4 |
toll-like receptor 4 |
decreases expression multiple interactions |
EXP ISO |
baicalin results in decreased expression of TLR4 protein baicalin inhibits the reaction [Arsenic Trioxide results in increased expression of TLR4 protein] baicalin inhibits the reaction [Lipopolysaccharides results in increased expression of TLR4 protein] |
CTD |
PMID:22019745 PMID:24312512 PMID:34333357 |
|
NCBI chr 5:80,145,867...80,159,501
Ensembl chr 5:80,145,826...80,159,628
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions decreases expression |
ISO EXP |
baicalin inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of TNF mRNA]; baicalin inhibits the reaction [[1-Methyl-4-phenylpyridinium co-treated with SNCA protein] results in increased expression of TNF mRNA]; baicalin inhibits the reaction [Arsenic Trioxide results in increased expression of TNF protein]; baicalin inhibits the reaction [Carbon Tetrachloride results in increased expression of TNF mRNA]; baicalin inhibits the reaction [Carbon Tetrachloride results in increased expression of TNF protein] baicalin results in decreased expression of TNF mRNA; baicalin results in decreased expression of TNF protein baicalin inhibits the reaction [Paraquat results in increased expression of TNF protein] |
CTD |
PMID:16824337 PMID:18187930 PMID:22019745 PMID:34333357 PMID:35088608 PMID:38016618 More...
|
|
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
G |
Tp53 |
tumor protein p53 |
increases expression |
ISO |
baicalin results in increased expression of TP53 protein |
CTD |
PMID:21457722 |
|
NCBI chr10:54,300,070...54,311,525
Ensembl chr10:54,300,048...54,311,524
|
|
G |
Txnip |
thioredoxin interacting protein |
multiple interactions |
ISO |
baicalin inhibits the reaction [Palmitic Acid results in increased expression of TXNIP protein]; dorsomorphin inhibits the reaction [baicalin inhibits the reaction [Palmitic Acid results in increased expression of TXNIP protein]] |
CTD |
PMID:29031535 |
|
NCBI chr 2:184,093,079...184,096,882
Ensembl chr 2:184,092,991...184,096,886
|
|
G |
Usp27x |
ubiquitin specific peptidase 27, X-linked |
multiple interactions |
EXP |
baicalin inhibits the reaction [Streptozocin results in increased expression of USP27X protein] |
CTD |
PMID:34414639 |
|
NCBI chr X:15,123,620...15,126,855
Ensembl chr X:15,124,596...15,125,912
|
|
G |
Vegfa |
vascular endothelial growth factor A |
multiple interactions |
EXP |
baicalin inhibits the reaction [ITGA4 protein results in increased expression of VEGFA protein] |
CTD |
PMID:36731809 |
|
NCBI chr 9:14,955,300...14,970,641
Ensembl chr 9:14,955,300...14,970,641
|
|
G |
Vegfc |
vascular endothelial growth factor C |
multiple interactions |
EXP |
baicalin inhibits the reaction [Streptozocin results in decreased expression of VEGFC mRNA] |
CTD |
PMID:34414639 |
|
NCBI chr16:37,712,251...37,827,845
Ensembl chr16:37,712,262...37,827,848
|
|
G |
Xdh |
xanthine dehydrogenase |
multiple interactions |
ISO |
baicalin inhibits the reaction [[Biological Products co-treated with potassium oxonate] results in increased activity of XDH protein] |
CTD |
PMID:34044073 |
|
NCBI chr 6:21,530,463...21,592,172
Ensembl chr 6:21,530,113...21,592,268
|
|
|
G |
Abca1 |
ATP binding cassette subfamily A member 1 |
increases expression |
ISO |
berberine increases expression of abca1 protein in mouse liver and human hepatocytes |
RGD |
PMID:29505790 |
RGD:19165131 |
NCBI chr 5:67,678,267...67,801,162
Ensembl chr 5:67,681,297...67,801,170
|
|
G |
Abcb1a |
ATP binding cassette subfamily B member 1A |
increases expression |
EXP |
Berberine results in increased expression of ABCB1A mRNA |
CTD |
PMID:20410605 |
|
NCBI chr 4:25,357,467...25,529,941
Ensembl chr 4:25,158,362...25,442,709
|
|
G |
Abcb1b |
ATP-binding cassette, sub-family B member 1B |
increases expression |
EXP |
Berberine results in increased expression of ABCB1B mRNA |
CTD |
PMID:20410605 |
|
NCBI chr 4:25,242,761...25,325,194
Ensembl chr 4:25,242,798...25,325,199
|
|
G |
Acadm |
acyl-CoA dehydrogenase medium chain |
multiple interactions |
ISO |
Berberine inhibits the reaction [Ethanol results in decreased expression of ACADM mRNA] |
CTD |
PMID:25455889 |
|
NCBI chr 2:242,858,865...242,883,036
Ensembl chr 2:242,858,865...242,883,147
|
|
G |
Acan |
aggrecan |
decreases expression |
ISO |
Berberine results in decreased expression of ACAN mRNA |
CTD |
PMID:26478571 |
|
NCBI chr 1:132,981,582...133,044,416
Ensembl chr 1:132,981,582...133,043,627
|
|
G |
Ache |
acetylcholinesterase |
multiple interactions decreases activity |
EXP ISO |
Berberine inhibits the reaction [[Cadmium co-treated with Aluminum co-treated with Fluorides] results in increased activity of ACHE protein]; Berberine inhibits the reaction [[Cadmium co-treated with Aluminum co-treated with Fluorides] results in increased expression of ACHE mRNA]; Berberine inhibits the reaction [acetamiprid results in increased activity of ACHE protein] Berberine results in decreased activity of ACHE protein |
CTD |
PMID:29170048 PMID:33844597 PMID:37350525 |
|
NCBI chr12:19,406,133...19,413,713
Ensembl chr12:19,407,360...19,413,651
|
|
G |
Acox1 |
acyl-CoA oxidase 1 |
multiple interactions |
ISO |
Berberine inhibits the reaction [Ethanol results in decreased expression of ACOX1 mRNA] |
CTD |
PMID:25455889 |
|
NCBI chr10:101,406,197...101,431,252
Ensembl chr10:101,406,197...101,431,232
|
|
G |
Acta2 |
actin alpha 2, smooth muscle |
decreases expression multiple interactions |
EXP ISO |
Berberine results in decreased expression of ACTA2 protein Berberine inhibits the reaction [Particulate Matter results in increased expression of ACTA2 mRNA] |
CTD |
PMID:17973934 PMID:37839514 |
|
NCBI chr 1:231,746,527...231,759,307
Ensembl chr 1:231,746,548...231,759,554
|
|
G |
Adipoq |
adiponectin, C1Q and collagen domain containing |
multiple interactions |
ISO |
Berberine inhibits the reaction [Clozapine results in increased expression of ADIPOQ mRNA]; Berberine inhibits the reaction [Risperidone results in increased expression of ADIPOQ mRNA] |
CTD |
PMID:20564506 |
|
NCBI chr11:77,721,912...77,735,644
Ensembl chr11:77,721,912...77,735,564
|
|
G |
Ager |
advanced glycosylation end product-specific receptor |
multiple interactions |
EXP |
Berberine inhibits the reaction [Bortezomib results in increased expression of AGER mRNA] |
CTD |
PMID:35121005 |
|
NCBI chr20:4,148,150...4,151,361
Ensembl chr20:4,147,890...4,151,078
|
|
G |
Ahr |
aryl hydrocarbon receptor |
increases activity |
EXP ISO |
Berberine results in increased activity of AHR protein |
CTD |
PMID:16046213 |
|
NCBI chr 6:52,234,089...52,271,568
Ensembl chr 6:52,234,089...52,271,568
|
|
G |
Akt1 |
AKT serine/threonine kinase 1 |
multiple interactions decreases phosphorylation increases phosphorylation |
ISO EXP |
Berberine inhibits the reaction [Glucose results in decreased phosphorylation of AKT1 protein] Berberine results in decreased phosphorylation of AKT1 protein Berberine inhibits the reaction [Thioacetamide results in increased phosphorylation of AKT1 protein] Berberine results in increased phosphorylation of AKT1 protein |
CTD |
PMID:23954465 PMID:30138605 PMID:33325633 |
|
NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921
|
|
G |
Akt2 |
AKT serine/threonine kinase 2 |
multiple interactions |
ISO |
Berberine inhibits the reaction [Dexamethasone results in decreased expression of AKT2 mRNA] |
CTD |
PMID:20462044 |
|
NCBI chr 1:82,877,228...82,933,828
Ensembl chr 1:82,883,547...82,933,817
|
|
G |
Alb |
albumin |
multiple interactions |
EXP |
Berberine inhibits the reaction [Thioacetamide results in decreased expression of ALB protein] |
CTD |
PMID:30138605 |
|
NCBI chr14:17,607,397...17,622,814
Ensembl chr14:17,607,381...17,622,836
|
|
G |
App |
amyloid beta precursor protein |
multiple interactions |
EXP |
Berberine inhibits the reaction [[Cadmium co-treated with Aluminum co-treated with Fluorides] results in increased expression of APP mRNA] |
CTD |
PMID:29170048 |
|
NCBI chr11:24,019,774...24,236,584
Ensembl chr11:24,019,778...24,236,561
|
|
G |
Aurkb |
aurora kinase B |
decreases expression |
ISO |
Berberine results in decreased expression of AURKB mRNA |
CTD |
PMID:27311644 |
|
NCBI chr10:53,744,290...53,750,831
Ensembl chr10:53,745,142...53,750,837
|
|
G |
Aurkc |
aurora kinase C |
increases expression |
ISO |
Berberine results in increased expression of AURKC mRNA |
CTD |
PMID:27311644 |
|
NCBI chr 1:66,843,653...66,849,775
Ensembl chr 1:66,843,653...66,864,386
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
multiple interactions increases expression |
EXP ISO |
[Berberine co-treated with Thioacetamide] results in increased expression of BAX mRNA; Berberine inhibits the reaction [Chlorpyrifos results in increased expression of BAX mRNA]; Berberine inhibits the reaction [Mercuric Chloride results in increased expression of BAX protein] Berberine results in increased expression of BAX mRNA; Berberine results in increased expression of BAX protein [Berberine co-treated with Cisplatin] results in increased expression of BAX protein; [Berberine co-treated with Niacinamide] results in increased expression of BAX protein; Acetylcysteine inhibits the reaction [[Berberine co-treated with Cisplatin] results in increased expression of BAX protein]; SRT1720 inhibits the reaction [Berberine results in increased expression of BAX protein] |
CTD |
PMID:16505103 PMID:20656010 PMID:25600690 PMID:26712469 PMID:30138605 PMID:35439518 PMID:36070022 More...
|
|
NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368
|
|
G |
Bbc3 |
Bcl-2 binding component 3 |
increases expression multiple interactions |
ISO |
Berberine results in increased expression of BBC3 mRNA [Berberine co-treated with Niacinamide] results in increased expression of BBC3 mRNA |
CTD |
PMID:26712469 |
|
NCBI chr 1:77,013,281...77,022,509
Ensembl chr 1:77,014,543...77,022,509
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
decreases expression increases expression multiple interactions |
ISO EXP |
Berberine results in decreased expression of BCL2 mRNA; Berberine results in decreased expression of BCL2 protein Berberine results in increased expression of BCL2 protein Berberine inhibits the reaction [Chlorpyrifos results in decreased expression of BCL2 mRNA]; Berberine inhibits the reaction [Mercuric Chloride results in decreased expression of BCL2 protein]; Berberine inhibits the reaction [Thioacetamide results in increased expression of BCL2 mRNA] [Berberine co-treated with Cisplatin] results in decreased expression of BCL2 protein; [Berberine co-treated with Niacinamide] results in decreased expression of BCL2 protein; Berberine inhibits the reaction [Glucose results in decreased expression of BCL2 protein] |
CTD |
PMID:16505103 PMID:20656010 PMID:23954465 PMID:24751971 PMID:25600690 PMID:26712469 PMID:30138605 PMID:35439518 PMID:36070022 More...
|
|
NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743 Ensembl chr13:22,684,989...22,853,743
|
|
G |
Bcl2l1 |
Bcl2-like 1 |
decreases expression |
ISO |
Berberine results in decreased expression of BCL2L1 protein |
CTD |
PMID:16505103 |
|
NCBI chr 3:141,253,508...141,304,582
Ensembl chr 3:141,253,523...141,303,479 Ensembl chr 1:141,253,523...141,303,479
|
|
G |
Bcl2l11 |
Bcl2-like 11 |
multiple interactions increases expression |
ISO |
[Berberine co-treated with Niacinamide] results in increased expression of BCL2L11 mRNA Berberine results in increased expression of BCL2L11 mRNA |
CTD |
PMID:26712469 |
|
NCBI chr 3:115,366,783...115,404,068
Ensembl chr 3:115,366,646...115,404,068
|
|
G |
Becn1 |
beclin 1 |
multiple interactions |
EXP ISO |
Berberine inhibits the reaction [Chlorpyrifos results in decreased expression of BECN1 mRNA] Berberine promotes the reaction [[Water deficiency co-treated with NG-Nitroarginine Methyl Ester co-treated with Indomethacin co-treated with Iohexol] results in increased expression of BECN1 protein] |
CTD |
PMID:35439518 PMID:38705399 |
|
NCBI chr10:86,231,387...86,246,742
Ensembl chr10:86,231,388...86,246,742
|
|
G |
Bglap |
bone gamma-carboxyglutamate protein |
increases expression multiple interactions |
ISO |
Berberine results in increased expression of BGLAP mRNA; Berberine results in increased expression of BGLAP protein CTNNB1 mutant form inhibits the reaction [Berberine results in increased expression of BGLAP protein]; DKK1 protein inhibits the reaction [Berberine results in increased expression of BGLAP protein] |
CTD |
PMID:26478571 |
|
NCBI chr 2:173,838,518...173,839,495
Ensembl chr 2:173,838,518...173,839,495
|
|
G |
Birc5 |
baculoviral IAP repeat-containing 5 |
affects binding |
ISO |
Berberine binds to BIRC5 promoter |
CTD |
PMID:17968851 |
|
NCBI chr10:103,072,530...103,081,382
Ensembl chr10:103,073,408...103,081,380
|
|
G |
Bnip3 |
BCL2 interacting protein 3 |
multiple interactions increases expression |
ISO |
[Cisplatin co-treated with Berberine] results in increased expression of BNIP3 protein Berberine promotes the reaction [[Water deficiency co-treated with NG-Nitroarginine Methyl Ester co-treated with Indomethacin co-treated with Iohexol] results in increased expression of BNIP3 protein] Berberine results in increased expression of BNIP3 protein |
CTD |
PMID:36070022 PMID:38705399 |
|
NCBI chr 1:193,708,164...193,725,348
Ensembl chr 1:193,708,167...193,725,359
|
|
G |
Bnip3l |
BCL2 interacting protein 3 like |
increases expression multiple interactions |
ISO |
Berberine results in increased expression of BNIP3L protein [Cisplatin co-treated with Berberine] results in increased expression of BNIP3L protein; BNIP3L protein affects the reaction [[Berberine co-treated with Cisplatin] results in increased lipidation of MAP1LC3B protein] |
CTD |
PMID:36070022 |
|
NCBI chr15:41,174,594...41,197,730
Ensembl chr15:41,174,594...41,197,803
|
|
G |
Casp1 |
caspase 1 |
multiple interactions |
ISO |
Berberine inhibits the reaction [[Water deficiency co-treated with NG-Nitroarginine Methyl Ester co-treated with Indomethacin co-treated with Iohexol] results in increased expression of and results in increased cleavage of CASP1 protein]; Berberine inhibits the reaction [[Water deficiency co-treated with NG-Nitroarginine Methyl Ester co-treated with Indomethacin co-treated with Iohexol] results in increased expression of CASP1 mRNA] |
CTD |
PMID:38705399 |
|
NCBI chr 8:2,587,812...2,597,403
Ensembl chr 8:2,587,831...2,597,383
|
|
G |
Casp3 |
caspase 3 |
multiple interactions increases activity increases cleavage increases expression |
ISO EXP |
[Berberine co-treated with Cisplatin] results in increased cleavage of CASP3 protein; [Berberine co-treated with Niacinamide] results in increased cleavage of CASP3 protein; Acetylcysteine inhibits the reaction [[Berberine co-treated with Cisplatin] results in increased cleavage of CASP3 protein]; Berberine results in increased cleavage of and results in increased activity of CASP3 protein Berberine inhibits the reaction [Particulate Matter results in increased expression of CASP3 protein] Berberine increases activity of CASP3 protein in colon epithelial cells Berberine results in increased cleavage of CASP3 protein [Berberine co-treated with Thioacetamide] results in increased expression of CASP3 mRNA; Berberine inhibits the reaction [Chlorpyrifos results in increased expression of CASP3 mRNA]; Berberine inhibits the reaction [Cyclophosphamide results in increased expression of CASP3 protein]; Berberine inhibits the reaction [Mercuric Chloride results in increased activity of CASP3 protein]; Berberine inhibits the reaction [Mercuric Chloride results in increased expression of CASP3 mRNA] Berberine results in increased activity of CASP3 protein Berberine results in increased expression of CASP3 mRNA |
CTD RGD |
PMID:16505103 PMID:20656010 PMID:25600690 PMID:26712469 PMID:30138605 PMID:33460233 PMID:35439518 PMID:36070022 PMID:37839514 PMID:37955270 PMID:29564000 More...
|
RGD:152995489 |
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Casp8 |
caspase 8 |
increases activity |
ISO |
Berberine results in increased activity of CASP8 protein |
CTD |
PMID:20656010 |
|
NCBI chr 9:60,263,863...60,312,542
Ensembl chr 9:60,264,075...60,312,542
|
|
G |
Casp9 |
caspase 9 |
increases cleavage multiple interactions |
ISO EXP |
Berberine results in increased cleavage of CASP9 protein Berberine inhibits the reaction [Particulate Matter results in increased expression of CASP9 protein] [Berberine co-treated with Thioacetamide] results in increased expression of CASP9 mRNA [Berberine co-treated with Niacinamide] results in increased cleavage of CASP9 protein |
CTD |
PMID:16505103 PMID:26712469 PMID:30138605 PMID:37839514 |
|
NCBI chr 5:154,108,872...154,126,628
Ensembl chr 5:154,109,046...154,126,626
|
|
G |
Cat |
catalase |
multiple interactions |
EXP ISO |
Berberine affects the reaction [[Streptozocin co-treated with Dietary Carbohydrates co-treated with Dietary Fats] affects the activity of CAT protein]; Berberine inhibits the reaction [acetamiprid results in decreased activity of CAT protein]; Berberine inhibits the reaction [Bortezomib results in decreased expression of CAT protein]; Berberine inhibits the reaction [Chlorpyrifos results in decreased activity of CAT protein]; Berberine inhibits the reaction [Mercuric Chloride results in decreased activity of CAT protein]; Berberine inhibits the reaction [Thioacetamide results in decreased activity of CAT protein] Berberine inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in decreased expression of CAT protein]; Berberine inhibits the reaction [Particulate Matter results in decreased expression of CAT protein] |
CTD |
PMID:20828602 PMID:24751971 PMID:25600690 PMID:30138605 PMID:33460233 PMID:35121005 PMID:35439518 PMID:35691465 PMID:37350525 PMID:37839514 More...
|
|
NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478
|
|
G |
Ccl2 |
C-C motif chemokine ligand 2 |
multiple interactions |
ISO |
Berberine inhibits the reaction [IL1B protein results in increased expression of CCL2 mRNA]; Berberine inhibits the reaction [IL1B protein results in increased secretion of CCL2 protein]; Berberine inhibits the reaction [TNF protein results in increased expression of CCL2 mRNA]; Berberine inhibits the reaction [TNF protein results in increased secretion of CCL2 protein] Berberine inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of CCL2 protein]; Berberine inhibits the reaction [[Water deficiency co-treated with NG-Nitroarginine Methyl Ester co-treated with Indomethacin co-treated with Iohexol] results in increased expression of CCL2 mRNA] |
CTD |
PMID:16391493 PMID:35691465 PMID:38705399 |
|
NCBI chr10:67,005,424...67,007,222
Ensembl chr10:67,005,424...67,007,226
|
|
G |
Ccnd1 |
cyclin D1 |
decreases expression multiple interactions |
ISO |
Berberine results in decreased expression of CCND1 protein Berberine inhibits the reaction [CDK4 mRNA binds to CCND1 mRNA] |
CTD |
PMID:16505103 PMID:33325633 PMID:36822301 |
|
NCBI chr 1:200,089,002...200,098,524
Ensembl chr 1:200,089,002...200,098,602
|
|
G |
Ccnd2 |
cyclin D2 |
decreases expression |
ISO |
Berberine results in decreased expression of CCND2 protein |
CTD |
PMID:16505103 |
|
NCBI chr 4:159,966,883...159,989,261
Ensembl chr 4:159,962,363...159,989,495
|
|
G |
Ccne1 |
cyclin E1 |
decreases expression |
ISO |
Berberine results in decreased expression of CCNE1 protein |
CTD |
PMID:16505103 |
|
NCBI chr 1:90,781,947...90,791,188
Ensembl chr 1:90,781,949...90,791,101
|
|
G |
Ccnt1 |
cyclin T1 |
multiple interactions |
EXP |
Berberine affects the reaction [[Streptozocin co-treated with Dietary Carbohydrates co-treated with Dietary Fats] affects the expression of CCNT1 mRNA]; Berberine affects the reaction [[Streptozocin co-treated with Dietary Carbohydrates co-treated with Dietary Fats] affects the expression of CCNT1 protein] |
CTD |
PMID:20828602 |
|
NCBI chr 7:129,687,146...129,718,080
Ensembl chr 7:129,691,209...129,717,871
|
|
G |
Cd36 |
CD36 molecule |
increases expression multiple interactions |
ISO |
Berberine results in increased expression of CD36 mRNA Berberine results in increased expression of CD36 mRNA; Berberine results in increased expression of CD36 protein 15-deoxyprostaglandin J2 promotes the reaction [Berberine results in increased expression of CD36 mRNA]; 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Berberine results in increased expression of CD36 protein]; Berberine promotes the reaction [15-deoxyprostaglandin J2 results in increased expression of CD36 mRNA]; Berberine results in increased expression of and affects the localization of CD36 protein; CEBPB protein promotes the reaction [Berberine results in increased expression of CD36 mRNA] |
CTD |
PMID:28038998 PMID:29408570 |
|
NCBI chr 4:17,317,343...17,410,084
Ensembl chr 4:17,354,466...17,513,903
|
|
G |
Cdh1 |
cadherin 1 |
multiple interactions |
ISO |
Berberine inhibits the reaction [Particulate Matter results in decreased expression of CDH1 mRNA] |
CTD |
PMID:37839514 |
|
NCBI chr19:34,492,371...34,561,775
Ensembl chr19:34,492,371...34,561,775
|
|
G |
Cdh2 |
cadherin 2 |
decreases expression |
ISO |
Berberine results in decreased expression of CDH2 mRNA |
CTD |
PMID:26478571 |
|
NCBI chr18:7,776,704...7,990,934
Ensembl chr18:7,776,704...7,990,167
|
|
G |
Cdk2 |
cyclin dependent kinase 2 |
decreases expression |
ISO |
Berberine results in decreased expression of CDK2 protein |
CTD |
PMID:16505103 |
|
NCBI chr 7:1,129,878...1,137,431
Ensembl chr 7:1,129,811...1,137,403
|
|
G |
Cdk4 |
cyclin-dependent kinase 4 |
decreases expression multiple interactions |
ISO |
Berberine results in decreased expression of CDK4 protein Berberine inhibits the reaction [CDK4 mRNA binds to CCND1 mRNA] |
CTD |
PMID:16505103 PMID:36822301 |
|
NCBI chr 7:62,886,124...62,889,562
Ensembl chr 7:62,883,105...62,942,403
|
|
G |
Cdk6 |
cyclin-dependent kinase 6 |
decreases expression |
ISO |
Berberine results in decreased expression of CDK6 protein |
CTD |
PMID:16505103 |
|
NCBI chr 4:30,637,650...30,829,688
Ensembl chr 4:30,646,460...30,829,634
|
|
G |
Cdk9 |
cyclin-dependent kinase 9 |
multiple interactions |
EXP |
Berberine affects the reaction [[Streptozocin co-treated with Dietary Carbohydrates co-treated with Dietary Fats] affects the expression of CDK9 mRNA]; Berberine affects the reaction [[Streptozocin co-treated with Dietary Carbohydrates co-treated with Dietary Fats] affects the expression of CDK9 protein] |
CTD |
PMID:20828602 |
|
NCBI chr 3:15,996,467...16,001,315
Ensembl chr 3:15,996,468...16,002,410
|
|
G |
Cdkn1a |
cyclin-dependent kinase inhibitor 1A |
increases expression |
ISO |
Berberine results in increased expression of CDKN1A protein |
CTD |
PMID:16505103 PMID:23747414 |
|
NCBI chr20:7,149,177...7,159,727
Ensembl chr20:7,149,217...7,159,585
|
|
G |
Cdkn1b |
cyclin-dependent kinase inhibitor 1B |
increases expression |
ISO |
Berberine results in increased expression of CDKN1B protein |
CTD |
PMID:16505103 |
|
NCBI chr 4:167,760,067...167,765,177
Ensembl chr 4:167,760,181...167,764,982
|
|
G |
Cdkn1c |
cyclin-dependent kinase inhibitor 1C |
increases expression |
ISO |
Berberine results in increased expression of CDKN1C mRNA |
CTD |
PMID:26478571 |
|
NCBI chr 1:198,655,394...198,658,097
Ensembl chr 1:198,655,407...198,658,048
|
|
G |
Cebpa |
CCAAT/enhancer binding protein alpha |
multiple interactions decreases expression |
ISO |
Berberine inhibits the reaction [Clozapine results in increased expression of CEBPA mRNA]; Berberine inhibits the reaction [Clozapine results in increased expression of CEBPA protein]; Berberine inhibits the reaction [Risperidone results in increased expression of CEBPA mRNA]; Berberine inhibits the reaction [Risperidone results in increased expression of CEBPA protein] Berberine results in decreased expression of CEBPA mRNA; Berberine results in decreased expression of CEBPA protein |
CTD |
PMID:20564506 PMID:26478571 PMID:37511356 |
|
NCBI chr 1:87,759,631...87,762,303
Ensembl chr 1:87,759,433...87,762,412
|
|
G |
Cebpb |
CCAAT/enhancer binding protein beta |
affects phosphorylation multiple interactions increases expression |
ISO |
Berberine affects the phosphorylation of CEBPB protein 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Berberine results in increased phosphorylation of CEBPB protein]; CEBPB protein promotes the reaction [Berberine results in increased expression of CD36 mRNA] Berberine results in increased expression of CEBPB mRNA |
CTD |
PMID:28038998 |
|
NCBI chr 3:156,398,035...156,399,466
Ensembl chr 3:156,397,052...156,399,473
|
|
G |
Chek1 |
checkpoint kinase 1 |
increases expression |
ISO |
Berberine results in increased expression of CHEK1 protein modified form |
CTD |
PMID:23747414 |
|
NCBI chr 8:36,420,565...36,443,477
Ensembl chr 8:36,420,569...36,441,009
|
|
G |
Chek2 |
checkpoint kinase 2 |
increases expression |
ISO |
Berberine results in increased expression of CHEK2 protein modified form |
CTD |
PMID:23747414 |
|
NCBI chr12:45,788,823...45,821,382
Ensembl chr12:45,788,827...45,821,286
|
|
G |
Col10a1 |
collagen type X alpha 1 chain |
increases expression |
ISO |
Berberine results in increased expression of COL10A1 mRNA |
CTD |
PMID:26478571 |
|
NCBI chr20:38,183,103...38,189,488
Ensembl chr20:38,182,494...38,189,494
|
|
G |
Col1a1 |
collagen type I alpha 1 chain |
increases expression multiple interactions |
ISO |
Berberine results in increased expression of COL1A1 mRNA Berberine inhibits the reaction [Particulate Matter results in increased expression of COL1A1 mRNA] |
CTD |
PMID:26478571 PMID:37839514 |
|
NCBI chr10:79,883,622...79,900,625
Ensembl chr10:79,883,622...79,900,624
|
|
G |
Col2a1 |
collagen type II alpha 1 chain |
decreases expression |
ISO |
Berberine results in decreased expression of COL2A1 mRNA |
CTD |
PMID:26478571 |
|
NCBI chr 7:129,098,489...129,127,560
Ensembl chr 7:129,098,786...129,127,546
|
|
G |
Col3a1 |
collagen type III alpha 1 chain |
multiple interactions |
ISO |
Berberine inhibits the reaction [Particulate Matter results in increased expression of COL3A1 mRNA] |
CTD |
PMID:37839514 |
|
NCBI chr 9:47,374,611...47,410,547
Ensembl chr 9:47,374,593...47,410,547
|
|
G |
Cox4i1 |
cytochrome c oxidase subunit 4i1 |
multiple interactions |
EXP |
Berberine inhibits the reaction [acetamiprid results in decreased expression of COX4I1 mRNA] |
CTD |
PMID:37350525 |
|
NCBI chr19:48,721,680...48,727,920
Ensembl chr19:48,721,199...48,727,921
|
|
G |
Cpt1a |
carnitine palmitoyltransferase 1A |
multiple interactions |
ISO |
Berberine inhibits the reaction [Ethanol results in decreased expression of CPT1A mRNA] |
CTD |
PMID:25455889 |
|
NCBI chr 1:200,564,634...200,627,059
Ensembl chr 1:200,565,613...200,627,055
|
|
G |
Creb1 |
cAMP responsive element binding protein 1 |
multiple interactions |
EXP |
Berberine inhibits the reaction [Bortezomib results in decreased expression of CREB1 protein] |
CTD |
PMID:35121005 |
|
NCBI chr 9:65,903,511...65,972,562
Ensembl chr 9:65,903,547...65,970,816
|
|
G |
Crebbp |
CREB binding protein |
increases expression |
ISO |
Berberine results in increased expression of CREBBP mRNA |
CTD |
PMID:27311644 |
|
NCBI chr10:11,335,551...11,461,888
Ensembl chr10:11,335,953...11,461,888
|
|
G |
Cst3 |
cystatin C |
multiple interactions |
ISO |
Berberine inhibits the reaction [[Water deficiency co-treated with NG-Nitroarginine Methyl Ester co-treated with Indomethacin co-treated with Iohexol] results in increased expression of CST3 protein] |
CTD |
PMID:38705399 |
|
NCBI chr 3:136,336,923...136,340,796
Ensembl chr 3:136,336,920...136,340,822
|
|
G |
Ctnnb1 |
catenin beta 1 |
increases expression multiple interactions |
ISO |
Berberine results in increased expression of CTNNB1 protein CTNNB1 mutant form inhibits the reaction [Berberine results in increased expression of BGLAP protein]; CTNNB1 mutant form inhibits the reaction [Berberine results in increased expression of RUNX2 mRNA]; CTNNB1 mutant form inhibits the reaction [Berberine results in increased expression of SPP1 protein]; DKK1 protein inhibits the reaction [Berberine results in increased expression of CTNNB1 protein] |
CTD |
PMID:26478571 |
|
NCBI chr 8:120,640,008...120,667,110
Ensembl chr 8:120,639,995...120,667,111
|
|
G |
Ctsd |
cathepsin D |
multiple interactions decreases cleavage |
ISO |
GSK2795039 affects the reaction [Berberine results in decreased cleavage of CTSD protein] |
CTD |
PMID:36070022 |
|
NCBI chr 1:197,527,467...197,539,343
Ensembl chr 1:197,527,467...197,539,488
|
|
G |
Ctsl |
cathepsin L |
decreases cleavage multiple interactions |
ISO |
Berberine results in decreased cleavage of CTSL protein Acetylcysteine inhibits the reaction [Berberine results in decreased cleavage of CTSL protein]; GSK2795039 affects the reaction [Berberine results in decreased cleavage of CTSL protein] |
CTD |
PMID:36070022 |
|
NCBI chr17:764,370...770,533
Ensembl chr17:764,309...770,548
|
|
G |
Cybb |
cytochrome b-245 beta chain |
multiple interactions |
ISO |
Berberine promotes the reaction [CYBB protein binds to NCF1 protein binds to NCF2 protein binds to RAC2 protein]; Berberine promotes the reaction [CYBB protein binds to NCF1 protein]; Berberine promotes the reaction [CYBB protein binds to NCF2 protein]; Berberine promotes the reaction [CYBB protein binds to RAC2 protein] |
CTD |
PMID:36070022 |
|
NCBI chr X:13,358,101...13,392,570
Ensembl chr X:13,359,430...13,392,586
|
|
G |
Cycs |
cytochrome c, somatic |
affects localization multiple interactions |
ISO |
Berberine affects the localization of CYCS protein [Berberine co-treated with Cisplatin] results in increased expression of CYCS protein |
CTD |
PMID:16505103 PMID:36070022 |
|
NCBI chr 4:79,651,894...79,653,994
Ensembl chr 4:79,651,378...79,654,054 Ensembl chr18:79,651,378...79,654,054
|
|
G |
Cyp17a1 |
cytochrome P450, family 17, subfamily a, polypeptide 1 |
multiple interactions |
ISO |
Berberine inhibits the reaction [Dexamethasone results in increased expression of CYP17A1 mRNA] |
CTD |
PMID:20462044 |
|
NCBI chr 1:245,535,462...245,543,148
Ensembl chr 1:245,535,462...245,541,573
|
|
G |
Cyp1a1 |
cytochrome P450, family 1, subfamily a, polypeptide 1 |
decreases activity increases expression multiple interactions |
ISO EXP |
Berberine results in decreased activity of CYP1A1 protein Berberine results in increased expression of CYP1A1 mRNA Berberine inhibits the reaction [beta-Naphthoflavone results in increased expression of CYP1A1 mRNA] |
CTD |
PMID:16046213 PMID:22342832 PMID:24583342 |
|
NCBI chr 8:58,096,021...58,102,130
Ensembl chr 8:58,096,077...58,102,125
|
|
G |
Cyp1a2 |
cytochrome P450, family 1, subfamily a, polypeptide 2 |
multiple interactions |
ISO |
Berberine inhibits the reaction [beta-Naphthoflavone results in increased expression of CYP1A2 mRNA] |
CTD |
PMID:22342832 |
|
NCBI chr 8:58,075,367...58,082,255
Ensembl chr 8:58,075,367...58,082,312
|
|
G |
Cyp2b3 |
cytochrome P450, family 2, subfamily b, polypeptide 3 |
increases expression multiple interactions |
ISO |
Berberine results in increased expression of CYP2B10 mRNA Berberine inhibits the reaction [Streptozocin results in increased expression of CYP2B10 mRNA]; Berberine promotes the reaction [Phenobarbital results in increased expression of CYP2B10 mRNA] |
CTD |
PMID:22342832 |
|
NCBI chr 1:81,652,762...81,732,153
Ensembl chr 1:81,652,787...81,732,143
|
|
G |
Cyp2e1 |
cytochrome P450, family 2, subfamily e, polypeptide 1 |
decreases expression multiple interactions |
ISO |
Berberine results in decreased expression of CYP2E1 mRNA Berberine inhibits the reaction [Ethanol results in increased expression of CYP2E1 protein]; Berberine inhibits the reaction [Isoniazid results in increased expression of CYP2E1 mRNA] |
CTD |
PMID:22342832 PMID:25455889 |
|
NCBI chr 1:195,840,330...195,850,728
Ensembl chr 1:195,840,058...195,864,023
|
|
G |
Cyp3a2 |
cytochrome P450, family 3, subfamily a, polypeptide 2 |
decreases expression multiple interactions decreases activity |
EXP ISO |
Berberine results in decreased expression of CYP3A4 mRNA; Berberine results in decreased expression of CYP3A4 protein [Berberine results in increased activity of NR1I2 protein] which results in increased expression of CYP3A4 mRNA Berberine results in decreased activity of CYP3A4 protein Atorvastatin promotes the reaction [Berberine results in decreased activity of CYP3A4 protein]; Berberine promotes the reaction [Atorvastatin results in decreased activity of CYP3A4 protein]; Berberine promotes the reaction [Atorvastatin results in decreased expression of CYP3A4 mRNA]; Berberine promotes the reaction [Atorvastatin results in decreased expression of CYP3A4 protein]; Berberine promotes the reaction [Simvastatin results in decreased activity of CYP3A4 protein]; Berberine promotes the reaction [Simvastatin results in decreased expression of CYP3A4 protein]; Simvastatin promotes the reaction [Berberine results in decreased activity of CYP3A4 protein] |
CTD |
PMID:21524698 PMID:30086269 |
|
NCBI chr12:9,207,978...9,230,064
Ensembl chr12:9,015,383...9,285,008
|
|
G |
Dkk1 |
dickkopf WNT signaling pathway inhibitor 1 |
multiple interactions |
ISO |
DKK1 protein inhibits the reaction [Berberine results in increased expression of BGLAP protein]; DKK1 protein inhibits the reaction [Berberine results in increased expression of CTNNB1 protein]; DKK1 protein inhibits the reaction [Berberine results in increased expression of RUNX2 mRNA]; DKK1 protein inhibits the reaction [Berberine results in increased expression of SPP1 protein] |
CTD |
PMID:26478571 |
|
NCBI chr 1:228,381,521...228,385,202
Ensembl chr 1:228,381,521...228,385,202
|
|
G |
Dnmt1 |
DNA methyltransferase 1 |
decreases expression |
ISO |
Berberine results in decreased expression of DNMT1 mRNA |
CTD |
PMID:27311644 |
|
NCBI chr 8:19,440,611...19,486,659
Ensembl chr 8:19,440,611...19,486,659
|
|
G |
Dnmt3b |
DNA methyltransferase 3 beta |
decreases expression |
ISO |
Berberine results in decreased expression of DNMT3B mRNA |
CTD |
PMID:27311644 |
|
NCBI chr 3:142,130,588...142,169,128
Ensembl chr 3:142,130,592...142,169,124
|
|
G |
Dzip3 |
DAZ interacting zinc finger protein 3 |
increases expression |
ISO |
Berberine results in increased expression of DZIP3 mRNA |
CTD |
PMID:27311644 |
|
NCBI chr11:51,823,235...51,893,353
Ensembl chr11:51,823,231...51,893,353
|
|
G |
Egf |
epidermal growth factor |
multiple interactions |
ISO |
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [EGF protein inhibits the reaction [Berberine results in decreased activity of MMP2 protein]]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [EGF protein inhibits the reaction [Berberine results in decreased activity of MMP9 protein]]; EGF protein inhibits the reaction [Berberine results in decreased activity of MMP2 protein]; EGF protein inhibits the reaction [Berberine results in decreased activity of MMP9 protein] |
CTD |
PMID:33325633 |
|
NCBI chr 2:218,219,408...218,302,359
Ensembl chr 2:218,219,415...218,302,064
|
|
G |
Egfr |
epidermal growth factor receptor |
decreases expression |
ISO |
Berberine results in decreased expression of EGFR protein |
CTD |
PMID:33325633 |
|
NCBI chr14:91,176,979...91,349,722
Ensembl chr14:91,177,067...91,344,382
|
|
G |
Eif4ebp1 |
eukaryotic translation initiation factor 4E binding protein 1 |
multiple interactions |
ISO |
Berberine results in decreased phosphorylation of and results in increased expression of EIF4EBP1 protein |
CTD |
PMID:23363784 |
|
NCBI chr16:64,792,595...64,805,984
Ensembl chr16:64,790,226...64,805,984
|
|
G |
Ep300 |
E1A binding protein p300 |
increases expression |
ISO |
Berberine results in increased expression of EP300 mRNA |
CTD |
PMID:27311644 |
|
NCBI chr 7:113,108,476...113,178,529
Ensembl chr 7:113,106,247...113,136,088 Ensembl chr 7:113,106,247...113,136,088
|
|
G |
Erbb2 |
erb-b2 receptor tyrosine kinase 2 |
multiple interactions |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Berberine results in decreased expression of ERBB2 protein]; Berberine results in decreased expression of and results in increased ubiquitination of ERBB2 protein |
CTD |
PMID:33325633 |
|
NCBI chr10:83,411,197...83,435,078
Ensembl chr10:83,411,313...83,435,078
|
|
G |
Esr1 |
estrogen receptor 1 |
multiple interactions |
ISO |
Berberine inhibits the reaction [Estradiol results in increased activity of ESR1 protein] |
CTD |
PMID:30818834 |
|
NCBI chr 1:41,106,335...41,499,104
Ensembl chr 1:41,210,475...41,495,002
|
|
G |
Esrra |
estrogen related receptor, alpha |
multiple interactions |
ISO |
Berberine inhibits the reaction [XCT790 results in decreased activity of ESRRA protein] |
CTD |
PMID:30818834 |
|
NCBI chr 1:204,104,100...204,114,182
Ensembl chr 1:204,104,101...204,114,268
|
|
G |
Fabp4 |
fatty acid binding protein 4 |
decreases expression multiple interactions increases expression |
ISO |
Berberine results in decreased expression of FABP4 mRNA 15-deoxyprostaglandin J2 promotes the reaction [Berberine results in increased expression of FABP4 mRNA]; Berberine promotes the reaction [15-deoxyprostaglandin J2 results in increased expression of FABP4 mRNA] |
CTD |
PMID:26478571 PMID:29408570 |
|
NCBI chr 2:91,580,879...91,585,567
Ensembl chr 2:91,580,885...91,585,578
|
|
G |
Fas |
Fas cell surface death receptor |
multiple interactions increases expression |
ISO |
[Clozapine co-treated with Berberine] results in decreased expression of FAS mRNA; Berberine inhibits the reaction [Risperidone results in increased expression of FAS mRNA] Berberine results in increased expression of FAS mRNA; Berberine results in increased expression of FAS protein |
CTD |
PMID:20564506 PMID:20656010 |
|
NCBI chr 1:231,798,963...231,832,591
Ensembl chr 1:231,798,960...231,832,591
|
|
G |
Faslg |
Fas ligand |
increases expression |
ISO |
Berberine results in increased expression of FASLG mRNA; Berberine results in increased expression of FASLG protein |
CTD |
PMID:20656010 |
|
NCBI chr13:74,151,519...74,172,760
Ensembl chr13:74,154,954...74,162,215
|
|
G |
Fn1 |
fibronectin 1 |
multiple interactions |
EXP ISO |
Berberine inhibits the reaction [Thioacetamide results in increased expression of FN1 mRNA] Berberine inhibits the reaction [Particulate Matter results in increased expression of FN1 mRNA] |
CTD |
PMID:30138605 PMID:37839514 |
|
NCBI chr 9:73,196,044...73,264,695
Ensembl chr 9:73,196,044...73,264,678
|
|
G |
Foxo1 |
forkhead box O1 |
multiple interactions |
ISO |
[Berberine co-treated with Niacinamide] results in increased expression of and results in increased acetylation of FOXO1 protein; Berberine results in increased expression of and results in increased acetylation of FOXO1 protein |
CTD |
PMID:26712469 |
|
NCBI chr 2:136,312,168...136,390,603
Ensembl chr 2:136,312,168...136,387,790
|
|
G |
Foxo3 |
forkhead box O3 |
multiple interactions |
ISO |
[Berberine co-treated with Niacinamide] results in increased expression of and results in increased acetylation of FOXO3 protein; Berberine results in increased expression of and results in increased acetylation of FOXO3 protein |
CTD |
PMID:26712469 |
|
NCBI chr20:45,669,708...45,764,606
Ensembl chr20:45,672,995...45,764,561
|
|
G |
Fundc1 |
FUN14 domain containing 1 |
increases expression multiple interactions |
ISO |
Berberine results in increased expression of FUNDC1 protein [Cisplatin co-treated with Berberine] results in increased expression of FUNDC1 protein; FUNDC1 protein affects the reaction [[Berberine co-treated with Cisplatin] results in increased lipidation of MAP1LC3B protein] |
CTD |
PMID:36070022 |
|
NCBI chr X:5,083,635...5,100,293
Ensembl chr X:5,083,617...5,100,284
|
|
G |
Gata2 |
GATA binding protein 2 |
increases expression |
ISO |
Berberine results in increased expression of GATA2 mRNA |
CTD |
PMID:37511356 |
|
NCBI chr 4:120,654,205...120,667,763
Ensembl chr 4:120,658,986...120,667,761
|
|
G |
Gata3 |
GATA binding protein 3 |
increases expression |
ISO |
Berberine results in increased expression of GATA3 mRNA |
CTD |
PMID:37511356 |
|
NCBI chr17:68,643,760...68,666,000
Ensembl chr17:68,643,873...68,665,391
|
|
G |
Gclc |
glutamate-cysteine ligase, catalytic subunit |
multiple interactions |
EXP |
Berberine inhibits the reaction [Bortezomib results in increased expression of GCLC mRNA] |
CTD |
PMID:35121005 |
|
NCBI chr 8:78,629,899...78,668,547
Ensembl chr 8:78,630,127...78,668,544
|
|
G |
Gclm |
glutamate cysteine ligase, modifier subunit |
multiple interactions |
EXP |
Berberine inhibits the reaction [Bortezomib results in increased expression of GCLM mRNA] |
CTD |
PMID:35121005 |
|
NCBI chr 2:210,347,482...210,367,537
Ensembl chr 2:210,347,482...210,367,535
|
|
G |
Gdf5 |
growth differentiation factor 5 |
decreases expression |
ISO |
Berberine results in decreased expression of GDF5 mRNA |
CTD |
PMID:26478571 |
|
NCBI chr 3:144,454,316...144,458,508
Ensembl chr 3:144,454,338...144,458,612
|
|
G |
Gfap |
glial fibrillary acidic protein |
multiple interactions |
EXP |
Berberine inhibits the reaction [Bortezomib results in increased expression of GFAP mRNA] |
CTD |
PMID:35121005 |
|
NCBI chr10:87,852,891...87,861,631
Ensembl chr10:87,852,890...87,861,589
|
|
G |
Gpt |
glutamic--pyruvic transaminase |
multiple interactions |
ISO EXP |
Berberine inhibits the reaction [Ethanol results in increased activity of GPT protein] Berberine inhibits the reaction [Mercuric Chloride results in increased activity of GPT protein]; Berberine inhibits the reaction [Thioacetamide results in increased activity of GPT protein] |
CTD |
PMID:24751971 PMID:25455889 PMID:30138605 |
|
NCBI chr 7:108,416,646...108,419,495
Ensembl chr 7:108,416,642...108,419,494
|
|
G |
Gpx1 |
glutathione peroxidase 1 |
multiple interactions |
EXP |
Berberine inhibits the reaction [Mercuric Chloride results in decreased expression of GPX1 mRNA] |
CTD |
PMID:24751971 PMID:33460233 |
|
NCBI chr 8:109,026,905...109,028,031
Ensembl chr 8:109,026,905...109,028,024
|
|
G |
Gsk3b |
glycogen synthase kinase 3 beta |
multiple interactions increases phosphorylation |
ISO |
Berberine inhibits the reaction [Dexamethasone results in decreased expression of GSK3B mRNA] Berberine results in increased phosphorylation of GSK3B protein Berberine inhibits the reaction [Glucose results in decreased phosphorylation of GSK3B protein] |
CTD |
PMID:20462044 PMID:23954465 |
|
NCBI chr11:62,498,997...62,648,665
Ensembl chr11:62,504,316...62,648,646
|
|
G |
Gsr |
glutathione-disulfide reductase |
multiple interactions |
EXP |
Berberine inhibits the reaction [Chlorpyrifos results in decreased activity of GSR protein]; Berberine inhibits the reaction [Mercuric Chloride results in decreased activity of GSR protein] |
CTD |
PMID:24751971 PMID:25600690 PMID:33460233 PMID:35439518 |
|
NCBI chr16:58,482,209...58,525,256
Ensembl chr16:58,482,505...58,525,661
|
|
G |
H2ac12 |
H2A clustered histone 12 |
decreases expression |
ISO |
Berberine results in decreased expression of H2AC12 mRNA |
CTD |
PMID:27311644 |
|
NCBI chr17:42,486,415...42,486,880
Ensembl chr17:42,486,415...42,486,941
|
|
G |
H2ac18 |
H2A clustered histone 18 |
decreases expression |
ISO |
Berberine results in decreased expression of H2AC18 mRNA |
CTD |
PMID:27311644 |
|
NCBI chr 2:183,808,398...183,808,992
|
|
G |
H2ac25 |
H2A clustered histone 25 |
decreases expression |
ISO |
Berberine results in decreased expression of H2AC25 mRNA |
CTD |
PMID:27311644 |
|
NCBI chr10:43,733,702...43,735,254
Ensembl chr10:43,733,668...43,744,874
|
|
G |
H2ac4 |
H2A clustered histone 4 |
decreases expression |
ISO |
Berberine results in decreased expression of H2AC4 mRNA |
CTD |
PMID:27311644 |
|
NCBI chr17:42,799,884...42,800,387
Ensembl chr17:42,799,652...42,800,381
|
|
G |
H2ax |
H2A.X variant histone |
increases expression decreases expression multiple interactions |
ISO |
Berberine results in increased expression of H2AX protein modified form Berberine results in decreased expression of H2AX mRNA; Berberine results in decreased expression of H2AX protein TOP2A protein affects the reaction [Berberine results in increased expression of H2AX protein modified form] |
CTD |
PMID:23363784 PMID:23747414 PMID:27311644 |
|
NCBI chr 8:44,671,907...44,673,262
Ensembl chr 8:44,671,786...44,673,239 Ensembl chr 4:44,671,786...44,673,239
|
|
G |
H2bc12 |
H2B clustered histone 12 |
decreases expression |
ISO |
Berberine results in decreased expression of H2BC12 mRNA |
CTD |
PMID:27311644 |
|
NCBI chr17:42,485,699...42,486,162
|
|
G |
H2bc6 |
H2B clustered histone 6 |
decreases expression |
ISO |
Berberine results in decreased expression of H2BC6 mRNA |
CTD |
PMID:27311644 |
|
NCBI chr17:41,520,775...41,521,238
|
|
G |
H2bc8 |
H2B clustered histone 8 |
decreases expression |
ISO |
Berberine results in decreased expression of H2BC8 mRNA |
CTD |
PMID:27311644 |
|
NCBI chr17:42,708,658...42,709,408
|
|
G |
H2bc9 |
H2B clustered histone 9 |
decreases expression |
ISO |
Berberine results in decreased expression of H2BC9 mRNA |
CTD |
PMID:27311644 |
|
NCBI chr17:42,470,593...42,478,590
|
|
G |
H3c1 |
H3 clustered histone 1 |
decreases expression |
ISO |
Berberine results in decreased expression of H3C1 mRNA |
CTD |
PMID:27311644 |
|
NCBI chr17:41,368,379...41,368,902
Ensembl chr17:41,368,386...41,368,856 Ensembl chr17:41,368,386...41,368,856 Ensembl chr17:41,368,386...41,368,856 Ensembl chr17:41,368,386...41,368,856
|
|
G |
H3f3a |
H3.3 histone A |
decreases expression |
ISO |
Berberine results in decreased expression of H3-3A mRNA |
CTD |
PMID:27311644 |
|
NCBI chr13:92,533,289...92,544,902
Ensembl chr13:92,533,298...92,544,908
|
|
G |
H3f4 |
H3.4 histone, cluster member |
decreases expression |
ISO |
Berberine results in decreased expression of H3-4 mRNA |
CTD |
PMID:27311644 |
|
NCBI chr10:43,740,702...43,741,262
|
|
G |
H4c14 |
H4 clustered histone 14 |
decreases expression |
ISO |
Berberine results in decreased expression of H4C2 mRNA |
CTD |
PMID:27311644 |
|
NCBI chr 2:183,831,601...183,831,996
Ensembl chr 2:183,825,994...183,832,048
|
|
G |
Hat1 |
histone acetyltransferase 1 |
increases expression |
ISO |
Berberine results in increased expression of HAT1 mRNA |
CTD |
PMID:27311644 |
|
NCBI chr 3:56,217,344...56,265,021
Ensembl chr 3:56,217,342...56,275,517
|
|
G |
Hdac2 |
histone deacetylase 2 |
decreases expression |
ISO |
Berberine results in decreased expression of HDAC2 mRNA |
CTD |
PMID:27311644 |
|
NCBI chr20:40,548,244...40,571,609
Ensembl chr20:40,548,250...40,571,609
|
|
G |
Hdac5 |
histone deacetylase 5 |
increases expression |
ISO |
Berberine results in increased expression of HDAC5 mRNA |
CTD |
PMID:27311644 |
|
NCBI chr10:87,152,978...87,187,921
Ensembl chr10:87,152,978...87,188,235
|
|
G |
Hdac8 |
histone deacetylase 8 |
decreases expression |
ISO |
Berberine results in decreased expression of HDAC8 mRNA |
CTD |
PMID:27311644 |
|
NCBI chr X:67,385,288...67,593,014
Ensembl chr X:67,385,289...67,592,923
|
|
G |
Hdac9 |
histone deacetylase 9 |
decreases expression increases expression |
ISO |
Berberine results in decreased expression of HDAC9 mRNA Berberine results in increased expression of HDAC9 mRNA |
CTD |
PMID:27311644 |
|
NCBI chr 6:50,762,074...51,624,311
Ensembl chr 6:50,763,590...51,625,333
|
|
G |
Hgf |
hepatocyte growth factor |
increases expression multiple interactions |
ISO |
Berberine results in increased expression of HGF mRNA; Berberine results in increased expression of HGF protein Berberine inhibits the reaction [Bleomycin results in decreased expression of HGF mRNA] 15-deoxyprostaglandin J2 promotes the reaction [Berberine results in increased expression of HGF mRNA]; 15-deoxyprostaglandin J2 promotes the reaction [Berberine results in increased expression of HGF protein]; 2-chloro-5-nitrobenzanilide inhibits the reaction [Berberine results in increased expression of HGF protein]; Berberine promotes the reaction [15-deoxyprostaglandin J2 results in increased expression of HGF mRNA]; Berberine promotes the reaction [15-deoxyprostaglandin J2 results in increased expression of HGF protein]; Dactinomycin inhibits the reaction [Berberine results in increased expression of HGF protein]; PPARG mRNA promotes the reaction [Berberine results in increased expression of HGF protein] |
CTD |
PMID:29408570 |
|
NCBI chr 4:18,673,736...18,745,582
Ensembl chr 4:18,677,101...18,745,409
|
|
G |
Hist1h2af |
histone cluster 1 H2A family member F |
decreases expression |
ISO |
Berberine results in decreased expression of H2AC8 mRNA |
CTD |
PMID:27311644 |
|
NCBI chr17:41,379,404...41,379,796
Ensembl chr17:41,379,404...41,379,796
|
|
G |
Hist1h2ah |
histone cluster 1 H2A family member H |
decreases expression |
ISO |
Berberine results in decreased expression of H2AC11 mRNA |
CTD |
PMID:27311644 |
|
NCBI chr17:41,384,521...41,385,018
|
|
G |
Hist1h2al1 |
histone cluster 1 H2A family like 1 |
decreases expression |
ISO |
Berberine results in decreased expression of H2AC6 mRNA |
CTD |
PMID:27311644 |
|
NCBI chr17:42,707,954...42,708,420
|
|
G |
Hist1h2bd |
histone cluster 1 H2B family member D |
decreases expression |
ISO |
Berberine results in decreased expression of H2BC5 mRNA |
CTD |
PMID:27311644 |
|
NCBI chr17:42,792,887...42,793,268
|
|
G |
Hist1h2bq |
histone cluster 1 H2B family member Q |
decreases expression |
ISO |
Berberine results in decreased expression of H2BC7 mRNA |
CTD |
PMID:27311644 |
|
NCBI chr17:41,432,100...41,441,487
Ensembl chr17:41,429,164...41,442,153 Ensembl chr17:41,429,164...41,442,153 Ensembl chr17:41,429,164...41,442,153
|
|
G |
Hist1h4b |
histone cluster 1 H4 family member B |
decreases expression |
ISO |
Berberine results in decreased expression of H4C9 mRNA |
CTD |
PMID:27311644 |
|
NCBI chr17:42,480,467...42,484,912
Ensembl chr17:42,480,313...42,485,370
|
|
G |
Hist2h2be |
histone cluster 2 H2B family member E |
decreases expression |
ISO |
Berberine results in decreased expression of H2BC11 mRNA |
CTD |
PMID:27311644 |
|
NCBI chr 2:183,780,583...183,783,030
|
|
G |
Hmgb1 |
high mobility group box 1 |
multiple interactions |
ISO |
Berberine inhibits the reaction [[Water deficiency co-treated with NG-Nitroarginine Methyl Ester co-treated with Indomethacin co-treated with Iohexol] results in increased expression of HMGB1 protein] |
CTD |
PMID:38705399 |
|
NCBI chr12:5,972,950...5,979,658
Ensembl chr12:5,901,586...5,978,565 Ensembl chr16:5,901,586...5,978,565
|
|
G |
Hmox1 |
heme oxygenase 1 |
increases expression multiple interactions |
ISO EXP |
Berberine results in increased expression of HMOX1 protein Berberine results in increased expression of HMOX1 mRNA; Berberine results in increased expression of HMOX1 protein Berberine inhibits the reaction [Particulate Matter results in decreased expression of HMOX1 protein] Berberine inhibits the reaction [Bortezomib results in increased expression of HMOX1 mRNA] Berberine promotes the reaction [Glucose results in increased expression of HMOX1 protein]; NFE2L2 mutant form inhibits the reaction [Berberine results in increased expression of HMOX1 protein] |
CTD |
PMID:23954465 PMID:35121005 PMID:37511356 PMID:37839514 |
|
NCBI chr19:13,466,287...13,474,082
Ensembl chr19:13,467,244...13,474,079
|
|
G |
Hnf4a |
hepatocyte nuclear factor 4, alpha |
multiple interactions |
EXP ISO |
Berberine inhibits the reaction [Fructose results in decreased expression of HNF4A mRNA]; Berberine inhibits the reaction [Fructose results in decreased expression of HNF4A protein] Berberine inhibits the reaction [Ethanol results in decreased expression of HNF4 protein] |
CTD |
PMID:18563319 PMID:25455889 |
|
NCBI chr 3:152,186,787...152,248,320
Ensembl chr 3:152,186,787...152,248,320
|
|
G |
Idh3a |
isocitrate dehydrogenase (NAD(+)) 3 catalytic subunit alpha |
decreases expression |
ISO |
Berberine results in decreased expression of IDH3A mRNA |
CTD |
PMID:30818834 |
|
NCBI chr 8:54,971,694...54,991,085
Ensembl chr 8:54,971,740...54,991,084
|
|
G |
Ifng |
interferon gamma |
multiple interactions |
EXP |
Berberine inhibits the reaction [Thioacetamide results in increased expression of IFNG mRNA] |
CTD |
PMID:30138605 |
|
NCBI chr 7:53,903,339...53,907,375
Ensembl chr 7:53,903,337...53,907,375
|
|
G |
Igf1r |
insulin-like growth factor 1 receptor |
multiple interactions increases expression |
ISO |
Berberine inhibits the reaction [Glucose results in decreased expression of IGF1R protein] Berberine results in increased expression of IGF1R protein |
CTD |
PMID:23954465 |
|
NCBI chr 1:121,549,831...121,838,548
Ensembl chr 1:121,550,743...121,831,777
|
|
G |
Igf2bp3 |
insulin-like growth factor 2 mRNA binding protein 3 |
multiple interactions decreases expression |
ISO |
Berberine inhibits the reaction [[Dextran Sulfate co-treated with azomethane] results in increased expression of IGF2BP3 protein] [Chloroquine co-treated with Berberine] results in decreased expression of IGF2BP3 protein; Berberine promotes the reaction [IGF2BP3 protein binds to TRIM21 protein]; Cycloheximide promotes the reaction [Berberine results in decreased expression of IGF2BP3 protein] |
CTD |
PMID:36822301 |
|
NCBI chr 4:78,060,494...78,195,007
Ensembl chr 4:78,060,494...78,194,865
|
|
G |
Il10 |
interleukin 10 |
multiple interactions increases expression |
ISO EXP |
Berberine affects the reaction [Lipopolysaccharides affects the expression of IL10 mRNA] [Berberine co-treated with Thioacetamide] results in increased expression of IL10 mRNA; Berberine inhibits the reaction [Cyclophosphamide results in decreased expression of IL10 protein] Berberine results in increased expression of IL10 mRNA |
CTD |
PMID:21867779 PMID:30138605 PMID:37955270 |
|
NCBI chr13:42,472,625...42,477,308
Ensembl chr13:42,472,839...42,477,313
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions |
ISO EXP |
Berberine inhibits the reaction [IL1B protein results in increased expression of CCL2 mRNA]; Berberine inhibits the reaction [IL1B protein results in increased expression of CXCL8 mRNA]; Berberine inhibits the reaction [IL1B protein results in increased secretion of CCL2 protein]; Berberine inhibits the reaction [IL1B protein results in increased secretion of CXCL8 protein] Berberine inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of IL1B mRNA]; Berberine inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of IL1B protein]; Berberine inhibits the reaction [[Water deficiency co-treated with NG-Nitroarginine Methyl Ester co-treated with Indomethacin co-treated with Iohexol] results in increased expression of IL1B mRNA]; Berberine inhibits the reaction [[Water deficiency co-treated with NG-Nitroarginine Methyl Ester co-treated with Indomethacin co-treated with Iohexol] results in increased expression of IL1B protein]; Berberine inhibits the reaction [Particulate Matter results in increased expression of IL1B protein] Berberine inhibits the reaction [[Cadmium co-treated with Aluminum co-treated with Fluorides] results in increased expression of IL1B protein]; Berberine inhibits the reaction [Bortezomib results in increased expression of IL1B mRNA]; Berberine inhibits the reaction [Thioacetamide results in increased expression of IL1B mRNA] |
CTD |
PMID:16391493 PMID:29170048 PMID:30138605 PMID:35121005 PMID:35691465 PMID:37839514 PMID:38705399 More...
|
|
NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
|
|
G |
Il2 |
interleukin 2 |
increases expression |
ISO |
Berberine results in increased expression of IL2 mRNA |
CTD |
PMID:21867779 |
|
NCBI chr 2:120,004,862...120,009,566
Ensembl chr 2:120,004,862...120,009,566
|
|
G |
Il23a |
interleukin 23 subunit alpha |
multiple interactions |
ISO |
Berberine inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with TNF protein] results in increased expression of IL23A mRNA]; Berberine inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with TNF protein] results in increased secretion of IL23A protein] |
CTD |
PMID:30240693 |
|
NCBI chr 7:721,809...723,923
Ensembl chr 7:721,809...723,923
|
|
G |
Il4 |
interleukin 4 |
multiple interactions increases expression |
ISO |
Berberine inhibits the reaction [Lipopolysaccharides results in decreased expression of IL4 mRNA] Berberine results in increased expression of IL4 mRNA |
CTD |
PMID:21867779 |
|
NCBI chr10:37,771,203...37,776,750
Ensembl chr10:37,771,203...37,776,750
|
|
G |
Il6 |
interleukin 6 |
multiple interactions |
EXP ISO |
Berberine inhibits the reaction [[Cadmium co-treated with Aluminum co-treated with Fluorides] results in increased expression of IL6 protein]; Berberine inhibits the reaction [Bortezomib results in increased expression of IL6 mRNA]; Berberine inhibits the reaction [Cyclophosphamide results in increased expression of IL6 protein]; Berberine inhibits the reaction [Thioacetamide results in increased expression of IL6 mRNA]; Berberine inhibits the reaction [Thioacetamide results in increased expression of IL6 protein] Berberine inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with TNF protein] results in increased expression of IL6 mRNA]; Berberine inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with TNF protein] results in increased secretion of IL6 protein]; Berberine inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of IL6 mRNA]; Berberine inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of IL6 protein]; Berberine inhibits the reaction [[Water deficiency co-treated with NG-Nitroarginine Methyl Ester co-treated with Indomethacin co-treated with Iohexol] results in increased expression of IL6 mRNA]; Berberine inhibits the reaction [Particulate Matter results in increased expression of IL6 protein] Berberine inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased expression of IL6 protein]; Berberine inhibits the reaction [Mustard Gas results in increased secretion of IL6 protein]; KPNA4 protein inhibits the reaction [Berberine inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased expression of IL6 protein]]; LINC00943 inhibits the reaction [Berberine inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased expression of IL6 protein]]; MIR142 affects the reaction [Berberine inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased expression of IL6 protein]] |
CTD |
PMID:28916288 PMID:29170048 PMID:30138605 PMID:30240693 PMID:34427876 PMID:35121005 PMID:35691465 PMID:37839514 PMID:37955270 PMID:38705399 More...
|
|
NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
|
|
G |
Ins2 |
insulin 2 |
multiple interactions |
EXP |
[Berberine co-treated with Streptozocin] results in increased secretion of INS protein |
CTD |
PMID:15066220 |
|
NCBI chr 1:197,843,277...197,992,522
Ensembl chr 1:197,843,281...197,864,775
|
|
G |
Itga1 |
integrin subunit alpha 1 |
increases expression |
ISO |
Berberine results in increased expression of ITGA1 mRNA |
CTD |
PMID:26478571 |
|
NCBI chr 2:46,646,125...46,812,237
Ensembl chr 2:46,653,193...46,812,238
|
|
G |
Itgb4 |
integrin subunit beta 4 |
increases expression |
ISO |
berberine increases expression of ITGB4 protein in colon epithelial cells |
RGD |
PMID:29564000 |
RGD:152995489 |
NCBI chr10:101,206,657...101,243,012
Ensembl chr10:101,206,665...101,243,012
|
|
G |
Jun |
Jun proto-oncogene, AP-1 transcription factor subunit |
affects localization multiple interactions |
EXP |
Berberine affects the localization of JUN protein arsenic trioxide promotes the reaction [Berberine affects the localization of JUN protein] |
CTD |
PMID:18294404 |
|
NCBI chr 5:109,894,175...109,897,268
Ensembl chr 5:109,893,145...109,897,656
|
|
G |
Kcnh2 |
potassium voltage-gated channel subfamily H member 2 |
decreases activity multiple interactions |
EXP |
Berberine results in decreased activity of KCNH2 protein Berberine promotes the reaction [Atorvastatin results in decreased activity of KCNH2 protein]; Berberine promotes the reaction [Simvastatin results in decreased activity of KCNH2 protein] |
CTD |
PMID:30086269 |
|
NCBI chr 4:10,826,834...10,859,009
Ensembl chr 4:10,826,928...10,859,008
|
|
G |
Kdm1a |
lysine demethylase 1A |
increases expression |
ISO |
Berberine results in increased expression of KDM1A mRNA |
CTD |
PMID:27311644 |
|
NCBI chr 5:148,782,976...148,838,319
Ensembl chr 5:148,782,976...148,838,319
|
|
G |
Kdm4a |
lysine demethylase 4A |
increases expression |
ISO |
Berberine results in increased expression of KDM4A mRNA |
CTD |
PMID:27311644 |
|
NCBI chr 5:131,672,754...131,719,534
Ensembl chr 5:131,672,754...131,719,501
|
|
G |
Kdm5b |
lysine demethylase 5B |
increases expression |
ISO |
Berberine results in increased expression of KDM5B mRNA |
CTD |
PMID:27311644 |
|
NCBI chr13:46,001,589...46,073,868
Ensembl chr13:46,002,542...46,073,872
|
|
G |
Kdm6a |
lysine demethylase 6A |
increases expression |
ISO |
Berberine results in increased expression of KDM6A mRNA |
CTD |
PMID:27311644 |
|
NCBI chr X:4,337,466...4,477,100
Ensembl chr X:4,337,750...4,477,062
|
|
G |
Kdm6b |
lysine demethylase 6B |
increases expression |
ISO |
Berberine results in increased expression of KDM6B mRNA |
CTD |
PMID:27311644 |
|
NCBI chr10:54,120,716...54,142,212
Ensembl chr10:54,121,848...54,130,794
|
|
G |
Kmt5a |
lysine methyltransferase 5A |
increases expression |
ISO |
Berberine results in increased expression of KMT5A mRNA |
CTD |
PMID:27311644 |
|
NCBI chr12:32,139,353...32,167,777
Ensembl chr12:32,139,178...32,162,711
|
|
G |
Kpna4 |
karyopherin subunit alpha 4 |
multiple interactions |
ISO |
Berberine inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased expression of KPNA4 protein]; KPNA4 protein inhibits the reaction [Berberine inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased expression of IL6 protein]]; KPNA4 protein inhibits the reaction [Berberine inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased expression of KPNA4 protein]]; KPNA4 protein inhibits the reaction [Berberine inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased expression of TNF protein]]; KPNA4 protein inhibits the reaction [Berberine inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased phosphorylation of NFKBIA protein]]; KPNA4 protein inhibits the reaction [Berberine inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased phosphorylation of RELA protein]]; LINC00943 inhibits the reaction [Berberine inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased expression of KPNA4 protein]]; MIR142 affects the reaction [Berberine inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased expression of KPNA4 protein]] |
CTD |
PMID:34427876 |
|
NCBI chr 2:153,319,380...153,381,085
Ensembl chr 2:153,324,273...153,381,081
|
|
G |
Ldlr |
low density lipoprotein receptor |
multiple interactions increases expression |
ISO EXP |
Berberine inhibits the reaction [Clozapine results in increased expression of LDLR mRNA]; Berberine inhibits the reaction [Risperidone results in increased expression of LDLR mRNA] Berberine results in increased expression of LDLR mRNA Berberine promotes the reaction [Simvastatin results in increased expression of LDLR mRNA]; Simvastatin promotes the reaction [Berberine results in increased expression of LDLR mRNA] |
CTD |
PMID:18640378 PMID:20564506 |
|
NCBI chr 8:20,270,020...20,292,981
Ensembl chr 8:20,270,041...20,294,580
|
|
G |
Map1lc3b |
microtubule-associated protein 1 light chain 3 beta |
multiple interactions increases localization |
ISO EXP |
[Berberine co-treated with Cisplatin] results in increased lipidation of MAP1LC3B protein; Berberine results in increased expression of and results in increased lipidation of MAP1LC3B protein; BNIP3L protein affects the reaction [[Berberine co-treated with Cisplatin] results in increased lipidation of MAP1LC3B protein]; FUNDC1 protein affects the reaction [[Berberine co-treated with Cisplatin] results in increased lipidation of MAP1LC3B protein] Berberine results in increased localization of MAP1LC3B protein Berberine inhibits the reaction [Chlorpyrifos results in decreased expression of MAP1LC3B mRNA] |
CTD |
PMID:35439518 PMID:36070022 |
|
NCBI chr19:49,665,795...49,673,655
Ensembl chr19:49,665,791...49,677,690 Ensembl chr16:49,665,791...49,677,690
|
|
G |
Map3k5 |
mitogen-activated protein kinase kinase kinase 5 |
multiple interactions |
ISO |
Berberine inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with TNF protein] results in decreased expression of and results in increased phosphorylation of MAP3K5 protein] |
CTD |
PMID:30240693 |
|
NCBI chr 1:14,685,776...14,904,935
Ensembl chr 1:14,685,492...14,904,800
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
decreases phosphorylation |
EXP |
Berberine results in decreased phosphorylation of MAPK1 protein |
CTD |
PMID:18294404 |
|
NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
decreases phosphorylation multiple interactions |
EXP ISO |
Berberine results in decreased phosphorylation of MAPK3 protein Berberine inhibits the reaction [Dexamethasone results in decreased expression of MAPK3 mRNA] |
CTD |
PMID:18294404 PMID:20462044 |
|
NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863
|
|
G |
Mapk8 |
mitogen-activated protein kinase 8 |
multiple interactions |
ISO |
[Berberine co-treated with Cisplatin] results in increased phosphorylation of MAPK8 protein; Acetylcysteine inhibits the reaction [[Berberine co-treated with Cisplatin] results in increased phosphorylation of MAPK8 protein] |
CTD |
PMID:36070022 |
|
NCBI chr16:8,638,897...8,721,960
Ensembl chr16:8,638,924...8,721,981
|
|
G |
Mapt |
microtubule-associated protein tau |
multiple interactions |
EXP |
Berberine inhibits the reaction [[Cadmium co-treated with Aluminum co-treated with Fluorides] results in increased expression of MAPT mRNA] |
CTD |
PMID:29170048 |
|
NCBI chr10:89,138,644...89,236,137
Ensembl chr10:89,138,627...89,236,129
|
|
G |
Mcm2 |
minichromosome maintenance complex component 2 |
multiple interactions |
ISO |
Berberine inhibits the reaction [Dexamethasone results in increased expression of MCM2 mRNA] |
CTD |
PMID:20462044 |
|
NCBI chr 4:121,346,434...121,360,962
Ensembl chr 4:121,346,434...121,360,847
|
|
G |
Mir142 |
microRNA 142 |
multiple interactions |
ISO |
Berberine inhibits the reaction [1-Methyl-4-phenylpyridinium results in decreased expression of MIR142 mRNA]; MIR142 affects the reaction [Berberine inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased expression of IL6 protein]]; MIR142 affects the reaction [Berberine inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased expression of KPNA4 protein]]; MIR142 affects the reaction [Berberine inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased expression of TNF protein]] |
CTD |
PMID:34427876 |
|
NCBI chr10:72,557,864...72,557,950
Ensembl chr10:72,557,857...72,557,967
|
|
G |
Mir19a |
microRNA 19a |
decreases expression |
ISO |
Berberine results in decreased expression of MIR19A mRNA |
CTD |
PMID:29687521 |
|
NCBI chr15:92,180,912...92,180,993
Ensembl chr15:92,180,912...92,180,993
|
|
G |
Mir21 |
microRNA 21 |
decreases expression |
ISO |
berberine decreases expression of MIR21 RNA in colon epithelial cell |
RGD |
PMID:29564000 |
RGD:152995489 |
NCBI chr10:71,405,257...71,405,348
Ensembl chr10:71,405,257...71,405,348
|
|
G |
Mir92a1 |
microRNA 92a-1 |
decreases expression |
ISO |
Berberine results in decreased expression of MIR92A1 mRNA |
CTD |
PMID:29687521 |
|
NCBI chr15:92,181,336...92,181,413
Ensembl chr15:92,181,336...92,181,413
|
|
G |
Mmp13 |
matrix metallopeptidase 13 |
increases expression |
ISO |
Berberine results in increased expression of MMP13 mRNA |
CTD |
PMID:26478571 |
|
NCBI chr 8:4,497,960...4,508,239
Ensembl chr 8:4,497,960...4,508,239
|
|
G |
Mmp14 |
matrix metallopeptidase 14 |
multiple interactions decreases expression |
EXP |
arsenic trioxide promotes the reaction [Berberine results in decreased expression of MMP14 protein] |
CTD |
PMID:18294404 |
|
NCBI chr15:27,887,795...27,897,020
Ensembl chr15:27,887,727...27,899,864
|
|
G |
Mmp2 |
matrix metallopeptidase 2 |
multiple interactions decreases activity decreases expression |
ISO EXP |
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [EGF protein inhibits the reaction [Berberine results in decreased activity of MMP2 protein]]; Arsenic Trioxide promotes the reaction [Berberine results in decreased activity of MMP2 protein]; Berberine promotes the reaction [Arsenic Trioxide results in decreased activity of MMP2 protein]; EGF protein inhibits the reaction [Berberine results in decreased activity of MMP2 protein] Berberine results in decreased expression of MMP2 protein arsenic trioxide promotes the reaction [Berberine results in decreased activity of MMP2 protein]; arsenic trioxide promotes the reaction [Berberine results in decreased expression of MMP2 protein]; Berberine promotes the reaction [arsenic trioxide results in decreased activity of MMP2 protein] |
CTD |
PMID:18294404 PMID:33325633 |
|
NCBI chr19:14,154,657...14,182,870
Ensembl chr19:14,154,657...14,182,870
|
|
G |
Mmp9 |
matrix metallopeptidase 9 |
decreases activity multiple interactions |
ISO |
Berberine results in decreased activity of MMP9 protein 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [EGF protein inhibits the reaction [Berberine results in decreased activity of MMP9 protein]]; EGF protein inhibits the reaction [Berberine results in decreased activity of MMP9 protein] |
CTD |
PMID:33325633 |
|
NCBI chr 3:153,684,158...153,692,118
Ensembl chr 3:153,683,858...153,692,120
|
|
G |
Mpo |
myeloperoxidase |
multiple interactions |
ISO |
Berberine inhibits the reaction [Lipopolysaccharides results in increased expression of MPO protein] |
CTD |
PMID:21963898 |
|
NCBI chr10:72,594,883...72,608,862
Ensembl chr10:72,594,661...72,604,819
|
|
G |
Mt-co1 |
mitochondrially encoded cytochrome c oxidase I |
multiple interactions |
EXP |
Berberine inhibits the reaction [acetamiprid results in decreased expression of COX1 mRNA] |
CTD |
PMID:37350525 |
|
NCBI chr MT:5,323...6,867 NCBI chr MT:5,323...6,867 NCBI chr MT:5,323...6,867 NCBI chr MT:5,323...6,867 NCBI chr MT:5,323...6,867 NCBI chr MT:5,323...6,867 NCBI chr MT:5,323...6,867 NCBI chr MT:5,323...6,867 NCBI chr MT:5,323...6,867 NCBI chr MT:5,323...6,867 NCBI chr MT:5,323...6,867 NCBI chr MT:5,323...6,867
Ensembl chr MT:5,323...6,867
|
|
G |
Mt-nd1 |
mitochondrially encoded NADH:ubiquinone oxidoreductase core subunit 1 |
multiple interactions |
EXP |
Berberine inhibits the reaction [acetamiprid results in decreased expression of ND1 mRNA] |
CTD |
PMID:37350525 |
|
NCBI chr MT:2,740...3,694 NCBI chr MT:2,740...3,694 NCBI chr MT:2,740...3,694
Ensembl chr MT:2,740...3,694
|
|
G |
Mt-nd2 |
mitochondrially encoded NADH:ubiquinone oxidoreductase core subunit 2 |
multiple interactions |
EXP |
Berberine inhibits the reaction [acetamiprid results in decreased expression of ND2 mRNA] |
CTD |
PMID:37350525 |
|
NCBI chr MT:3,904...4,942 NCBI chr MT:3,904...4,942 NCBI chr MT:3,904...4,942 NCBI chr MT:3,904...4,942 NCBI chr MT:3,904...4,942 NCBI chr MT:3,904...4,942 NCBI chr MT:3,904...4,942 NCBI chr MT:3,904...4,942 NCBI chr MT:3,904...4,942 NCBI chr MT:3,904...4,942 NCBI chr MT:3,904...4,942 NCBI chr MT:3,904...4,942 NCBI chr MT:3,904...4,942
Ensembl chr MT:3,904...4,942
|
|
G |
Mtor |
mechanistic target of rapamycin kinase |
multiple interactions |
EXP |
Berberine inhibits the reaction [Chlorpyrifos results in increased expression of MTOR mRNA]; Berberine inhibits the reaction [Chlorpyrifos results in increased expression of MTOR protein] |
CTD |
PMID:35439518 |
|
NCBI chr 5:158,884,856...158,994,311
Ensembl chr 5:158,884,804...158,994,311
|
|
G |
Mttp |
microsomal triglyceride transfer protein |
multiple interactions |
ISO |
Berberine inhibits the reaction [Ethanol results in decreased expression of MTTP protein] |
CTD |
PMID:25455889 |
|
NCBI chr 2:226,613,090...226,654,239
Ensembl chr 2:226,613,090...226,654,239
|
|
G |
Myc |
MYC proto-oncogene, bHLH transcription factor |
multiple interactions affects localization |
EXP |
arsenic trioxide promotes the reaction [Berberine affects the localization of MYC protein] |
CTD |
PMID:18294404 |
|
NCBI chr 7:93,593,705...93,598,633
Ensembl chr 7:93,593,705...93,598,630
|
|
G |
Nampt |
nicotinamide phosphoribosyltransferase |
multiple interactions decreases expression |
ISO |
[Berberine co-treated with Niacinamide] results in decreased expression of NAMPT protein; SRT1720 inhibits the reaction [Berberine results in decreased expression of NAMPT protein] |
CTD |
PMID:26712469 |
|
NCBI chr 6:49,425,316...49,462,109
Ensembl chr 6:49,424,332...49,462,100
|
|
G |
Ncf1 |
neutrophil cytosolic factor 1 |
multiple interactions |
ISO |
Berberine promotes the reaction [CYBB protein binds to NCF1 protein binds to NCF2 protein binds to RAC2 protein]; Berberine promotes the reaction [CYBB protein binds to NCF1 protein] |
CTD |
PMID:36070022 |
|
NCBI chr12:22,485,382...22,494,647
Ensembl chr12:22,485,451...22,494,646
|
|
G |
Ncf2 |
neutrophil cytosolic factor 2 |
multiple interactions |
ISO |
Berberine promotes the reaction [CYBB protein binds to NCF1 protein binds to NCF2 protein binds to RAC2 protein]; Berberine promotes the reaction [CYBB protein binds to NCF2 protein] |
CTD |
PMID:36070022 |
|
NCBI chr13:64,955,622...64,986,144
Ensembl chr13:64,955,503...64,986,277
|
|
G |
Nfe2l2 |
NFE2 like bZIP transcription factor 2 |
increases expression multiple interactions increases activity |
ISO EXP |
Berberine results in increased expression of NFE2L2 protein Berberine inhibits the reaction [Particulate Matter results in decreased expression of NFE2L2 protein] Berberine results in increased activity of NFE2L2 protein Berberine inhibits the reaction [Bortezomib results in increased expression of NFE2L2 mRNA]; Berberine promotes the reaction [Bleomycin results in increased expression of NFE2L2 protein] NFE2L2 mutant form inhibits the reaction [Berberine inhibits the reaction [Glucose results in increased abundance of Reactive Oxygen Species]]; NFE2L2 mutant form inhibits the reaction [Berberine results in increased expression of HMOX1 protein]; NFE2L2 mutant form inhibits the reaction [Berberine results in increased expression of NGF protein] |
CTD |
PMID:23523906 PMID:23954465 PMID:30818834 PMID:35121005 PMID:37839514 |
|
NCBI chr 3:60,594,239...60,621,712
Ensembl chr 3:60,594,242...60,621,737
|
|
G |
Nfkb1 |
nuclear factor kappa B subunit 1 |
multiple interactions |
EXP |
Berberine inhibits the reaction [Bortezomib results in increased expression of NFKB1 mRNA] |
CTD |
PMID:35121005 |
|
NCBI chr 2:224,016,214...224,132,135
Ensembl chr 2:224,016,214...224,110,404
|
|
G |
Nfkbia |
NFKB inhibitor alpha |
multiple interactions |
ISO |
Berberine inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of NFKBIA protein] Berberine inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased phosphorylation of NFKBIA protein]; KPNA4 protein inhibits the reaction [Berberine inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased phosphorylation of NFKBIA protein]] |
CTD |
PMID:21963898 PMID:34427876 |
|
NCBI chr 6:72,858,713...72,861,941
Ensembl chr 6:72,858,712...72,861,941
|
|
G |
Ngf |
nerve growth factor |
multiple interactions |
ISO |
Berberine inhibits the reaction [Glucose results in decreased expression of NGF protein]; NFE2L2 mutant form inhibits the reaction [Berberine results in increased expression of NGF protein] |
CTD |
PMID:23954465 |
|
NCBI chr 2:189,901,058...189,954,452
Ensembl chr 2:189,901,058...189,954,452
|
|
G |
Nlrp3 |
NLR family, pyrin domain containing 3 |
multiple interactions |
EXP ISO |
Berberine inhibits the reaction [Bortezomib results in increased expression of NLRP3 mRNA] Berberine inhibits the reaction [[Water deficiency co-treated with NG-Nitroarginine Methyl Ester co-treated with Indomethacin co-treated with Iohexol] results in increased expression of NLRP3 mRNA]; Berberine inhibits the reaction [[Water deficiency co-treated with NG-Nitroarginine Methyl Ester co-treated with Indomethacin co-treated with Iohexol] results in increased expression of NLRP3 protein] |
CTD |
PMID:35121005 PMID:38705399 |
|
NCBI chr10:44,326,770...44,353,814
Ensembl chr10:44,328,566...44,352,811
|
|
G |
Nos2 |
nitric oxide synthase 2 |
multiple interactions |
ISO EXP |
Berberine inhibits the reaction [Carbon Tetrachloride results in increased expression of NOS2 protein] Berberine inhibits the reaction [Bleomycin results in increased expression of NOS2 protein] |
CTD |
PMID:21095217 PMID:23523906 |
|
NCBI chr10:63,815,308...63,851,208
Ensembl chr10:63,815,308...63,851,210
|
|
G |
Nqo1 |
NAD(P)H quinone dehydrogenase 1 |
multiple interactions |
IEP EXP |
Berberine reverses reaction [Carbon tetrachloride decreases Nqo1 mRNA in liver] Berberine inhibits the reaction [Bortezomib results in increased expression of NQO1 mRNA] |
CTD RGD |
PMID:35121005 PMID:31432116 |
RGD:25823187 |
NCBI chr19:35,295,633...35,310,528
Ensembl chr19:35,295,573...35,310,557
|
|
G |
Nr1h3 |
nuclear receptor subfamily 1, group H, member 3 |
increases localization |
ISO |
Berberine increases localization of NR1H3 protein in macrophage nucleus |
RGD |
PMID:20506155 |
RGD:401827279 |
NCBI chr 3:77,158,808...77,168,907
Ensembl chr 3:77,158,808...77,168,722
|
|
G |
Nr1i2 |
nuclear receptor subfamily 1, group I, member 2 |
increases activity multiple interactions |
ISO |
Berberine results in increased activity of NR1I2 protein [Berberine results in increased activity of NR1I2 protein] which results in increased expression of CYP3A4 mRNA |
CTD |
PMID:21524698 |
|
NCBI chr11:62,460,213...62,496,665
Ensembl chr11:62,460,213...62,496,658
|
|
G |
Nr1i3 |
nuclear receptor subfamily 1, group I, member 3 |
increases activity |
ISO |
Berberine results in increased activity of NR1I3 protein |
CTD |
PMID:30818834 |
|
NCBI chr13:83,632,940...83,638,193
Ensembl chr13:83,632,899...83,637,906
|
|
G |
Nsd2 |
nuclear receptor binding SET domain protein 2 |
decreases expression |
ISO |
Berberine results in decreased expression of NSD2 mRNA |
CTD |
PMID:27311644 |
|
NCBI chr14:76,833,179...76,911,304
Ensembl chr14:76,835,637...76,913,641
|
|
G |
Odc1 |
ornithine decarboxylase 1 |
multiple interactions decreases expression |
EXP |
arsenic trioxide promotes the reaction [Berberine results in decreased expression of ODC1 protein] |
CTD |
PMID:18294404 |
|
NCBI chr 6:40,329,831...40,336,444
Ensembl chr 6:40,329,964...40,336,440
|
|
G |
Omd |
osteomodulin |
increases expression |
ISO |
Berberine results in increased expression of OMD mRNA |
CTD |
PMID:26478571 |
|
NCBI chr17:15,060,217...15,068,441
Ensembl chr17:15,060,217...15,068,441
|
|
G |
P2rx7 |
purinergic receptor P2X 7 |
multiple interactions |
ISO |
Berberine affects the reaction [3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate results in increased activity of P2RX7 protein] |
CTD |
PMID:21320518 |
|
NCBI chr12:33,889,709...33,934,168
Ensembl chr12:33,879,745...33,934,619
|
|
G |
Parp1 |
poly (ADP-ribose) polymerase 1 |
increases cleavage multiple interactions |
ISO |
Berberine results in increased cleavage of PARP1 protein [Berberine co-treated with Cisplatin] results in increased cleavage of PARP1 protein; [Berberine co-treated with Niacinamide] results in increased cleavage of PARP1 protein; Acetylcysteine inhibits the reaction [[Berberine co-treated with Cisplatin] results in increased cleavage of PARP1 protein] |
CTD |
PMID:16505103 PMID:26712469 PMID:36070022 |
|
NCBI chr13:92,307,593...92,339,406
Ensembl chr13:92,307,586...92,339,404
|
|
G |
Pdcd4 |
programmed cell death 4 |
increases expression |
ISO |
Berberine increases expression of PDCD4 protein in colon epithelial cells |
RGD |
PMID:29564000 |
RGD:152995489 |
NCBI chr 1:252,921,342...252,944,278
Ensembl chr 1:252,921,392...252,944,275
|
|
G |
Pdk4 |
pyruvate dehydrogenase kinase 4 |
increases expression |
ISO |
Berberine results in increased expression of PDK4 mRNA |
CTD |
PMID:37511356 |
|
NCBI chr 4:33,591,796...33,601,798
Ensembl chr 4:33,589,799...33,601,850
|
|
G |
Ppara |
peroxisome proliferator activated receptor alpha |
multiple interactions |
ISO EXP |
Berberine inhibits the reaction [Ethanol results in decreased expression of PPARA mRNA] Berberine inhibits the reaction [[Streptozocin co-treated with Dietary Fats co-treated with Dietary Carbohydrates] results in increased expression of PPARA protein] |
CTD |
PMID:18338635 PMID:25455889 |
|
NCBI chr 7:116,832,405...116,900,878
Ensembl chr 7:116,832,756...116,895,346
|
|
G |
Ppard |
peroxisome proliferator-activated receptor delta |
increases activity multiple interactions increases expression |
ISO EXP |
Berberine results in increased activity of PPARD protein Berberine inhibits the reaction [[Streptozocin co-treated with Dietary Fats co-treated with Dietary Carbohydrates] results in increased expression of PPARD protein] Berberine results in increased expression of PPARD mRNA; Berberine results in increased expression of PPARD protein |
CTD |
PMID:18338635 PMID:37511356 |
|
NCBI chr20:6,298,785...6,363,970
Ensembl chr20:6,298,785...6,363,968
|
|
G |
Pparg |
peroxisome proliferator-activated receptor gamma |
multiple interactions decreases expression increases response to substance increases expression |
ISO EXP |
Berberine inhibits the reaction [Clozapine results in increased expression of PPARG mRNA]; Berberine inhibits the reaction [Clozapine results in increased expression of PPARG protein]; Berberine inhibits the reaction [Particulate Matter results in decreased expression of PPARG mRNA]; Berberine inhibits the reaction [Risperidone results in increased expression of PPARG mRNA]; Berberine inhibits the reaction [Risperidone results in increased expression of PPARG protein] Berberine inhibits the reaction [[Streptozocin co-treated with Dietary Fats co-treated with Dietary Carbohydrates] results in decreased expression of PPARG protein] Berberine results in decreased expression of PPARG mRNA; Berberine results in decreased expression of PPARG protein 15-deoxyprostaglandin J2 promotes the reaction [Berberine affects the localization of and results in increased activity of PPARG protein]; Berberine inhibits the reaction [Bleomycin binds to PPARG protein]; Berberine promotes the reaction [15-deoxyprostaglandin J2 affects the localization of and results in increased activity of PPARG protein]; Berberine results in increased activity of and affects the localization of PPARG protein; PPARG mRNA promotes the reaction [Berberine results in increased expression of HGF protein] PPARG mRNA results in increased susceptibility to Berberine Berberine results in increased expression of PPARG mRNA |
CTD |
PMID:18338635 PMID:20564506 PMID:26478571 PMID:29408570 PMID:37511356 PMID:37839514 More...
|
|
NCBI chr 4:148,423,102...148,548,471
Ensembl chr 4:148,423,194...148,548,468
|
|
G |
Ppargc1a |
PPARG coactivator 1 alpha |
multiple interactions |
ISO |
Berberine inhibits the reaction [Ethanol results in decreased expression of PPARGC1A mRNA] |
CTD |
PMID:25455889 |
|
NCBI chr14:58,860,752...59,516,525
Ensembl chr14:58,861,144...59,512,656
|
|
G |
Prg4 |
proteoglycan 4 |
decreases expression |
ISO |
Berberine results in decreased expression of PRG4 mRNA |
CTD |
PMID:26478571 |
|
NCBI chr13:62,487,257...62,504,657
Ensembl chr13:62,487,257...62,504,119
|
|
G |
Prkaa1 |
protein kinase AMP-activated catalytic subunit alpha 1 |
increases phosphorylation |
ISO |
Berberine results in increased phosphorylation of PRKAA1 protein |
CTD |
PMID:28298333 |
|
NCBI chr 2:54,240,298...54,275,978
Ensembl chr 2:54,240,137...54,275,978
|
|
G |
Prkca |
protein kinase C, alpha |
multiple interactions |
EXP |
arsenic trioxide promotes the reaction [Berberine results in decreased activity of PRKCA protein]; Berberine results in decreased activity of and affects the localization of PRKCA protein |
CTD |
PMID:18294404 |
|
NCBI chr10:92,889,390...93,288,013
Ensembl chr10:92,894,012...93,288,012
|
|
G |
Prkce |
protein kinase C, epsilon |
multiple interactions decreases activity |
EXP |
arsenic trioxide promotes the reaction [Berberine results in decreased activity of PRKCE protein]; Berberine results in decreased activity of and affects the localization of PRKCE protein |
CTD |
PMID:18294404 |
|
NCBI chr 6:7,965,048...8,451,966
Ensembl chr 6:7,965,048...8,451,719
|
|
G |
Prmt1 |
protein arginine methyltransferase 1 |
decreases expression |
ISO |
Berberine results in decreased expression of PRMT1 mRNA |
CTD |
PMID:27311644 |
|
NCBI chr 1:95,458,853...95,468,176
Ensembl chr 1:95,458,850...95,468,345
|
|
G |
Prmt2 |
protein arginine methyltransferase 2 |
increases expression |
ISO |
Berberine results in increased expression of PRMT2 mRNA |
CTD |
PMID:27311644 |
|
NCBI chr20:12,394,748...12,420,643
Ensembl chr20:12,394,798...12,420,643
|
|
G |
Prmt5 |
protein arginine methyltransferase 5 |
increases expression |
ISO |
Berberine results in increased expression of PRMT5 mRNA |
CTD |
PMID:27311644 |
|
NCBI chr15:27,968,893...27,978,291
Ensembl chr15:27,968,910...27,978,296
|
|
G |
Prmt6 |
protein arginine methyltransferase 6 |
increases expression |
ISO |
Berberine results in increased expression of PRMT6 mRNA |
CTD |
PMID:27311644 |
|
NCBI chr 2:197,927,750...197,932,760
Ensembl chr 2:197,927,220...197,933,648
|
|
G |
Prmt7 |
protein arginine methyltransferase 7 |
increases expression |
ISO |
Berberine results in increased expression of PRMT7 mRNA |
CTD |
PMID:27311644 |
|
NCBI chr19:34,110,724...34,161,531
Ensembl chr19:34,110,747...34,162,577
|
|
G |
Prmt8 |
protein arginine methyltransferase 8 |
increases expression |
ISO |
Berberine results in increased expression of PRMT8 mRNA |
CTD |
PMID:27311644 |
|
NCBI chr 4:160,535,813...160,618,193
Ensembl chr 4:160,535,813...160,617,930
|
|
G |
Pten |
phosphatase and tensin homolog |
multiple interactions increases expression |
ISO |
((3Z)-N-(3-chlorophenyl)-3-((3,5-dimethyl-4-((4-methylpiperazin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-N-methyl-2-oxo-2,3-dihydro-1H-indole-5-sulfonamide) inhibits the reaction [Berberine inhibits the reaction [Bleomycin results in decreased expression of PTEN mRNA]]; Berberine inhibits the reaction [Bleomycin results in decreased expression of PTEN mRNA]; Berberine inhibits the reaction [Bleomycin results in decreased expression of PTEN protein] Berberine results in increased expression of PTEN protein |
CTD |
PMID:29408570 |
|
NCBI chr 1:230,630,443...230,697,070
Ensembl chr 1:230,630,338...230,696,838
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
multiple interactions |
ISO |
Berberine inhibits the reaction [Carbon Tetrachloride results in increased expression of PTGS2 protein] |
CTD |
PMID:21095217 |
|
NCBI chr13:62,163,936...62,172,193
Ensembl chr13:62,163,932...62,172,188
|
|
G |
Pycard |
PYD and CARD domain containing |
multiple interactions |
ISO |
Berberine inhibits the reaction [[Water deficiency co-treated with NG-Nitroarginine Methyl Ester co-treated with Indomethacin co-treated with Iohexol] results in increased expression of PYCARD mRNA] |
CTD |
PMID:38705399 |
|
NCBI chr 1:182,601,657...182,603,013
Ensembl chr 1:182,601,174...182,602,955
|
|
G |
Rac2 |
Rac family small GTPase 2 |
multiple interactions |
ISO |
Berberine promotes the reaction [CYBB protein binds to NCF1 protein binds to NCF2 protein binds to RAC2 protein]; Berberine promotes the reaction [CYBB protein binds to RAC2 protein]; Berberine results in increased expression of and results in increased activity of RAC2 protein |
CTD |
PMID:36070022 |
|
NCBI chr 7:110,101,344...110,128,718
Ensembl chr 7:110,116,260...110,128,720
|
|
G |
Rbp4 |
retinol binding protein 4 |
multiple interactions |
EXP |
Berberine inhibits the reaction [[Dietary Fats co-treated with Streptozocin] results in increased secretion of RBP4 protein] |
CTD |
PMID:19080170 |
|
NCBI chr 1:235,893,917...235,901,315
Ensembl chr 1:235,893,917...235,901,399
|
|
G |
Rela |
RELA proto-oncogene, NF-kB subunit |
multiple interactions |
EXP ISO |
Berberine inhibits the reaction [Bleomycin affects the localization of and results in increased expression of RELA protein] Berberine inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased phosphorylation of RELA protein]; KPNA4 protein inhibits the reaction [Berberine inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased phosphorylation of RELA protein]] |
CTD |
PMID:23523906 PMID:34427876 |
|
NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484
|
|
G |
Rln1 |
relaxin 1 |
affects binding increases expression multiple interactions |
EXP |
Berberine binds to RLN1 promoter Berberine results in increased expression of RLN1 mRNA [Berberine binds to RLN1 promoter] which results in increased expression of RLN1 mRNA |
CTD |
PMID:22363579 |
|
NCBI chr 1:227,079,960...227,082,960
Ensembl chr 1:227,079,966...227,082,882
|
|
G |
Rps6 |
ribosomal protein S6 |
decreases phosphorylation |
ISO |
Berberine results in decreased phosphorylation of RPS6 protein |
CTD |
PMID:23363784 |
|
NCBI chr 5:101,371,716...101,374,576
Ensembl chr 5:101,371,136...101,374,602 Ensembl chr 5:101,371,136...101,374,602
|
|
G |
Runx2 |
RUNX family transcription factor 2 |
multiple interactions increases expression |
ISO |
CTNNB1 mutant form inhibits the reaction [Berberine results in increased expression of RUNX2 mRNA]; DKK1 protein inhibits the reaction [Berberine results in increased expression of RUNX2 mRNA] |
CTD |
PMID:26478571 |
|
NCBI chr 9:16,167,504...16,492,826
Ensembl chr 9:16,167,482...16,492,167
|
|
G |
Setd1b |
SET domain containing 1B, histone lysine methyltransferase |
increases expression |
ISO |
Berberine results in increased expression of SETD1B mRNA |
CTD |
PMID:27311644 |
|
NCBI chr12:33,395,963...33,421,671
Ensembl chr12:33,396,120...33,426,934
|
|
G |
Setd2 |
SET domain containing 2, histone lysine methyltransferase |
increases expression |
ISO |
Berberine results in increased expression of SETD2 mRNA |
CTD |
PMID:27311644 |
|
NCBI chr 8:110,511,808...110,597,475
Ensembl chr 8:110,511,772...110,597,489
|
|
G |
Setd3 |
SET domain containing 3, actin N3(tau)-histidine methyltransferase |
increases expression |
ISO |
Berberine results in increased expression of SETD3 mRNA |
CTD |
PMID:27311644 |
|
NCBI chr 6:127,023,058...127,090,020
Ensembl chr 6:127,023,058...127,090,008
|
|
G |
Setd5 |
SET domain containing 5 |
increases expression |
ISO |
Berberine results in increased expression of SETD5 mRNA |
CTD |
PMID:27311644 |
|
NCBI chr 4:146,217,172...146,294,896
Ensembl chr 4:146,217,180...146,294,894
|
|
G |
Setd6 |
SET domain containing 6, protein lysine methyltransferase |
increases expression |
ISO |
Berberine results in increased expression of SETD6 mRNA |
CTD |
PMID:27311644 |
|
NCBI chr19:9,343,309...9,350,477
Ensembl chr19:9,347,458...9,350,453
|
|
G |
Setd7 |
SET domain containing 7, histone lysine methyltransferase |
increases expression |
ISO |
Berberine results in increased expression of SETD7 mRNA |
CTD |
PMID:27311644 |
|
NCBI chr 2:135,562,683...135,605,468
Ensembl chr 2:135,562,683...135,605,468
|
|
G |
Setdb1 |
SET domain bifurcated histone lysine methyltransferase 1 |
increases expression |
ISO |
Berberine results in increased expression of SETDB1 mRNA |
CTD |
PMID:27311644 |
|
NCBI chr 2:182,898,738...182,930,283
Ensembl chr 2:182,898,738...182,930,506
|
|
G |
Setdb2 |
SET domain bifurcated histone lysine methyltransferase 2 |
increases expression |
ISO |
Berberine results in increased expression of SETDB2 mRNA |
CTD |
PMID:27311644 |
|
NCBI chr15:33,553,657...33,606,586
Ensembl chr15:33,453,952...33,606,470
|
|
G |
Si |
sucrase-isomaltase |
decreases expression multiple interactions |
ISO EXP |
Berberine results in decreased expression of SI mRNA N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Berberine results in decreased expression of SI mRNA] |
CTD |
PMID:20229011 |
|
NCBI chr 2:157,505,893...157,586,228
Ensembl chr 2:157,506,342...157,585,260
|
|
G |
Sirt1 |
sirtuin 1 |
decreases expression multiple interactions |
ISO EXP |
Berberine results in decreased expression of SIRT1 mRNA; Berberine results in decreased expression of SIRT1 protein Berberine inhibits the reaction [Bortezomib results in decreased expression of SIRT1 protein] [Berberine co-treated with Niacinamide] results in decreased expression of SIRT1 protein; SRT1720 inhibits the reaction [Berberine results in decreased expression of SIRT1 protein] |
CTD |
PMID:26712469 PMID:35121005 |
|
NCBI chr20:25,307,225...25,329,273
Ensembl chr20:25,306,917...25,329,260
|
|
G |
Sirt2 |
sirtuin 2 |
multiple interactions |
ISO |
[Berberine co-treated with Niacinamide] results in decreased expression of SIRT2 protein |
CTD |
PMID:26712469 |
|
NCBI chr 1:84,053,883...84,076,975
Ensembl chr 1:84,052,903...84,076,975
|
|
G |
Sirt3 |
sirtuin 3 |
multiple interactions increases expression decreases expression |
ISO |
[Berberine co-treated with Niacinamide] results in decreased expression of SIRT3 protein Berberine results in increased expression of SIRT3 mRNA Berberine results in decreased expression of SIRT3 mRNA; Berberine results in decreased expression of SIRT3 protein |
CTD |
PMID:26712469 PMID:27311644 |
|
NCBI chr 1:195,942,066...195,964,472
Ensembl chr 1:195,942,073...195,964,808
|
|
G |
Slc27a5 |
solute carrier family 27 member 5 |
decreases expression |
ISO |
Berberine results in decreased expression of SLC27A5 mRNA |
CTD |
PMID:28038998 |
|
NCBI chr 1:73,616,556...73,627,149
Ensembl chr 1:73,616,564...73,627,172
|
|
G |
Slc2a4 |
solute carrier family 2 member 4 |
multiple interactions |
EXP |
Berberine inhibits the reaction [[Dietary Fats co-treated with Streptozocin] results in decreased expression of SLC2A4 protein] |
CTD |
PMID:19080170 |
|
NCBI chr10:54,666,015...54,671,581
Ensembl chr10:54,666,015...54,671,565
|
|
G |
Slc6a19 |
solute carrier family 6 member 19 |
multiple interactions |
EXP |
Berberine affects the reaction [Lipopolysaccharides affects the expression of SLC6A19 mRNA]; Berberine affects the reaction [Lipopolysaccharides affects the expression of SLC6A19 protein] |
CTD |
PMID:21073932 |
|
NCBI chr 1:29,586,191...29,604,964
Ensembl chr 1:29,586,195...29,604,962
|
|
G |
Smyd3 |
SET and MYND domain containing 3 |
affects expression |
ISO |
Berberine affects the expression of SMYD3 mRNA |
CTD |
PMID:27311644 |
|
NCBI chr13:90,709,263...91,266,209
Ensembl chr13:90,709,270...91,266,253
|
|
G |
Socs3 |
suppressor of cytokine signaling 3 |
multiple interactions |
ISO |
Berberine inhibits the reaction [Particulate Matter results in decreased expression of SOCS3 mRNA]; Berberine inhibits the reaction [Particulate Matter results in decreased expression of SOCS3 protein] |
CTD |
PMID:37839514 |
|
NCBI chr10:103,193,909...103,197,322
Ensembl chr10:103,193,537...103,197,787
|
|
G |
Sod1 |
superoxide dismutase 1 |
multiple interactions |
ISO EXP |
Berberine inhibits the reaction [Carbon Tetrachloride results in decreased activity of SOD1 protein]; Berberine inhibits the reaction [Particulate Matter results in decreased expression of SOD1 protein]; Berberine inhibits the reaction [Streptozocin affects the expression of SOD1 mRNA] Berberine inhibits the reaction [Chlorpyrifos results in decreased activity of SOD1 protein] |
CTD |
PMID:21095217 PMID:22775417 PMID:35439518 PMID:37839514 |
|
NCBI chr11:29,456,673...29,462,249
Ensembl chr11:29,456,558...29,462,249
|
|
G |
Sod2 |
superoxide dismutase 2 |
multiple interactions |
ISO EXP |
Berberine inhibits the reaction [Streptozocin affects the expression of SOD2 mRNA] Berberine inhibits the reaction [acetamiprid results in decreased expression of SOD2 mRNA]; Berberine inhibits the reaction [Mercuric Chloride results in decreased expression of SOD2 mRNA] |
CTD |
PMID:22775417 PMID:24751971 PMID:33460233 PMID:37350525 |
|
NCBI chr 1:47,638,318...47,645,163
Ensembl chr 1:47,636,528...47,645,189
|
|
G |
Sox9 |
SRY-box transcription factor 9 |
decreases expression |
ISO |
Berberine results in decreased expression of SOX9 mRNA |
CTD |
PMID:26478571 |
|
NCBI chr10:97,806,485...97,811,994
Ensembl chr10:97,806,485...97,811,994
|
|
G |
Sp7 |
Sp7 transcription factor |
increases expression |
ISO |
Berberine results in increased expression of SP7 mRNA |
CTD |
PMID:26478571 |
|
NCBI chr 7:133,484,609...133,494,788
Ensembl chr 7:133,484,609...133,494,847
|
|
G |
Sparc |
secreted protein acidic and cysteine rich |
increases expression |
ISO |
Berberine results in increased expression of SPARC mRNA |
CTD |
PMID:26478571 |
|
NCBI chr10:39,516,394...39,538,252
Ensembl chr10:39,516,406...39,538,396
|
|
G |
Spp1 |
secreted phosphoprotein 1 |
increases expression multiple interactions |
ISO |
Berberine results in increased expression of SPP1 mRNA; Berberine results in increased expression of SPP1 protein CTNNB1 mutant form inhibits the reaction [Berberine results in increased expression of SPP1 protein]; DKK1 protein inhibits the reaction [Berberine results in increased expression of SPP1 protein] |
CTD |
PMID:26478571 |
|
NCBI chr14:5,308,885...5,315,120
Ensembl chr14:5,308,885...5,315,162
|
|
G |
Sqstm1 |
sequestosome 1 |
increases expression multiple interactions |
ISO |
Berberine results in increased expression of SQSTM1 protein [Berberine co-treated with Water deficiency co-treated with NG-Nitroarginine Methyl Ester co-treated with Indomethacin co-treated with Iohexol] results in increased expression of SQSTM1 protein |
CTD |
PMID:36070022 PMID:38705399 |
|
NCBI chr10:34,525,517...34,536,670
Ensembl chr10:34,525,519...34,536,673
|
|
G |
Srebf1 |
sterol regulatory element binding transcription factor 1 |
multiple interactions decreases expression |
ISO |
Berberine inhibits the reaction [Clozapine results in increased expression of SREBF1 mRNA]; Berberine inhibits the reaction [Clozapine results in increased expression of SREBF1 protein]; Berberine inhibits the reaction [Risperidone results in increased expression of SREBF1 mRNA]; Berberine inhibits the reaction [Risperidone results in increased expression of SREBF1 protein] Berberine results in decreased expression of SREBF1 mRNA |
CTD |
PMID:20564506 PMID:26478571 |
|
NCBI chr10:45,007,637...45,029,650
Ensembl chr10:45,007,637...45,029,650
|
|
G |
Stat3 |
signal transducer and activator of transcription 3 |
multiple interactions |
EXP ISO |
Berberine inhibits the reaction [Bortezomib results in increased expression of STAT3 mRNA] Berberine inhibits the reaction [Particulate Matter results in increased expression of STAT3 mRNA] |
CTD |
PMID:35121005 PMID:37839514 |
|
NCBI chr10:85,811,206...85,863,057
Ensembl chr10:85,811,218...85,863,057
|
|
G |
Tert |
telomerase reverse transcriptase |
decreases activity |
ISO |
Berberine results in decreased activity of TERT protein |
CTD |
PMID:25265580 |
|
NCBI chr 1:29,637,213...29,659,561
Ensembl chr 1:29,637,506...29,659,561
|
|
G |
Tgfb1 |
transforming growth factor, beta 1 |
decreases expression multiple interactions |
EXP ISO |
Berberine results in decreased expression of TGFB1 protein Berberine inhibits the reaction [Particulate Matter results in increased expression of TGFB1 mRNA] Berberine inhibits the reaction [Bleomycin results in increased expression of TGFB1 protein]; Berberine inhibits the reaction [Thioacetamide results in increased expression of TGFB1 mRNA] |
CTD |
PMID:17973934 PMID:23523906 PMID:30138605 PMID:37839514 |
|
NCBI chr 1:81,196,532...81,212,848
Ensembl chr 1:81,196,532...81,212,847
|
|
G |
Tlr4 |
toll-like receptor 4 |
multiple interactions |
ISO EXP |
Berberine inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with TNF protein] results in increased expression of TLR4 mRNA]; Berberine inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with TNF protein] results in increased secretion of TLR4 protein]; Berberine inhibits the reaction [Lipopolysaccharides results in increased expression of TLR4 mRNA] Berberine inhibits the reaction [Bortezomib results in increased expression of TLR4 protein] |
CTD |
PMID:21963898 PMID:30240693 PMID:35121005 |
|
NCBI chr 5:80,145,867...80,159,501
Ensembl chr 5:80,145,826...80,159,628
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions increases secretion increases expression |
ISO EXP |
Berberine inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased expression of TNF protein]; Berberine inhibits the reaction [TNF protein results in increased expression of CCL2 mRNA]; Berberine inhibits the reaction [TNF protein results in increased expression of CXCL8 mRNA]; Berberine inhibits the reaction [TNF protein results in increased secretion of CCL2 protein]; Berberine inhibits the reaction [TNF protein results in increased secretion of CXCL8 protein]; KPNA4 protein inhibits the reaction [Berberine inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased expression of TNF protein]]; LINC00943 inhibits the reaction [Berberine inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased expression of TNF protein]]; MIR142 affects the reaction [Berberine inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased expression of TNF protein]] Berberine inhibits the reaction [[Cadmium co-treated with Aluminum co-treated with Fluorides] results in increased expression of TNF mRNA]; Berberine inhibits the reaction [[Cadmium co-treated with Aluminum co-treated with Fluorides] results in increased expression of TNF protein]; Berberine inhibits the reaction [Bleomycin results in increased expression of TNF protein]; Berberine inhibits the reaction [Bortezomib results in increased expression of TNF mRNA]; Berberine inhibits the reaction [Cyclophosphamide results in increased expression of TNF protein]; Berberine inhibits the reaction [Mercuric Chloride results in increased expression of TNF protein] Berberine results in increased secretion of TNF protein Berberine results in increased expression of TNF mRNA Berberine inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with TNF protein] results in decreased expression of and results in increased phosphorylation of MAP3K5 protein]; Berberine inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with TNF protein] results in increased expression of IL23A mRNA]; Berberine inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with TNF protein] results in increased expression of IL6 mRNA]; Berberine inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with TNF protein] results in increased expression of TLR4 mRNA]; Berberine inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with TNF protein] results in increased expression of TRAF2 mRNA]; Berberine inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with TNF protein] results in increased secretion of IL23A protein]; Berberine inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with TNF protein] results in increased secretion of IL6 protein]; Berberine inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with TNF protein] results in increased secretion of TLR4 protein]; Berberine inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with TNF protein] results in increased secretion of TRAF2 protein]; Berberine inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of TNF mRNA]; Berberine inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of TNF protein]; Berberine inhibits the reaction [[Water deficiency co-treated with NG-Nitroarginine Methyl Ester co-treated with Indomethacin co-treated with Iohexol] results in increased expression of TNF mRNA]; Berberine inhibits the reaction [Benzo(a)pyrene results in increased expression of TNF mRNA]; Berberine inhibits the reaction [Carbon Tetrachloride results in increased expression of TNF protein]; Berberine inhibits the reaction [Dietary Fats results in increased secretion of TNF protein]; Berberine inhibits the reaction [Lipopolysaccharides results in increased expression of TNF mRNA]; Berberine inhibits the reaction [Particulate Matter results in increased expression of TNF protein] |
CTD |
PMID:16391493 PMID:20656010 PMID:21095217 PMID:21867779 PMID:23523906 PMID:25600690 PMID:28533128 PMID:29170048 PMID:30240693 PMID:34427876 PMID:35121005 PMID:35691465 PMID:37511356 PMID:37839514 PMID:37955270 PMID:38705399 More...
|
|
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
G |
Top1 |
DNA topoisomerase I |
decreases activity |
ISO |
Berberine results in decreased activity of TOP1 protein |
CTD |
PMID:23747414 |
|
NCBI chr 3:149,293,469...149,376,618
Ensembl chr 3:149,293,403...149,376,623
|
|
G |
Top2a |
DNA topoisomerase II alpha |
multiple interactions affects response to substance |
ISO |
TOP2A protein affects the reaction [Berberine results in increased expression of H2AX protein modified form] TOP2A protein affects the susceptibility to Berberine |
CTD |
PMID:23747414 |
|
NCBI chr10:83,945,731...83,976,874
Ensembl chr10:83,945,735...83,976,874
|
|
G |
Tp53 |
tumor protein p53 |
increases expression multiple interactions |
ISO |
Berberine results in increased expression of TP53 mRNA; Berberine results in increased expression of TP53 protein [Berberine co-treated with Niacinamide] results in increased expression of and results in increased acetylation of TP53 protein; Berberine results in increased phosphorylation of and results in increased acetylation of TP53 protein |
CTD |
PMID:20656010 PMID:26712469 |
|
NCBI chr10:54,300,070...54,311,525
Ensembl chr10:54,300,048...54,311,524
|
|
G |
Traf1 |
TNF receptor-associated factor 1 |
increases expression |
ISO |
Berberine results in increased expression of TRAF1 protein |
CTD |
PMID:20656010 |
|
NCBI chr 3:18,222,024...18,242,163
Ensembl chr 3:18,222,054...18,241,807
|
|
G |
Traf2 |
Tnf receptor-associated factor 2 |
multiple interactions |
ISO |
Berberine inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with TNF protein] results in increased expression of TRAF2 mRNA]; Berberine inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with TNF protein] results in increased secretion of TRAF2 protein] |
CTD |
PMID:30240693 |
|
NCBI chr 3:8,341,950...8,366,609
Ensembl chr 3:8,341,951...8,366,538
|
|
G |
Trim21 |
tripartite motif-containing 21 |
multiple interactions |
ISO |
Berberine promotes the reaction [IGF2BP3 protein binds to TRIM21 protein] |
CTD |
PMID:36822301 |
|
NCBI chr 1:156,964,896...156,987,504
Ensembl chr 1:156,964,913...156,987,440
|
|
G |
Tstd1 |
thiosulfate sulfurtransferase like domain containing 1 |
increases expression |
ISO |
Berberine results in increased expression of TSTD1 mRNA |
CTD |
PMID:27311644 |
|
NCBI chr13:83,853,421...83,854,875
Ensembl chr13:83,822,035...83,854,885
|
|
G |
Ube2a |
ubiquitin-conjugating enzyme E2A |
decreases expression |
ISO |
Berberine results in decreased expression of UBE2A mRNA |
CTD |
PMID:27311644 |
|
NCBI chr X:116,114,339...116,125,076
Ensembl chr X:116,113,875...116,125,070
|
|
G |
Ube2b |
ubiquitin-conjugating enzyme E2B |
decreases expression |
ISO |
Berberine results in decreased expression of UBE2B mRNA |
CTD |
PMID:27311644 |
|
NCBI chr10:36,248,434...36,263,379
Ensembl chr10:36,248,438...36,264,665
|
|
G |
Ucp2 |
uncoupling protein 2 |
multiple interactions increases expression |
ISO |
Berberine inhibits the reaction [Benzo(a)pyrene results in increased expression of UCP2 mRNA] Berberine results in increased expression of UCP2 mRNA |
CTD |
PMID:28533128 PMID:37511356 |
|
NCBI chr 1:154,839,242...154,845,612
Ensembl chr 1:154,839,209...154,845,611
|
|
G |
Vegfa |
vascular endothelial growth factor A |
decreases expression |
ISO |
Berberine results in decreased expression of VEGFA protein |
CTD |
PMID:33325633 |
|
NCBI chr 9:14,955,300...14,970,641
Ensembl chr 9:14,955,300...14,970,641
|
|
G |
Vegfc |
vascular endothelial growth factor C |
increases expression |
ISO |
Berberine results in increased expression of VEGFC mRNA |
CTD |
PMID:26478571 |
|
NCBI chr16:37,712,251...37,827,845
Ensembl chr16:37,712,262...37,827,848
|
|
|
G |
Aass |
aminoadipate-semialdehyde synthase |
increases expression |
EXP |
Buspirone results in increased expression of AASS mRNA |
CTD |
PMID:24136188 |
|
NCBI chr 4:51,606,461...51,663,136
Ensembl chr 4:51,606,462...51,663,136
|
|
G |
Abca1 |
ATP binding cassette subfamily A member 1 |
increases expression |
EXP |
Buspirone results in increased expression of ABCA1 mRNA |
CTD |
PMID:24136188 |
|
NCBI chr 5:67,678,267...67,801,162
Ensembl chr 5:67,681,297...67,801,170
|
|
G |
Abcc2 |
ATP binding cassette subfamily C member 2 |
decreases expression |
EXP |
Buspirone results in decreased expression of ABCC2 mRNA |
CTD |
PMID:24136188 |
|
NCBI chr 1:242,664,657...242,723,239
Ensembl chr 1:242,664,657...242,723,238
|
|
G |
Abcf1 |
ATP binding cassette subfamily F member 1 |
decreases expression |
EXP |
Buspirone results in decreased expression of ABCF1 mRNA |
CTD |
PMID:24136188 |
|
NCBI chr20:2,802,519...2,815,433
Ensembl chr20:2,802,488...2,815,433
|
|
G |
Abcg2 |
ATP binding cassette subfamily G member 2 |
decreases expression |
EXP |
Buspirone results in decreased expression of ABCG2 mRNA |
CTD |
PMID:24136188 |
|
NCBI chr 4:87,676,241...87,802,757
Ensembl chr 4:87,745,319...87,802,409
|
|
G |
Abhd14b |
abhydrolase domain containing 14b |
increases expression |
EXP |
Buspirone results in increased expression of ABHD14B mRNA |
CTD |
PMID:24136188 |
|
NCBI chr 8:107,087,157...107,092,122
Ensembl chr 8:107,088,069...107,092,119
|
|
G |
Abtb1 |
ankyrin repeat and BTB domain containing 1 |
increases expression |
EXP |
Buspirone results in increased expression of ABTB1 mRNA |
CTD |
PMID:24136188 |
|
NCBI chr 4:121,299,302...121,305,667
Ensembl chr 4:121,299,304...121,305,620
|
|
G |
Acaa2 |
acetyl-CoA acyltransferase 2 |
increases expression |
EXP |
Buspirone results in increased expression of ACAA2 mRNA |
CTD |
PMID:24136188 |
|
NCBI chr18:68,345,136...68,373,246
Ensembl chr18:68,345,012...68,373,249
|
|
G |
Acaca |
acetyl-CoA carboxylase alpha |
decreases expression |
EXP |
Buspirone results in decreased expression of ACACA mRNA |
CTD |
PMID:24136188 |
|
NCBI chr10:69,014,261...69,276,453
Ensembl chr10:69,014,170...69,276,457
|
|
G |
Acbd4 |
acyl-CoA binding domain containing 4 |
increases expression |
EXP |
Buspirone results in increased expression of ACBD4 mRNA |
CTD |
PMID:24136188 |
|
NCBI chr10:88,048,058...88,062,612
Ensembl chr10:88,048,108...88,058,500
|
|
G |
Acly |
ATP citrate lyase |
decreases expression |
EXP |
Buspirone results in decreased expression of ACLY mRNA |
CTD |
PMID:24136188 |
|
NCBI chr10:85,412,045...85,464,253
Ensembl chr10:85,412,049...85,463,320
|
|
G |
Acsf2 |
acyl-CoA synthetase family member 2 |
decreases expression |
EXP |
Buspirone results in decreased expression of ACSF2 mRNA |
CTD |
PMID:24136188 |
|
NCBI chr10:79,504,510...79,546,714
Ensembl chr10:79,504,511...79,546,673
|
|
G |
Acsl3 |
acyl-CoA synthetase long-chain family member 3 |
decreases expression |
EXP |
Buspirone results in decreased expression of ACSL3 mRNA |
CTD |
PMID:24136188 |
|
NCBI chr 9:80,115,164...80,164,636
Ensembl chr 9:80,115,112...80,164,627
|
|
G |
Acsl4 |
acyl-CoA synthetase long-chain family member 4 |
increases expression |
EXP |
Buspirone results in increased expression of ACSL4 mRNA |
CTD |
PMID:24136188 |
|
NCBI chr X:105,942,794...106,006,573
Ensembl chr X:105,942,799...106,006,427
|
|
G |
Acsl5 |
acyl-CoA synthetase long-chain family member 5 |
decreases expression |
EXP |
Buspirone results in decreased expression of ACSL5 mRNA |
CTD |
PMID:24136188 |
|
NCBI chr 1:254,289,513...254,336,608
Ensembl chr 1:254,292,521...254,336,607
|
|
G |
Actb |
actin, beta |
decreases expression |
EXP |
Buspirone results in decreased expression of ACTB mRNA |
CTD |
PMID:24136188 |
|
NCBI chr12:11,663,112...11,666,697
Ensembl chr12:11,663,109...11,672,877
|
|
G |
Actg1 |
actin, gamma 1 |
decreases expression |
EXP |
Buspirone results in decreased expression of ACTG1 mRNA |
CTD |
PMID:24136188 |
|
NCBI chr10:105,619,738...105,622,587
Ensembl chr10:105,619,737...105,624,232 Ensembl chr 3:105,619,737...105,624,232
|
|
G |
Actn1 |
actinin, alpha 1 |
decreases expression |
EXP |
Buspirone results in decreased expression of ACTN1 mRNA |
CTD |
PMID:24136188 |
|
NCBI chr 6:98,998,553...99,093,334
Ensembl chr 6:98,998,556...99,093,251
|
|
G |
Acy1 |
aminoacylase 1 |
decreases expression |
EXP |
Buspirone results in decreased expression of ACY1 mRNA |
CTD |
PMID:24136188 |
|
NCBI chr 8:107,072,354...107,077,756
Ensembl chr 8:107,072,358...107,077,682
|
|
G |
Adamtsl4 |
ADAMTS-like 4 |
increases expression |
EXP |
Buspirone results in increased expression of ADAMTSL4 mRNA |
CTD |
PMID:24136188 |
|
NCBI chr 2:183,235,634...183,247,091
Ensembl chr 2:183,235,646...183,246,848
|
|
G |
Adcy6 |
adenylate cyclase 6 |
increases expression |
EXP |
Buspirone results in increased expression of ADCY6 mRNA |
CTD |
PMID:24136188 |
|
NCBI chr 7:129,742,827...129,763,922
Ensembl chr 7:129,742,838...129,763,754
|
|
G |
Adipor2 |
adiponectin receptor 2 |
decreases expression |
EXP |
Buspirone results in decreased expression of ADIPOR2 mRNA |
CTD |
PMID:24136188 |
|
NCBI chr 4:152,524,604...152,588,848
Ensembl chr 4:152,524,623...152,559,355
|
|
G |
Adra1a |
adrenoceptor alpha 1A |
multiple interactions |
EXP |
Buspirone binds to and results in decreased activity of ADRA1A protein |
CTD |
PMID:16545797 |
|
NCBI chr15:40,830,125...40,935,902
Ensembl chr15:40,832,534...40,927,500
|
|
G |
Adra1d |
adrenoceptor alpha 1D |
multiple interactions |
EXP |
Buspirone binds to and results in increased activity of ADRA1D protein |
CTD |
PMID:15872040 |
|
NCBI chr 3:118,793,356...118,809,354
Ensembl chr 3:118,793,346...118,809,354
|
|
G |
Agmat |
agmatinase |
increases expression |
EXP |
Buspirone results in increased expression of AGMAT mRNA |
CTD |
PMID:24136188 |
|
NCBI chr 5:154,043,665...154,074,278
Ensembl chr 5:154,060,151...154,074,276
|
|
G |
Ahcy |
adenosylhomocysteinase |
increases expression |
EXP |
Buspirone results in increased expression of AHCY mRNA |
CTD |
PMID:24136188 |
|
NCBI chr 3:143,569,134...143,584,359
Ensembl chr 3:143,569,094...143,584,393
|
|
G |
Aif1 |
allograft inflammatory factor 1 |
decreases expression |
EXP |
Buspirone results in decreased expression of AIF1 mRNA |
CTD |
PMID:24136188 |
|
NCBI chr20:3,646,784...3,652,670
Ensembl chr20:3,646,777...3,652,668
|
|
G |
Aig1 |
androgen-induced 1 |
increases expression |
EXP |
Buspirone results in increased expression of AIG1 mRNA |
CTD |
PMID:24136188 |
|
NCBI chr 1:8,046,430...8,269,276
Ensembl chr 1:8,046,430...8,269,084
|
|
G |
Ak4 |
adenylate kinase 4 |
decreases expression |
EXP |
Buspirone results in decreased expression of AK4 mRNA |
CTD |
PMID:24136188 |
|
NCBI chr 5:116,039,222...116,099,064
Ensembl chr 5:116,039,616...116,098,618
|
|
G |
Akap8l |
A-kinase anchoring protein 8 like |
increases expression |
EXP |
Buspirone results in increased expression of AKAP8L mRNA |
CTD |
PMID:24136188 |
|
NCBI chr 7:11,332,671...11,362,287
Ensembl chr 7:11,332,672...11,362,275
|
|
G |
Akr7a3 |
aldo-keto reductase family 7 member A3 |
decreases expression |
EXP |
Buspirone results in decreased expression of AKR7A3 mRNA |
CTD |
PMID:24136188 |
|
NCBI chr 5:151,590,968...151,601,394
Ensembl chr 5:151,584,479...151,601,394
|
|
G |
Aldh1b1 |
aldehyde dehydrogenase 1 family, member B1 |
decreases expression |
EXP |
Buspirone results in decreased expression of ALDH1B1 mRNA |
CTD |
PMID:24136188 |
|
NCBI chr 5:60,063,370...60,068,378
Ensembl chr 5:60,063,225...60,068,378
|
|
G |
Alkbh7 |
alkB homolog 7 |
increases expression |
EXP |
Buspirone results in increased expression of ALKBH7 mRNA |
CTD |
PMID:24136188 |
|
NCBI chr 9:1,838,886...1,841,044
Ensembl chr 9:1,838,811...1,841,044
|
|
G |
Ankh |
ANKH inorganic pyrophosphate transport regulator |
decreases expression |
EXP |
Buspirone results in decreased expression of ANKH mRNA |
CTD |
PMID:24136188 |
|
NCBI chr 2:78,153,027...78,280,181
Ensembl chr 2:78,153,026...78,280,187
|
|
G |
Ankhd1 |
ankyrin repeat and KH domain containing 1 |
increases expression |
EXP |
Buspirone results in increased expression of ANKHD1-EIF4EBP3 mRNA |
CTD |
PMID:24136188 |
|
NCBI chr18:28,161,882...28,260,917
Ensembl chr18:28,162,311...28,268,024
|
|
G |
Ankrd46 |
ankyrin repeat domain 46 |
increases expression |
EXP |
Buspirone results in increased expression of ANKRD46 mRNA |
CTD |
PMID:24136188 |
|
NCBI chr 7:67,647,202...67,668,180
Ensembl chr 7:67,647,204...67,668,132
|
|
G |
Antxr2 |
ANTXR cell adhesion molecule 2 |
increases expression |
EXP |
Buspirone results in increased expression of ANTXR2 mRNA |
CTD |
PMID:24136188 |
|
NCBI chr14:11,541,718...11,682,110
Ensembl chr14:11,541,772...11,682,094
|
|
G |
Anxa3 |
annexin A3 |
decreases expression |
EXP |
Buspirone results in decreased expression of ANXA3 mRNA |
CTD |
PMID:24136188 |
|
NCBI chr14:12,727,708...12,781,717
Ensembl chr14:12,719,795...12,781,617
|
|
G |
Anxa5 |
annexin A5 |
decreases expression |
EXP |
Buspirone results in decreased expression of ANXA5 mRNA |
CTD |
PMID:24136188 |
|
NCBI chr 2:119,314,007...119,344,703
Ensembl chr 2:119,314,007...119,353,369
|
|
G |
Apob |
apolipoprotein B |
decreases expression |
EXP |
Buspirone results in decreased expression of APOB mRNA |
CTD |
PMID:24136188 |
|
NCBI chr 6:30,844,386...30,883,983
Ensembl chr 6:30,844,368...30,892,497
|
|
G |
Apol9a-Apol7a |
Apol9a-Apol7a readthrough |
decreases expression |
EXP |
Buspirone results in decreased expression of APOL7B mRNA |
CTD |
PMID:24136188 |
|
NCBI chr 7:109,118,559...109,149,798
Ensembl chr 7:109,131,064...109,147,649
|
|
G |
Apoo |
apolipoprotein O |
decreases expression |
EXP |
Buspirone results in decreased expression of APOO mRNA |
CTD |
PMID:24136188 |
|
NCBI chr X:59,157,971...59,262,940
Ensembl chr X:59,158,049...59,262,940
|
|
G |
Apool |
apolipoprotein O-like |
decreases expression |
EXP |
Buspirone results in decreased expression of APOOL mRNA |
CTD |
PMID:24136188 |
|
NCBI chr X:77,377,723...77,443,672
Ensembl chr X:77,377,781...77,443,900
|
|
G |
App |
amyloid beta precursor protein |
decreases expression |
EXP |
Buspirone results in decreased expression of APP mRNA |
CTD |
PMID:24136188 |
|
NCBI chr11:24,019,774...24,236,584
Ensembl chr11:24,019,778...24,236,561
|
|
G |
Arhgap24 |
Rho GTPase activating protein 24 |
decreases expression |
EXP |
Buspirone results in decreased expression of ARHGAP24 mRNA |
CTD |
PMID:24136188 |
|
NCBI chr14:6,800,624...7,183,877
Ensembl chr14:6,800,631...7,183,823
|
|
G |
Arhgdib |
Rho GDP dissociation inhibitor beta |
decreases expression |
EXP |
Buspirone results in decreased expression of ARHGDIB mRNA |
CTD |
PMID:24136188 |
|
NCBI chr 4:169,822,951...169,841,884
Ensembl chr 4:169,822,952...169,841,658
|
|
G |
Arl1 |
ARF like GTPase 1 |
decreases expression |
EXP |
Buspirone results in decreased expression of ARL1 mRNA |
CTD |
PMID:24136188 |
|
NCBI chr 7:23,120,004...23,131,173
Ensembl chr 7:23,119,589...23,131,898
|
|
G |
Arl4a |
ARF like GTPase 4A |
increases expression |
EXP |
Buspirone results in increased expression of ARL4A mRNA |
CTD |
PMID:24136188 |
|
NCBI chr 6:57,079,496...57,084,156
Ensembl chr 6:57,078,812...57,085,066
|
|
G |
Arl6ip1 |
ARL6 interacting reticulophagy regulator 1 |
decreases expression |
EXP |
Buspirone results in decreased expression of ARL6IP1 mRNA |
CTD |
PMID:24136188 |
|
NCBI chr 1:172,430,475...172,439,990
Ensembl chr 1:172,430,489...172,439,994
|
|
G |
Armt1 |
acidic residue methyltransferase 1 |
decreases expression |
EXP |
Buspirone results in decreased expression of ARMT1 mRNA |
CTD |
PMID:24136188 |
|
NCBI chr 1:40,894,558...40,918,302
Ensembl chr 1:40,894,550...40,918,302
|
|
G |
Arsb |
arylsulfatase B |
decreases expression |
EXP |
Buspirone results in decreased expression of ARSB mRNA |
CTD |
PMID:24136188 |
|
NCBI chr 2:25,002,210...25,162,675
Ensembl chr 2:25,002,346...25,162,671
|
|
G |
As3mt |
arsenite methyltransferase |
increases expression |
EXP |
Buspirone results in increased expression of AS3MT mRNA |
CTD |
PMID:24136188 |
|
NCBI chr 1:245,595,939...245,628,921
Ensembl chr 1:245,596,108...245,627,872
|
|
G |
Asap2 |
ArfGAP with SH3 domain, ankyrin repeat and PH domain 2 |
decreases expression |
EXP |
Buspirone results in decreased expression of ASAP2 mRNA |
CTD |
PMID:24136188 |
|
NCBI chr 6:40,658,201...40,821,017
Ensembl chr 6:40,657,880...40,820,975
|
|
G |
Asgr1 |
asialoglycoprotein receptor 1 |
increases expression |
EXP |
Buspirone results in increased expression of ASGR1 mRNA |
CTD |
PMID:24136188 |
|
NCBI chr10:54,775,727...54,779,642
Ensembl chr10:54,776,024...54,779,631
|
|
G |
Aspg |
asparaginase |
increases expression |
EXP |
Buspirone results in increased expression of ASPG mRNA |
CTD |
PMID:24136188 |
|
NCBI chr 6:131,176,727...131,196,268
Ensembl chr 6:131,176,874...131,196,268
|
|
G |
Atf5 |
activating transcription factor 5 |
increases expression |
EXP |
Buspirone results in increased expression of ATF5 mRNA |
CTD |
PMID:24136188 |
|
NCBI chr 1:95,295,602...95,299,755
Ensembl chr 1:95,295,610...95,299,707
|
|
G |
Atg2b |
autophagy related 2B |
increases expression |
EXP |
Buspirone results in increased expression of ATG2B mRNA |
CTD |
PMID:24136188 |
|
NCBI chr 6:124,522,283...124,592,412
Ensembl chr 6:124,525,523...124,592,015
|
|
G |
Atl2 |
atlastin GTPase 2 |
increases expression |
EXP |
Buspirone results in increased expression of ATL2 mRNA |
CTD |
PMID:24136188 |
|
NCBI chr 6:15,139,071...15,180,421
Ensembl chr 6:15,139,044...15,180,421
|
|
G |
Atp11c |
ATPase phospholipid transporting 11C |
increases expression |
EXP |
Buspirone results in increased expression of ATP11C mRNA |
CTD |
PMID:24136188 |
|
NCBI chr X:138,564,459...138,752,116
Ensembl chr X:138,565,836...138,751,204
|
|
G |
Atp6v0b |
ATPase H+ transporting V0 subunit B |
increases expression |
EXP |
Buspirone results in increased expression of ATP6V0B mRNA |
CTD |
PMID:24136188 |
|
NCBI chr 5:131,423,384...131,424,900
Ensembl chr 5:131,423,387...131,426,401
|
|
G |
Atp6v0e1 |
ATPase H+ transporting V0 subunit e1 |
increases expression |
EXP |
Buspirone results in increased expression of ATP6V0E1 mRNA |
CTD |
PMID:24136188 |
|
NCBI chr10:16,479,656...16,502,732
Ensembl chr10:16,479,567...16,524,434
|
|
G |
Atp6v1g1 |
ATPase H+ transporting V1 subunit G1 |
increases expression |
EXP |
Buspirone results in increased expression of ATP6V1G1 mRNA |
CTD |
PMID:24136188 |
|
NCBI chr 5:76,961,462...76,967,642
Ensembl chr 5:76,961,499...76,969,463
|
|
G |
Axl |
Axl receptor tyrosine kinase |
decreases expression |
EXP |
Buspirone results in decreased expression of AXL mRNA |
CTD |
PMID:24136188 |
|
NCBI chr 1:81,265,088...81,296,278
Ensembl chr 1:81,265,088...81,296,265
|
|
G |
Azin1 |
antizyme inhibitor 1 |
decreases expression |
EXP |
Buspirone results in decreased expression of AZIN1 mRNA |
CTD |
PMID:24136188 |
|
NCBI chr 7:69,654,773...69,681,578
Ensembl chr 7:69,654,663...69,681,578
|
|
G |
B4galnt1 |
beta-1,4-N-acetyl-galactosaminyl transferase 1 |
increases expression |
EXP |
Buspirone results in increased expression of B4GALNT1 mRNA |
CTD |
PMID:24136188 |
|
NCBI chr 7:62,988,429...62,996,190
Ensembl chr 7:62,988,930...62,996,190
|
|
G |
Baiap2l1 |
BAR/IMD domain containing adaptor protein 2 like 1 |
increases expression |
EXP |
Buspirone results in increased expression of BAIAP2L1 mRNA |
CTD |
PMID:24136188 |
|
NCBI chr12:10,250,434...10,339,937
Ensembl chr12:10,250,473...10,339,928
|
|
G |
Bgn |
biglycan |
decreases expression |
EXP |
Buspirone results in decreased expression of BGN mRNA |
CTD |
PMID:24136188 |
|
NCBI chr X:151,197,296...151,209,458
Ensembl chr X:151,197,273...151,209,461
|
|
G |
Bhlhe40 |
basic helix-loop-helix family, member e40 |
decreases expression |
EXP |
Buspirone results in decreased expression of BHLHE40 mRNA |
CTD |
PMID:24136188 |
|
NCBI chr 4:141,618,453...141,624,154
Ensembl chr 4:141,618,476...141,624,774
|
|
G |
Blvrb |
biliverdin reductase B |
increases expression |
EXP |
Buspirone results in increased expression of BLVRB mRNA |
CTD |
PMID:24136188 |
|
NCBI chr 1:82,738,646...82,756,312
Ensembl chr 1:82,738,695...82,770,375
|
|
G |
Bnip3 |
BCL2 interacting protein 3 |
increases expression |
EXP |
Buspirone results in increased expression of BNIP3 mRNA |
CTD |
PMID:24136188 |
|
NCBI chr 1:193,708,164...193,725,348
Ensembl chr 1:193,708,167...193,725,359
|
|
G |
Bola1 |
bolA family member 1 |
increases expression |
EXP |
Buspirone results in increased expression of BOLA1 mRNA |
CTD |
PMID:24136188 |
|
NCBI chr 2:183,758,515...183,771,445
Ensembl chr 2:183,758,441...183,781,576
|
|
G |
Bpgm |
bisphosphoglycerate mutase |
decreases expression |
EXP |
Buspirone results in decreased expression of BPGM mRNA |
CTD |
PMID:24136188 |
|
NCBI chr 4:63,139,730...63,168,581
Ensembl chr 4:63,140,018...63,168,581
|
|
G |
Btg2 |
BTG anti-proliferation factor 2 |
decreases expression |
EXP |
Buspirone results in decreased expression of BTG2 mRNA |
CTD |
PMID:24136188 |
|
NCBI chr13:45,531,881...45,535,642
Ensembl chr13:45,531,925...45,535,628
|
|
G |
C10h17orf58 |
similar to human chromosome 17 open reading frame 58 |
increases expression |
EXP |
Buspirone results in increased expression of C10H17ORF58 mRNA |
CTD |
PMID:24136188 |
|
NCBI chr10:91,972,938...91,977,606
Ensembl chr10:91,972,410...91,977,602
|
|
G |
C1qb |
complement C1q B chain |
decreases expression |
EXP |
Buspirone results in decreased expression of C1QB mRNA |
CTD |
PMID:24136188 |
|
NCBI chr 5:149,118,843...149,124,394
Ensembl chr 5:149,118,846...149,124,407
|
|
G |
C5h1orf50 |
similar to human chromosome 1 open reading frame 50 |
increases expression |
EXP |
Buspirone results in increased expression of C5H1ORF50 mRNA |
CTD |
PMID:24136188 |
|
NCBI chr 5:132,837,135...132,841,744
Ensembl chr 5:132,836,506...132,841,762
|
|
G |
C5l1 |
complement C5 like 1 |
increases expression |
EXP |
Buspirone results in increased expression of C5L1 mRNA |
CTD |
PMID:24136188 |
|
NCBI chr 3:18,401,716...18,420,064
Ensembl chr 3:18,404,899...18,420,054
|
|
G |
C6 |
complement C6 |
decreases expression |
EXP |
Buspirone results in decreased expression of C6 mRNA |
CTD |
PMID:24136188 |
|
NCBI chr 2:53,846,028...53,921,279
Ensembl chr 2:53,851,985...53,921,275
|
|
G |
C8g |
complement C8 gamma chain |
increases expression |
EXP |
Buspirone results in increased expression of C8G mRNA |
CTD |
PMID:24136188 |
|
NCBI chr 3:8,320,503...8,322,087
Ensembl chr 3:8,305,920...8,323,495
|
|
G |
C8h11orf54 |
similar to human chromosome 11 open reading frame 54 |
decreases expression |
EXP |
Buspirone results in decreased expression of C8H11ORF54 mRNA |
CTD |
PMID:24136188 |
|
NCBI chr 8:12,123,839...12,146,412
Ensembl chr 8:12,123,823...12,146,473
|
|
G |
C8h11orf65 |
similar to human chromosome 11 open reading frame 65 |
increases expression |
EXP |
Buspirone results in increased expression of C8H11ORF65 mRNA |
CTD |
PMID:24136188 |
|
NCBI chr 8:53,796,033...53,825,277
Ensembl chr 8:53,796,366...53,824,748
|
|
G |
C8h11orf71 |
similar to human chromosome 11 open reading frame 71 |
increases expression |
EXP |
Buspirone results in increased expression of C8H11ORF71 mRNA |
CTD |
PMID:24136188 |
|
NCBI chr 8:48,838,556...48,838,970
Ensembl chr 8:48,838,100...48,842,270
|
|
G |
C8h15orf61 |
similar to human chromosome 15 open reading frame 61 |
increases expression |
EXP |
Buspirone results in increased expression of C8H15ORF61 mRNA |
CTD |
PMID:24136188 |
|
NCBI chr 8:63,868,125...63,872,863
Ensembl chr 8:63,868,125...63,872,751
|
|
G |
Cald1 |
caldesmon 1 |
decreases expression |
EXP |
Buspirone results in decreased expression of CALD1 mRNA |
CTD |
PMID:24136188 |
|
NCBI chr 4:63,265,781...63,446,938
Ensembl chr 4:63,265,942...63,446,932
|
|
G |
Calm1 |
calmodulin 1 |
decreases expression |
EXP |
Buspirone results in decreased expression of CALM1 mRNA |
CTD |
PMID:24136188 |
|
NCBI chr 6:119,487,691...119,495,759
Ensembl chr 6:119,487,621...119,498,227
|
|
G |
Calm2 |
calmodulin 2 |
decreases expression |
EXP |
Buspirone results in decreased expression of CALM2 mRNA |
CTD |
PMID:24136188 |
|
NCBI chr 6:7,091,624...7,104,284
Ensembl chr 6:7,091,567...7,104,287 Ensembl chr15:7,091,567...7,104,287
|
|
G |
Calr |
calreticulin |
decreases expression |
EXP |
Buspirone results in decreased expression of CALR mRNA |
CTD |
PMID:24136188 |
|
NCBI chr19:23,308,525...23,313,420
Ensembl chr19:23,308,351...23,313,414
|
|
G |
Cap1 |
cyclase associated actin cytoskeleton regulatory protein 1 |
decreases expression |
EXP |
Buspirone results in decreased expression of CAP1 mRNA |
CTD |
PMID:24136188 |
|
NCBI chr 5:135,142,108...135,168,885
Ensembl chr 5:135,142,112...135,168,769
|
|
G |
Car3 |
carbonic anhydrase 3 |
decreases expression |
EXP |
Buspirone results in decreased expression of CAR3 mRNA |
CTD |
PMID:24136188 |
|
NCBI chr 2:86,770,418...86,780,011
Ensembl chr 2:86,770,420...86,784,280
|
|
G |
Car5a |
carbonic anhydrase 5A |
increases expression |
EXP |
Buspirone results in increased expression of CAR5A mRNA |
CTD |
PMID:24136188 |
|
NCBI chr19:49,973,092...50,002,948
Ensembl chr19:49,973,107...50,002,906
|
|
G |
Casp1 |
caspase 1 |
multiple interactions |
EXP |
Buspirone inhibits the reaction [Methotrexate results in increased cleavage of CASP1 protein] |
CTD |
PMID:37341015 |
|
NCBI chr 8:2,587,812...2,597,403
Ensembl chr 8:2,587,831...2,597,383
|
|
G |
Casp3 |
caspase 3 |
decreases expression |
EXP |
Buspirone results in decreased expression of CASP3 mRNA |
CTD |
PMID:24136188 |
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Casp6 |
caspase 6 |
increases expression |
EXP |
Buspirone results in increased expression of CASP6 mRNA |
CTD |
PMID:24136188 |
|
NCBI chr 2:218,466,063...218,478,503
Ensembl chr 2:218,466,076...218,478,502
|
|
G |
Casp7 |
caspase 7 |
decreases expression |
EXP |
Buspirone results in decreased expression of CASP7 mRNA |
CTD |
PMID:24136188 |
|
NCBI chr 1:255,437,438...255,476,737
Ensembl chr 1:255,437,172...255,476,729
|
|
G |
Cat |
catalase |
increases expression |
EXP |
Buspirone results in increased expression of CAT protein |
CTD |
PMID:19800952 |
|
NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478
|
|
G |
Cbr4 |
carbonyl reductase 4 |
increases expression |
EXP |
Buspirone results in increased expression of CBR4 mRNA |
CTD |
PMID:24136188 |
|
NCBI chr16:28,629,928...28,684,230
Ensembl chr16:28,617,224...28,645,712
|
|
G |
Ccdc6 |
coiled-coil domain containing 6 |
increases expression |
EXP |
Buspirone results in increased expression of CCDC6 mRNA |
CTD |
PMID:24136188 |
|
NCBI chr20:18,432,177...18,528,186
Ensembl chr20:18,433,695...18,528,658
|
|
G |
Ccdc80 |
coiled-coil domain containing 80 |
decreases expression |
EXP |
Buspirone results in decreased expression of CCDC80 mRNA |
CTD |
PMID:24136188 |
|
NCBI chr11:55,685,165...55,718,827
Ensembl chr11:55,685,872...55,719,137
|
|
G |
Ccl9 |
C-C motif chemokine ligand 9 |
decreases expression |
EXP |
Buspirone results in decreased expression of CCL6 mRNA |
CTD |
PMID:24136188 |
|
NCBI chr10:68,366,486...68,371,408
Ensembl chr10:68,366,487...68,371,369
|
|
G |
Ccnb2 |
cyclin B2 |
decreases expression |
EXP |
Buspirone results in decreased expression of CCNB2 mRNA |
CTD |
PMID:24136188 |
|
NCBI chr 8:71,087,594...71,100,794
Ensembl chr 8:71,087,595...71,100,874
|
|
G |
Ccnd1 |
cyclin D1 |
decreases expression |
EXP |
Buspirone results in decreased expression of CCND1 mRNA |
CTD |
PMID:24136188 |
|
NCBI chr 1:200,089,002...200,098,524
Ensembl chr 1:200,089,002...200,098,602
|
|
G |
Cd164 |
CD164 molecule |
decreases expression |
EXP |
Buspirone results in decreased expression of CD164 mRNA |
CTD |
PMID:24136188 |
|
NCBI chr20:45,024,051...45,035,628
Ensembl chr20:45,023,973...45,035,634
|
|
G |
Cd5l |
Cd5 molecule-like |
decreases expression |
EXP |
Buspirone results in decreased expression of CD5L mRNA |
CTD |
PMID:24136188 |
|
NCBI chr 2:172,791,007...172,802,018
Ensembl chr 2:172,790,934...172,829,753
|
|
G |
Cd68 |
Cd68 molecule |
decreases expression |
EXP |
Buspirone results in decreased expression of CD68 mRNA |
CTD |
PMID:24136188 |
|
NCBI chr10:54,381,814...54,383,693
Ensembl chr10:54,381,815...54,383,697
|
|
G |
Cd74 |
CD74 molecule |
decreases expression |
EXP |
Buspirone results in decreased expression of CD74 mRNA |
CTD |
PMID:24136188 |
|
NCBI chr18:54,256,757...54,266,003
Ensembl chr18:54,256,778...54,266,003
|
|
G |
Cdc20 |
cell division cycle 20 |
decreases expression |
EXP |
Buspirone results in decreased expression of CDC20 mRNA |
CTD |
PMID:24136188 |
|
NCBI chr 5:131,966,203...131,970,406
Ensembl chr 5:131,966,215...131,970,512
|
|
G |
Cdk1 |
cyclin-dependent kinase 1 |
decreases expression |
EXP |
Buspirone results in decreased expression of CDK1 mRNA |
CTD |
PMID:24136188 |
|
NCBI chr20:19,266,226...19,281,417
Ensembl chr20:19,266,248...19,281,408
|
|
G |
Cdkn2c |
cyclin-dependent kinase inhibitor 2C |
decreases expression |
EXP |
Buspirone results in decreased expression of CDKN2C mRNA |
CTD |
PMID:24136188 |
|
NCBI chr 5:124,411,123...124,416,278
Ensembl chr 5:124,411,124...124,416,278
|
|
G |
Cdkn3 |
cyclin-dependent kinase inhibitor 3 |
decreases expression |
EXP |
Buspirone results in decreased expression of CDKN3 mRNA |
CTD |
PMID:24136188 |
|
NCBI chr15:20,022,522...20,033,948
Ensembl chr15:20,022,664...20,033,945
|
|
G |
Ceacam1 |
CEA cell adhesion molecule 1 |
decreases expression |
EXP |
Buspirone results in decreased expression of CEACAM1 mRNA |
CTD |
PMID:24136188 |
|
NCBI chr 1:81,043,595...81,060,050
Ensembl chr 1:81,043,595...81,059,992
|
|
G |
Ceacam4 |
CEA cell adhesion molecule 4 |
decreases expression |
EXP |
Buspirone results in decreased expression of CEACAM10 mRNA |
CTD |
PMID:24136188 |
|
NCBI chr 1:80,376,667...80,382,943
Ensembl chr 1:80,376,648...80,382,915
|
|
G |
Cep20 |
centrosomal protein 20 |
decreases expression |
EXP |
Buspirone results in decreased expression of CEP20 mRNA |
CTD |
PMID:24136188 |
|
NCBI chr10:714,051...736,826
Ensembl chr10:714,151...736,837
|
|
G |
Cfl1 |
cofilin 1 |
decreases expression |
EXP |
Buspirone results in decreased expression of CFL1 mRNA |
CTD |
PMID:24136188 |
|
NCBI chr 1:202,796,012...202,801,337
Ensembl chr 1:202,786,627...202,817,587
|
|
G |
Cgn |
cingulin |
decreases expression |
EXP |
Buspirone results in decreased expression of CGN mRNA |
CTD |
PMID:24136188 |
|
NCBI chr 2:182,308,389...182,335,747
Ensembl chr 2:182,308,714...182,334,645
|
|
G |
Chpt1 |
choline phosphotransferase 1 |
increases expression |
EXP |
Buspirone results in increased expression of CHPT1 mRNA |
CTD |
PMID:24136188 |
|
NCBI chr 7:22,866,455...22,915,111
Ensembl chr 7:22,863,027...22,915,103
|
|
G |
Churc1 |
churchill domain containing 1 |
increases expression |
EXP |
Buspirone results in increased expression of CHURC1 mRNA |
CTD |
PMID:24136188 |
|
NCBI chr 6:95,464,488...95,485,208
Ensembl chr 6:95,470,683...95,619,586
|
|
G |
Cks2 |
CDC28 protein kinase regulatory subunit 2 |
decreases expression |
EXP |
Buspirone results in decreased expression of CKS2 mRNA |
CTD |
PMID:24136188 |
|
NCBI chr17:13,570,611...13,575,770
|
|
G |
Clec4f |
C-type lectin domain family 4, member F |
decreases expression |
EXP |
Buspirone results in decreased expression of CLEC4F mRNA |
CTD |
PMID:24136188 |
|
NCBI chr 4:116,129,023...116,138,744
Ensembl chr 4:116,129,023...116,138,775
|
|
G |
Clic1 |
chloride intracellular channel 1 |
decreases expression |
EXP |
Buspirone results in decreased expression of CLIC1 mRNA |
CTD |
PMID:24136188 |
|
NCBI chr20:3,764,867...3,773,711
Ensembl chr20:3,761,461...3,773,712
|
|
G |
Clpb |
ClpB family mitochondrial disaggregase |
decreases expression |
EXP |
Buspirone results in decreased expression of CLPB mRNA |
CTD |
PMID:24136188 |
|
NCBI chr 1:156,028,740...156,158,183
Ensembl chr 1:156,028,930...156,168,788
|
|
G |
Cltb |
clathrin, light chain B |
increases expression |
EXP |
Buspirone results in increased expression of CLTB mRNA |
CTD |
PMID:24136188 |
|
NCBI chr17:10,001,512...10,019,201
Ensembl chr17:10,001,513...10,019,169
|
|
G |
Cmtm6 |
CKLF-like MARVEL transmembrane domain containing 6 |
decreases expression |
EXP |
Buspirone results in decreased expression of CMTM6 mRNA |
CTD |
PMID:24136188 |
|
NCBI chr 8:114,422,934...114,441,034
Ensembl chr 8:114,422,921...114,441,033
|
|
G |
Cnppd1 |
cyclin Pas1/PHO80 domain containing 1 |
increases expression |
EXP |
Buspirone results in increased expression of CNPPD1 mRNA |
CTD |
PMID:24136188 |
|
NCBI chr 9:76,633,475...76,640,164
Ensembl chr 9:76,633,477...76,640,188
|
|
G |
Cnr1 |
cannabinoid receptor 1 |
affects response to substance |
ISO |
CNR1 affects the susceptibility to Buspirone |
CTD |
PMID:15081793 |
|
NCBI chr 5:48,408,543...48,436,099
Ensembl chr 5:48,408,574...48,435,099
|
|
G |
Cobll1 |
cordon-bleu WH2 repeat protein-like 1 |
increases expression |
EXP |
Buspirone results in increased expression of COBLL1 mRNA |
CTD |
PMID:24136188 |
|
NCBI chr 3:49,753,260...49,915,168
Ensembl chr 3:49,753,262...49,915,194
|
|
G |
Col14a1 |
collagen type XIV alpha 1 chain |
decreases expression |
EXP |
Buspirone results in decreased expression of COL14A1 mRNA |
CTD |
PMID:24136188 |
|
NCBI chr 7:86,722,093...86,937,215
Ensembl chr 7:86,722,094...86,937,214
|
|
G |
Col1a2 |
collagen type I alpha 2 chain |
decreases expression |
EXP |
Buspirone results in decreased expression of COL1A2 mRNA |
CTD |
PMID:24136188 |
|
NCBI chr 4:32,563,938...32,598,868
Ensembl chr 4:32,563,381...32,598,867
|
|
G |
Col3a1 |
collagen type III alpha 1 chain |
decreases expression |
EXP |
Buspirone results in decreased expression of COL3A1 mRNA |
CTD |
PMID:24136188 |
|
NCBI chr 9:47,374,611...47,410,547
Ensembl chr 9:47,374,593...47,410,547
|
|
G |
Commd5 |
COMM domain containing 5 |
increases expression |
EXP |
Buspirone results in increased expression of COMMD5 mRNA |
CTD |
PMID:24136188 |
|
NCBI chr 7:108,621,766...108,623,616
Ensembl chr 7:108,598,673...108,624,764
|
|
G |
Copg1 |
COPI coat complex subunit gamma 1 |
decreases expression |
EXP |
Buspirone results in decreased expression of COPG1 mRNA |
CTD |
PMID:24136188 |
|
NCBI chr 4:120,366,540...120,392,502
Ensembl chr 4:120,366,542...120,415,616
|
|
G |
Coro1c |
coronin 1C |
decreases expression |
EXP |
Buspirone results in decreased expression of CORO1C mRNA |
CTD |
PMID:24136188 |
|
NCBI chr12:42,713,024...42,785,179
Ensembl chr12:42,712,991...42,785,179
|
|
G |
Cox14 |
cytochrome c oxidase assembly factor COX14 |
increases expression |
EXP |
Buspirone results in increased expression of COX14 mRNA |
CTD |
PMID:24136188 |
|
NCBI chr 7:130,852,226...130,854,316
|
|
G |
Cox7a2l |
cytochrome c oxidase subunit 7A2 like |
increases expression |
EXP |
Buspirone results in increased expression of COX7A2L mRNA |
CTD |
PMID:24136188 |
|
NCBI chr 6:11,184,064...11,198,287
Ensembl chr 6:11,184,285...11,198,273
|
|
G |
Cpt1a |
carnitine palmitoyltransferase 1A |
increases expression |
EXP |
Buspirone results in increased expression of CPT1A mRNA |
CTD |
PMID:24136188 |
|
NCBI chr 1:200,564,634...200,627,059
Ensembl chr 1:200,565,613...200,627,055
|
|
G |
Cpt2 |
carnitine palmitoyltransferase 2 |
increases expression |
EXP |
Buspirone results in increased expression of CPT2 mRNA |
CTD |
PMID:24136188 |
|
NCBI chr 5:122,664,677...122,682,126
Ensembl chr 5:122,664,677...122,682,095
|
|
G |
Crem |
cAMP responsive element modulator |
decreases expression |
EXP |
Buspirone results in decreased expression of CREM mRNA |
CTD |
PMID:24136188 |
|
NCBI chr17:54,238,889...54,305,989
Ensembl chr17:54,239,030...54,305,989
|
|
G |
Cry1 |
cryptochrome circadian regulator 1 |
decreases expression |
EXP |
Buspirone results in decreased expression of CRY1 mRNA |
CTD |
PMID:24136188 |
|
NCBI chr 7:18,529,823...18,594,092
Ensembl chr 7:18,529,823...18,594,091
|
|
G |
Cse1l |
chromosome segregation 1 like |
decreases expression |
EXP |
Buspirone results in decreased expression of CSE1L mRNA |
CTD |
PMID:24136188 |
|
NCBI chr 3:155,641,104...155,678,866
Ensembl chr 3:155,641,166...155,678,865
|
|
G |
Csf1r |
colony stimulating factor 1 receptor |
decreases expression |
EXP |
Buspirone results in decreased expression of CSF1R mRNA |
CTD |
PMID:24136188 |
|
NCBI chr18:54,546,673...54,590,418
Ensembl chr18:54,546,659...54,590,415
|
|
G |
Csnk2a2 |
casein kinase 2 alpha 2 |
increases expression |
EXP |
Buspirone results in increased expression of CSNK2A2 mRNA |
CTD |
PMID:24136188 |
|
NCBI chr19:9,556,443...9,596,080
Ensembl chr19:9,556,260...9,596,080
|
|
G |
Csrp1 |
cysteine and glycine-rich protein 1 |
decreases expression |
EXP |
Buspirone results in decreased expression of CSRP1 mRNA |
CTD |
PMID:24136188 |
|
NCBI chr13:47,158,171...47,179,388
Ensembl chr13:47,167,789...47,179,384
|
|
G |
Ctsd |
cathepsin D |
increases expression |
EXP |
Buspirone results in increased expression of CTSD mRNA |
CTD |
PMID:24136188 |
|
NCBI chr 1:197,527,467...197,539,343
Ensembl chr 1:197,527,467...197,539,488
|
|
G |
Ctsl |
cathepsin L |
increases expression |
EXP |
Buspirone results in increased expression of CTSL mRNA |
CTD |
PMID:24136188 |
|
NCBI chr17:764,370...770,533
Ensembl chr17:764,309...770,548
|
|
G |
Ctss |
cathepsin S |
decreases expression |
EXP |
Buspirone results in decreased expression of CTSS mRNA |
CTD |
PMID:24136188 |
|
NCBI chr 2:183,086,437...183,114,483
Ensembl chr 2:183,086,437...183,114,483
|
|
G |
Ctsz |
cathepsin Z |
decreases expression |
EXP |
Buspirone results in decreased expression of CTSZ mRNA |
CTD |
PMID:24136188 |
|
NCBI chr 3:163,224,875...163,235,645
Ensembl chr 3:163,224,875...163,235,645
|
|
G |
Cxcl11 |
C-X-C motif chemokine ligand 11 |
increases expression |
EXP |
Buspirone results in increased expression of CXCL11 mRNA |
CTD |
PMID:24136188 |
|
NCBI chr14:15,689,432...15,692,207
Ensembl chr14:15,689,424...15,692,271
|
|
G |
Cybb |
cytochrome b-245 beta chain |
decreases expression |
EXP |
Buspirone results in decreased expression of CYBB mRNA |
CTD |
PMID:24136188 |
|
NCBI chr X:13,358,101...13,392,570
Ensembl chr X:13,359,430...13,392,586
|
|
G |
Cyp27a1 |
cytochrome P450, family 27, subfamily a, polypeptide 1 |
increases expression |
EXP |
Buspirone results in increased expression of CYP27A1 mRNA |
CTD |
PMID:24136188 |
|
NCBI chr 9:76,264,655...76,294,551
Ensembl chr 9:76,264,860...76,294,551
|
|
G |
Cyp2c22 |
cytochrome P450, family 2, subfamily c, polypeptide 22 |
decreases expression |
EXP |
Buspirone results in decreased expression of CYP2C22 mRNA |
CTD |
PMID:24136188 |
|
NCBI chr 1:238,991,698...239,031,323
Ensembl chr 1:238,991,610...239,021,738
|
|
G |
Cyp2d4 |
cytochrome P450, family 2, subfamily d, polypeptide 4 |
increases oxidation increases expression |
ISO EXP |
CYP2D6 protein results in increased oxidation of Buspirone Buspirone results in increased expression of CYP2D4 mRNA |
CTD |
PMID:15640381 PMID:24136188 |
|
NCBI chr 7:113,882,584...113,891,754
Ensembl chr 7:113,881,618...113,891,759
|
|
G |
Cyp2j3 |
cytochrome P450, family 2, subfamily j, polypeptide 3 |
increases expression |
EXP |
Buspirone results in increased expression of CYP2J3 mRNA |
CTD |
PMID:24136188 |
|
NCBI chr 5:111,219,921...111,244,987
Ensembl chr 5:111,178,703...111,244,794
|
|
G |
Cyp3a2 |
cytochrome P450, family 3, subfamily a, polypeptide 2 |
increases oxidation increases metabolic processing multiple interactions |
ISO |
CYP3A4 protein results in increased oxidation of Buspirone CYP3A4 protein results in increased metabolism of Buspirone Resveratrol inhibits the reaction [CYP3A4 protein results in increased metabolism of Buspirone] |
CTD |
PMID:15640381 PMID:20716633 |
|
NCBI chr12:9,207,978...9,230,064
Ensembl chr12:9,015,383...9,285,008
|
|
G |
Cyp3a9 |
cytochrome P450, family 3, subfamily a, polypeptide 9 |
increases oxidation increases expression |
ISO EXP |
CYP3A5 protein results in increased oxidation of Buspirone Buspirone results in increased expression of CYP3A9 mRNA |
CTD |
PMID:15640381 PMID:24136188 |
|
NCBI chr12:16,806,222...16,846,428
Ensembl chr12:16,806,207...16,846,422
|
|
G |
Cyp4a1 |
cytochrome P450, family 4, subfamily a, polypeptide 1 |
increases expression |
EXP |
Buspirone results in increased expression of CYP4A1 mRNA |
CTD |
PMID:24136188 |
|
NCBI chr 5:129,123,323...129,137,464
Ensembl chr 5:129,123,336...129,137,464
|
|
G |
Cyp4b1 |
cytochrome P450, family 4, subfamily b, polypeptide 1 |
increases expression |
EXP |
Buspirone results in increased expression of CYP4B1 mRNA |
CTD |
PMID:24136188 |
|
NCBI chr 5:129,139,019...129,176,860
Ensembl chr 5:129,139,038...129,156,348
|
|
G |
Cyp4f1 |
cytochrome P450, family 4, subfamily f, polypeptide 1 |
decreases expression |
EXP |
Buspirone results in decreased expression of CYP4F1 mRNA |
CTD |
PMID:24136188 |
|
NCBI chr 7:12,010,850...12,022,497
Ensembl chr 7:12,010,852...12,022,046
|
|
G |
Cyp4f4 |
cytochrome P450, family 4, subfamily f, polypeptide 4 |
increases expression |
EXP |
Buspirone results in increased expression of CYP4F4 mRNA |
CTD |
PMID:24136188 |
|
NCBI chr 7:11,717,208...11,733,507
Ensembl chr 7:11,717,208...11,733,506
|
|
G |
Cyp8b1 |
cytochrome P450 family 8 subfamily B member 1 |
increases expression |
EXP |
Buspirone results in increased expression of CYP8B1 mRNA |
CTD |
PMID:24136188 |
|
NCBI chr 8:121,578,123...121,580,093
Ensembl chr 8:121,557,062...121,580,166
|
|
G |
Daam1 |
dishevelled associated activator of morphogenesis 1 |
decreases expression |
EXP |
Buspirone results in decreased expression of DAAM1 mRNA |
CTD |
PMID:24136188 |
|
NCBI chr 6:90,389,544...90,550,114
Ensembl chr 6:90,389,688...90,550,114
|
|
G |
Dab2 |
DAB adaptor protein 2 |
decreases expression |
EXP |
Buspirone results in decreased expression of DAB2 mRNA |
CTD |
PMID:24136188 |
|
NCBI chr 2:55,514,692...55,567,476
Ensembl chr 2:55,514,700...55,567,476
|
|
G |
Dapk1 |
death associated protein kinase 1 |
decreases expression |
EXP |
Buspirone results in decreased expression of DAPK1 mRNA |
CTD |
PMID:24136188 |
|
NCBI chr17:3,930,223...4,090,991
Ensembl chr17:3,930,213...4,090,991
|
|
G |
Dbi |
diazepam binding inhibitor |
decreases expression |
EXP |
Buspirone results in decreased expression of DBI mRNA |
CTD |
PMID:24136188 |
|
NCBI chr13:31,241,466...31,249,853
Ensembl chr13:31,206,988...31,268,693
|
|
G |
Ddc |
dopa decarboxylase |
decreases expression |
EXP |
Buspirone results in decreased expression of DDC mRNA |
CTD |
PMID:24136188 |
|
NCBI chr14:86,378,685...86,469,189
Ensembl chr14:86,378,685...86,469,208
|
|
G |
Ddhd1 |
DDHD domain containing 1 |
decreases expression |
EXP |
Buspirone results in decreased expression of DDHD1 mRNA |
CTD |
PMID:24136188 |
|
NCBI chr15:18,824,389...18,891,036
Ensembl chr15:18,824,394...18,890,952
|
|
G |
Ddx1 |
DEAD-box helicase 1 |
decreases expression |
EXP |
Buspirone results in decreased expression of DDX1 mRNA |
CTD |
PMID:24136188 |
|
NCBI chr 6:35,996,469...36,027,340
Ensembl chr 6:35,996,469...36,027,365
|
|
G |
Decr1 |
2,4-dienoyl-CoA reductase 1 |
increases expression |
EXP |
Buspirone results in increased expression of DECR1 mRNA |
CTD |
PMID:24136188 |
|
| |